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Abstract  	  	   Deubiquitylases (DUBs) have been implicated in the regulation of cell 
signaling processes. However, the role of DUBs in the regulation of the 
Epidermal growth factor receptor (EGFR) signaling is not completely 
understood. This study has aimed to identify DUBs involved in the regulation 
of EGFR signaling and downstream cascades. The first part of this study has 
characterized the role of the DUB USP15 in the regulation of the mitogen 
activated protein kinase (MAPK) cascade, a pathway downstream of EGFR. 
An interaction between USP15 and the MAPK negative regulator BRAP had 
been previously reported. When we tested the USP15 depletion phenotype on 
MAPK signaling we observed a paradoxical decrease in MAPK activation. 
Examination of upstream components of the MAPK cascade revealed a 
decrease in the levels of the CRAF kinase following USP15 depletion. 
Concordant depletion of CRAF also caused a reduction in MAPK activation, 
showing that depletion of CRAF phenocopied that of USP15. This work 
demonstrated that USP15 has a dual role in the regulation of the MAPK 
through BRAP and CRAF. The dominant signaling effect in the cell lines 
studied is through maintenance of CRAF levels.  
  
 We employed a previously characterized GFP-DUB library to identify 
DUBs that exhibited EGF dependent distributions. One such DUB, USP46, 
exhibited MAPK dependent recruitment onto multi-vesicular bodies (MVB). To 
further characterize USP46 we generated a set of cell lines expressing GFP-
USP46 and catalytically inactive GFP-USP46-C44S using the Flp-in system. 
While the Flp-in cells lines did not exhibit the same EGF dependent 
recruitment onto the MVB compartment, they did localize to Saponin resistant 
punctate structures. Furthermore, I observed differential activation of 
downstream EGFR signaling pathways that USP46 may play an 
undetermined role in EGF signaling. We combining stable isotope labeling of 
amino acids in culture (SILAC) with immuno-precipitation (IP) to quantitatively 
identify interactors of USP46 using mass spectrometry. We identified a 
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number of candidate interactors and confirmed a novel interaction between 
USP46 and FBXO11 using western blotting.  
  
 Next we aimed to identify DUBs that regulate the retrograde trafficking 
pathway from the MVB to the trans Golgi network (TGN). We used the 
localization of the cation independent mannose 6-phosphate receptor (CI-
M6PR) as readout of the retrograde trafficking. CI-M6PR constitutively 
recycles from the TGN to the endo-lysosomal pathway, delivering newly 
synthesized acid hydrolases, required for degradative action of the lysosome.  
Depletion of USP8 trapped CI-M6PR in aberrant endosomes and caused a 
concomitant missorting of the acid hydrolase, Cathepsin D. Cathepsin D is 
activated through limited proteolysis in the acidic environment of the endo-
lysosomal pathway. Depletion of USP8 caused a decrease in the mature 
cellular form of Cathepsin D. The mislocalization of CI-M6PR could be 
rescued by re-expression of GFP-USP8. The activated EGFR is degraded via 
the lysosome and depletion of USP8 has been demonstrated to cause a delay 
in the degradation of EGFR. The results presented here suggest that the 
decrease in active acid hydrolases observed in USP8 depleted cells, may 
contribute to the delay in EGFR degradation.  
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Chapter 1 	  Introduction	  	  
1.1.1. The discovery of Epidermal Growth Factor (EGF).	  
 
To maintain correct tissue architecture cells need to grow and 
differentiate in a coordinated manner. The fate of individual cells is tightly 
controlled by extracellular growth factors. Mutations in the intracellular 
pathways that respond to growth factors can cause the cell to proliferate 
independent of these extracellular cues. This causes uncontrolled proliferation 
and can lead to the development of cancer. Research into understanding the 
regulation of these pathways and how they become deregulated in cancer has 
lead to the development of anti-cancer drugs. However, despite many 
successes there are still gaps in our understanding of how these pathways 
are regulated. By identifying new regulators there is still potential to open new 
means to pharmacologically inhibit these pathways.    
 
In 1951 Rita Levi-Montalcini observed that mouse sarcomas 
implanted in the sympathetic ganglia of chick embryos had growth-stimulating 
effects1. The factor responsible was isolated by Stanley Cohen in 1954, which 
was duly named Nerve Growth Factor (NGF)2. Whilst working on a project 
isolating NGF from mouse submaxillary glands, Cohen noted that when crude 
preparations were given to mice it accelerated their development3. He 
concluded that these effects were not attributable to NGF as the purified 
factor did not have the same effect, so there must be another factor in the 
crude extract. Using these observations as a readout, he isolated a factor that 
when given to mice caused the eyelids to open and teeth to erupt earlier in 
development4. By using electron microscopy, it was observed that there was 
an increase in the keratinization and differentiation of the epidermis in the eye 
lids of mice treated with the factor compared to control animals4.   
 
At this point it was unclear how these effects were being generated. 
Were they generated by the factor itself or did the factor stimulate the release 
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of another hormone5? In 1965 using chick skin organ cultures, it was 
definitively demonstrated that the factor was stimulating the growth and 
keratinization of epidermal cells6. The factor has since been known as 
epidermal growth factor (EGF). 
 
 This work had another important implication that mouse EGF (mEGF) 
was able to stimulate avian as well as mammalian tissues. This opened up 
the possibility that EGF was a conserved factor, which could be important in 
regulating human tissues. Addition of EGF to cultures of human fibroblast 3T3 
cells proved this hypothesis. mEGF could stimulate growth and overcome 
contact inhibition of human fibroblast cells7.  
 
The fact that mEGF could stimulate human cells meant that there 
must be a human equivalent of EGF. This began the search to find human 
equivalent to mEGF. Human EGF (EGF) was isolated from human urine using 
affinity column prepared with rabbit antiserum against mEGF8, 9. The isolated 
compound competed for the same receptor9 and cross-reacted with 
antibodies against mEGF8. Furthermore the isolated compound had similar 
biological effects on cultured cells as mEGF9. However, no sequence was 
available to confirm that the compounds were the homologous. In the 1970s 
the development of a two-step method to isolate mEGF from submaxillary 
glands10 enabled the biochemical characterization of mEGF.  
 
Greogory et al.11 (1977) isolated a compound called urogastrone from 
human urine a molecule known to inhibit gastric acid secretion. When they 
sequenced urogastrone they found that there was a remarkable similarity to 
mEGF. With further analysis it was revealed that they had in fact isolated 
EGF; both compounds elicited the same responses when tested. This work 
incidentally demonstrated a previously unsuspected role of EGF in regulating 
gastric acid secretion11.  
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1.1.2.  The identification of an EGF receptor and the discovery of receptor 
endocytosis. 
 
 Using radio ligand (I125EGF) assays a specific receptor for EGF was 
demonstrated12. I125EGF would bind to the surface of cells at 0˚C and at 37˚C, 
at 0˚C it takes 4 hours for the receptors to reach saturation compared to at 
37˚C, were saturation is achieved after approximately 15mins, furthermore the 
maximal binding at 37˚C was approximately twice that at 0˚C12. After 
prolonged incubation at 37˚C there was a decrease in the amount of bound 
EGF, decreasing to 20% of the maximum, whereas at 0˚C no decrease was 
observed. This effect was not due to destruction of free EGF in the media as 
the containing media and stimulate another set of cells12. Adding fresh EGF to 
pre-stimulated cells also does not overcome the desensitization12 and 
reapplying EGF to stimulated cells failed to illicit a response. These 
experiments suggested that there was active an cellular process that 
regulates the abundance of the receptor on the plasma membrane.  
 
 Using I125-hEGF bound to the receptor at different temperatures this 
regulation was teased out. By binding I125-hEGF at 0˚C then maintaining the 
cells at 0˚C the radio ligand could be washed off from the cells and recovered. 
Binding the radio ligand and maintaining the cells at 37˚C, there was a 
reduced amount of label at the cell surface and digestion products of EGF 
could be detected12. By binding at 37˚C and then maintaining the cells at 0˚C, 
there was a reduced amount radio ligand washed off the cells and now there 
was no degradation products observed. Additionally adding lysosomal 
inhibiters to the cells could block the degradation of I125-hEGF at 37˚C12. This 
data was consistent with the hypothesis that the receptor was being 
internalized following EGF binding and degraded in the	   endo-lysosomal 
system. 
 
 Using 2 different approaches this hypothesis was confirmed by Cohen 
and colleagues. The first was to couple EGF to a fluorophore, to test if the 
EGF molecule was being internalized. Fluorescence microscopy was 
employed to track EGF, at 0˚C EGF was observed bound to the membrane of 
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the cells13. When the samples were warmed to 37˚C there was internalization 
of the EGF consistent with the hypothesis that EGF receptor (EGFR) was 
being trafficked with the ligand into the lysosome. Proof of this hypothesis 
came when EGF was coupled to ferritin. By electron microscopy the trafficking 
of the ligand could be traced through the endocytic pathway. After 30mins free 
pools of ferritin were observed by electron microscopy, as the ligand was 
released from the degraded receptor14.  
 
These experiments produced two major findings. First they 
demonstrated that there was a receptor on the plasma membrane for EGF, 
the surface levels of which were controlled by EGF binding through the endo-
lysomal system. Secondly, because the EGFR was taken into the cell bound 
to ligand, it suggests that this was one mechanism by which EGFR can reach 
intracellular targets. Indeed this point still has not been resolved today with 
numerous groups reporting conflicting information on the importance of EGFR 
signaling from the endosome, see section 1.2.4 for further discussion.   
 
1.1.3. EGFR is a tyrosine kinase. 
 
 By 1978 application of EGF had been demonstrated to increase cell 
growth and induce changes in DNA synthesis15, 16. However, it still remained 
elusive how the EGFR was able to induce these changes. At the time there 
was mounting evidence that phosphorylation was an important regulator of 
metabolic processes and that kinases existed on the plasma membrane, 
leading to the hypothesis that EGFR may function as a kinase17, 18. In a 
landmark paper from Carpenter et al. (1978)19, the authors demonstrated that 
EGFR was amenable to phosphorylation. They took membrane preparations 
of A-431 cells, which were known to express large quantities of EGFR and 
using P32-ATP they demonstrated a substantial incorporation of P32 into the 
membrane fraction of A-431 cells after EGF application. When these 
membrane samples were run on SDS gels, multiple phosphorylated bands 
were observed by autoradiography, two prominent bands at 150 and 170kDa 
stood out19. Subsequent work identified the prominent bands as the receptor 
itself. One possibility from these experiments was that the EGF receptor was 
	   	   	  	  
	   20 
both a kinase and the substrate. In support of this hypothesis, phosphorylation 
of the receptor could still be observed in affinity-purified preparations of 
EGFR20, 21.  
 The next question was, what type of phosphorylation was this? In 1980 
Tony Hunter and colleges demonstrated that pp60SRC was a tyrosine kinase22 
and in doing so demonstrated for the first time the existence of tyrosine 
phosphorylation. At the same time there was mounting evidence of the 
relatedness of pp60SRC to EGFR, as antibodies against pp60SRC specifically 
cross-reacted with EGFR, suggesting that they shared a similar structure23 It 
had been originally reported that EGF receptor preferentially phosphorylated 
threonine residues24, however this was artifact of the system used as 
threonine and tyrosine migrated at the same levels. After Tony Hunter and 
colleagues established a method to analysis pTryosine it became clear that 
EGF receptor was in fact a Tyrosine kinase25.  
 
1.1.4. The structure of EGFR  
 
  In 1984 Ullrich et al.26 cloned the cDNA sequence of EGFR revealing 
it’s primary structure. Partial sequences had been previously cloned by 
Downward et al. (1984)27 indicating that there was a close similarity between 
the v-erb-B transforming protein and EGFR. The cloning of EGFR revealed a 
single pass transmembrane protein that was indeed highly homologous to v-
erb-B. This was a major breakthrough for two reasons because it linked 
EGFR to a known oncoprotein encoded by a transforming virus, 
demonstrating a clear link between EGFR and cancer.  
 
From the sequence of EGFR two distinct domains were identified, an 
extracellular EGF binding domain and an intracellular kinase domain, which is 
homologous to the SRC family of kinases. What’s more, by cloning EGFR 
from pancreas cDNA and from A431 cells Ullrich et al. (1984)26 identified that 
part of the EGF recognizing domain of EGFR was deleted (in A431 cells)26, 
suggesting a mechanism by which the receptor activity is disconnected from 
the control of extracellular EGF. Also demonstrating for the first time a 
structural change in EGFR that was linked to development of cancer.  
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The identification of EGFR as a single pass trans-membrane protein 
raised a problem. How does EGF binding to the extracellular domain influence 
kinase activity of the intracellular domain? There was mounting evidence to 
suggest that EGFR could oligomerize and induce trans-phosphorylation. 
Yarden et al. (1987)28 provided several lines of evidence for an allosteric 
activation of EGFR. By crosslinking EGFR derived from solubilized membrane 
extracts of A431 cells with monoclonal antibody (mAb), there was an increase 
in the phosphorylation of EGFR and in the affinity for EGF. Conversely 
immobilizing EGFR on solid matrices prevented EGF from inducing 
phosphorylation of EGFR. This demonstrated that trans-	  phosphorylation was 
required for activation of the receptor.  
 
EGFR is part of a larger family of RTK called the ErbB family named 
because of their homology to the erythroblastoma viral gene29. There are four 
family members, ErbB1-4, that form a basic functional unit of a dimer29. The 
different monomers have differing signaling properties and ligands between 
different heterodimers, which increase signal diversity. ErbB1/EGFR recruits a 
number of scaffolds (Grb2 and SHC)30, which recruit and activate downstream 
RAS and the MAPK cascades (discussed later in this chapter). Activated 
ErbB1 also recruits Cbl, an E3 ligase which ubiquitylates and triggers the 
internalization of the receptor31. ErbB1 receptor however, does not contain 
any sites, which directly activate AKT, but is activated via RAS. ErbB2 is the 
preferred partner for heterodimers and can be considered as a non-
autonomous amplifier of the network as it is unable to directly bind EGF like 
ligands32. ErbB2 receptors also under go a slower rate of endocytosis and 
recycle back to the cell surface more frequently33. ErbB3 is kinase deficient 
but is however strongly tyrosine phosphorylated by hetro-dimerization. It lacks 
binding sites for Grb2 but can strongly activate PI3K signaling and is able to 
evade ligand-induced degradation34. ErbB4 shares many of the features of 
ErbB1, it is unclear whether it can recruit Cbl and it exhibits a slower rate of 
degrtion than ErbB133.  
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The question remained how was the oligomerisation of the receptor 
being driven. Was it through bivalent EGF bringing two receptors together or 
did EGF binding confer structural changes that increased the affinity of the 
receptors to dimerize? A clue for this mechanism is provided by the fact that 
hetrodimers of the ErbB family can be formed with ErbB2, which is not 
activated by any known EGF ligand.  
 
It is now recognized that dimerization is a common feature of RTK 
activation35. There are some notable exceptions to this rule for example 
Inuslin receptor that forms a stable dimer. Growth factor induced dimerization 
through a bivalent ligand occurs in the RTK family members for example the 
VEGF receptor, in the case with EGFR ligand binding induces conformational 
changes which are more important35. The extracellular domain is split into 4 
domains, crystallography studies have reveled that ligand binding unmasks a 
binding arm in domain 2, which is buried in an intermolecular interaction in 
domain 4 in unstimulated conditions, which is unique to EGFR within the 
family of RTKs. In an inactive confirmation the arm in buried by intramolecular 
interactions in a “tethered” confirmation, which is broken with ligand binding. 
When exposed the arm allows an EGFR molecule to bind to other ligand 
bound receptors (Figure 1.1)36.  
 
Structures of EGFR activation show that EGFR forms an asymmetric 
dimer where one receptor acts as an “activator” and the other as a 
“receiver”37. Contacts between the two receptors induce conformational 
changes in the N-lobe of the “receiver” receptor that disrupts auto-inhibitory 
interactions that are present in the monomer. These structural changes cause 
the “receiver” receptor kinase domain to adopt an active confirmation37. 
Providing supporting evidence for these structural studies, mutations in the 
auto-inhibitory interaction interfaces are found in non-small cell lung cancer 
patients (NSCLC)38 and cause constitutive activation of the receptor without 
ligand binding37.   
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Figure 1.1. EGFR activation. 
Ligand binding induces changes in the structure of EGFR that activates the intracellular 
kinase domain. Ligand binding exposes a binding arm unique to EGFR, which drives 
dimerization. The intracellular domain forms an asymmetric dimer; one molecule acts as an 
activator while the other acts as a receiver, contacts between the two receptors disrupt auto-
inhibitory interactions that are present in the monomer and lead to the exposure of the 
activation loop.  
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Structural studies on the EGFR molecule in the 1990s and 2000s 
provide a mechanistic understanding of the EGFR. By studying EGFR in 
different disease states they helped establish EGFR as an oncogene and 
provided valuable insights for the development of therapeutics against EGFR. 
In many ways the development of inhibitors against EGFR has been a 
success story in the treatment of cancer, especially from the perspective of 
basic research, which played a key role in drug discovery. EGFR inhibitors 
are currently being used in the clinic but as I will discuss later in this chapter, 
there are still challenges and opportunities to exploit EGFR and downstream 
targets therapeutically.  
 
1.1.5 The emergence of EGFR as a drug target 
 
 In the 80s and 90s there began to be compelling evidence to suggest 
that EGFR would be a good cancer drug target. EGFR had been linked with 
cell proliferation and demonstrated to be overexpressed in tumor cell lines39. 
The localization of the EGFR further increased interest, as a plasma 
membrane protein it was seen as particularly accessible to inhibitory mAb and 
small molecule inhibitors39.  
 
 Work from Mendelson and Sato lab’s was instrumental in establishing 
EGFR as a target to treat cancer. Gill et al. (1984)40 developed a panel of 
mAb that inhibited the binding of EGF to the receptor by at least 95%. When 
applied to membrane extracts of A431 cells they inhibited EGF 
phosphorylation and when applied to human foreskin fibroblasts inhibited 
proliferation. In 1984 Masui et al.41 raised another mAb against EGFR. Using 
a xenograft of A431 and T222 cells in athymic mice, they demonstrated that 
administration of the mAb prevented tumor formation. This had two important 
conclusions, first the amount of receptor on the membrane was not a 
determining factor of mAb inhibitory effects, as A431 cells had approximately 
100 fold more receptors then T222, therefore EGFR inhibition was not limited 
to cases of overexpression. The second was the demonstration in vivo that 
mAb had anti-proliferative activity providing proof of principle for 
immunotherapeutic agents against EGFR. In 1989 Phase 1 trials were 
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initiated for mAb against EGFR39. The aims of the studies were to define 
toxicity and pharmokinetics of antibodies. Using radiolabelled antibodies the 
trials were able to confirm that antibodies reached sites of presumed 
metastasis. Importantly, patients treated with the anti-mAb displaced no 
toxicity over 3x 1-hour infusions, at levels that would be expected to saturate 
the receptors. Patients did however produce an anti-mouse immune 
response39.  
 
These studies laid the groundwork for development of humanized mAb 
therapy to treat EGFR driven cancers. Cetuximab (partially humanized EGFR 
mAb) was approved by the FDA for the treatment of colorectal cancer42 and 
has since been approved for treatment of Head and neck cancer in 200643. In 
2006 FDA granted approval for a second immunotherapeutic therapeutic 
agent, Panitumumab (a fully humanized mAb) for the treatment of colorectal 
cancer44.  
 
1.1.6 EGF signaling: A layered network. 
 
 By the end of the 80s, research into the EGFR had reached a 
bottleneck. EGFR had been demonstrated to be a receptor tyrosine kinase 
but it was unclear how EGFR activation lead to increases in proliferation and 
differentiation. One possible explanation was through the observation that 
EGF caused changes in DNA synthesis16 but how EGFR activation could 
affect process in cellular compartments distinct from its own was unclear. 
Work from Cohen’s lab had documented that EGFR could enter the cell 
through the endo-lysosomal system24, which was proposed to be one 
mechanism how EGFR could reach intracellular targets. But to causes 
changes in DNA synthesis it was clear that the must be processing steps, to 
stimulate changes in the nucleus.  
 
 During the 80s there was a rapid expansion in the capabilities of 
molecular biology techniques. From this there was recognition that the genes 
encoded in many transforming virus had cellular equivalents (such as CRAF 
and PLC-ϒ)45. These genes in turn became known as proto-oncogenes; 
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genes that had potential to become oncogenic factors. It is also frequently 
observed that when many of these the cellular equivalents where aberrantly 
expressed in cells, they caused similar effects as the transforming virus. 
These results lead to the hypothesis that proto-oncogenes that similar effects 
to vERB led to the hypothesis that they may all function as part of a larger 
network. 
 
 The first breakthroughs for this hypothesis came in 1989. A raft of 
papers identified that phospholipase-C-ϒ (PLC-ϒ) was tyrosine 
phosphorylated in response to PDGF or EGF stimulation46. Subsequent 
papers found an association between PLC-ϒ and EGFR through its SH2 
domain that was dependent on the activation of the receptor47. A second 
oncogene CRAF (also known as Raf-1) was also found to associate with 
PDGF receptor (PDGFR) in a ligand dependent manner. Importantly the 
interaction between CRAF and PDGFR could be reconstituted in a cell free 
system, were pre-treatment of the PDGFR with phosphatase prevented the 
interaction48. These and other papers introduced the concept that there was 
second messenger signaling downstream of RTKs. 
 
 Also during the 80s, there were major breakthroughs in the 
biochemistry of the RAS proto-oncogenes, which are signaling hubs tying 
together many signaling pathways. RAS are a family of small GTPases which 
are cyclically bound GTP and GDP, when in the GTP bound form an effector 
binding domain is exposed which is masked in its GDP bound form, this 
domain enables it assemble signaling complexes and act as a molecular 
switch. RAS families of proteins have intrinsic GTPase activity, which allows 
them to hydrolyze bound GTP with the help of GTPase activating protein 
(GAP).  Satoh et al. (1990)49 found the first direct link between EGFR and 
RAS; they were able to demonstrate that when cells were stimulated with 
EGF, RAS was found in a GTP bound (active) form. Furthermore they found 
that RAS mutated at G12V was insensitive to EGF and constitutively bound to 
GTP49 as the mutation prevents GTP hydrolysis trapping RAS in it’s active 
GTP bound form50, 51. 
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 In the following decades two canonical signaling pathways have 
emerged (although this is by no means the only signaling pathways that are 
downstream of EGFR). The PI3K-AKT (AKT) and RAS-RAF-MEK-ERK 
(MAPK) signaling pathways have been associated with many of the 
oncogenic effects of EGF signaling. Each pathway is comprised of a tier of 
kinases that are activated through phosphorylation and in turn phosphorylate 
downstream kinases (Figure 1.1). Both of these pathways, each converge on 
two master kinases AKT and ERK, which influence the regulation of apoptosis 
and gene transcription respectively. Each kinase is able to target transcription 
factors, which alter gene expression that drive cellular events52.  
 
 During the late 1980s there were still questions about how protein 
networks were recruited through tyrosine phosphorylation. Work from Tony 
Pawson’s laboratory identified a non-catalytic SRC homology domain in the v-
Fps kinase (SH2)53, 54. SH2 domains were identified in distinct proteins whose 
common feature was that they were signaling proteins, which interact with 
tyrosine-phosphorylated proteins55, 56. SH2 domains emerged as a 
mechanism to explain how signaling proteins interact with tyrosine- 
phosphorylated proteins. Anderson et al.56 demonstrated that SH2 domains of 
PLC-ϒ and SRC were critical for their interaction with EGFR56. This helped 
provide a framework for how networks of signaling proteins can be brought 
together through interactions with phosphorylated proteins.  
 
The identification of downstream signaling greatly advanced our 
understanding how RTK exert their effects on the cell. It described how 
signaling networks could be mediated by tyrosine phosphorylation. In the next 
section I will discuss how one downstream signaling cascade, the MAPK 
pathway (Figure 1.1), has emerged as a driver of cancer and how detailed 
understanding of the pathway has lead to pharmaceuticals to treat cancer. 
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1.1.7. Negative regulation of EGF signaling  
 
 EGF signaling is a dynamic process and as such there are multiple 
levels of negative feedback57. Discussed here are 3 ways in which EGF 
signaling can be negatively regulated, through phosphatases, through 
transcriptional responses and scaffold proteins that hold kinases in inactive 
confirmations. 
  The kinase action of EGFR can be apposed by phosphatases, several 
phosphatases have been identified that directly dephosphorylate and 
inactivate signaling components downstream of EGF. Examples would be 
PHLLP58 and PP2a59 phosphatases that dephosphorylate AKT at position 
S473 a site, phosphorylated by mTOR and required for AKT to adopt an 
active confirmation and T308, opposing the activating action of PLCγ 
respectively. In the MAPK pathway PP1 and PP2A can directly 
dephosphorylate MEK kinase and dual specificity phosphatases (DUSPs) 
such as MKP3 can inactivate by apposing the activating action of ERK 
phosphylation as well as other MAPKs, JNK and p3860. Many of the DUSPs 
are immediate early genes (IEG), which are transcribed rapidly after MAPK 
action. In this way, action of ERK can establish negative feedback loops 
which attenuate MAPK signaling61. Unbiased approaches to identify 
phosphatases involved in oncogenic RAS signaling identified several 
additional phosphatases that contribute to MAPK and AKT signaling, such as 
PTPN2 and PTPRJ, however, the mechanism of action are yet to be 
established62. 
 Phosphatases can be recruited directly to EGFR itself via SH2 domains 
which interact with pTry on the activated receptor such as, PTPN6 and 
PTPN1135. Phosphatases can also regulate EGFR activity by regulating 
internalization into MVBs, PTP1B is a tyrosine phosphatase located on the 
cytoplasmic face of the ER. It’s localization means that endocytosis is 
required for an interaction with EGFR to be possible; therefore it allows its 
phosphatases action is restricted to a pool of EGFR that is undergoing 
ESCRT mediated sorting. Functional studies have confirmed this 
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demonstrating that PTP1B activity is required for sorting of EGFR into 
MVBs63.  
 In addition to kinase and phosphatase there are a several other 
inhibitors of EGF signaling which regulate signaling complexes. The RAF 
kinase inhibitor protein (RKIP) is an example of a scaffolding protein that 
inhibits interactions between RAF kinase and downstream MEK kinases64. 
Sproty (SPRY) is another example of a negative regulator that can regulate 
signaling by interfering with formation of Grb2-SOS complex downstream of 
EGFR (figure 1.1)57, 65-67. 
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Figure 1.2. The EGF signaling cascade. 
EGF binding to its receptor at the plasma membrane initiates an activating auto-
phosphylation event, which then initiates downstream signaling cascades.  Activating 
phosphylation events can be apposed by phosphatases. Numerous scaffolds have been 
identified which can play both positive and negative regulating cell signaling. The two 
canonical pathways downstream of EGFR are annotated here, the RAS-RAF-MEK-ERK 
pathway which drives changes in cell proliferation through changes in gene transcription and 
the PLC-γ-PI3K- AKT pathway that drives changes in survival. 
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1.1.8. The MAPK pathway: A driver of cancer. 
 
 There has been a rapid increase in our understanding of how 
downstream signaling from the EGFR contributes to cancer in the last 
decade. The MAPK cascade has become a good example of where a 
molecular understanding has enabled the development of personalized 
medicine to treat cancer. As with the EGFR pharmacological intervention of 
the MAPK pathway has provided both opportunities and challenges. 
 
 In 1999 Hoshino et al.68 demonstrated using phospo-specific 
antibodies against activated ERK 1/2, that hyper activation of the MAPK 
pathway occurs in approximately 35% of tumor cell lines tested. Interestingly 
a tissue specific pattern emerged from the study; hyperactivation was 
frequently observed in pancreas, colon, lung, ovary and kidney but 
infrequently observed in brain, stomach, liver and cells derived from 
hematopoietic origin also had a lower frequency. Hyperactivation of ERK 1/2 
was correlated with activation of CRAF and MEK, even in cases with no RAS 
mutation68. This indicated hyperactivation was not necessary due to mutation 
of the MAPK or RAS but rather due to deregulation RAF/MEK kinases (Figure 
1.1).  
 
 It has been long known that components of the EGF signaling pathway 
could transform cells from work on transforming viruses (v-RAF, v-SRC, 
vERB)45. However there remained questions as to whether these exogenous 
forms of EGF signaling proteins were endogenously misregulated in cancer. 
Activating mutations in the EGFR signaling pathway were known since the 
cloning of EGFR from A-431 cells and since then approximately 15% of 
tumors have been demonstrated to carry activating RAS mutations26. In 2002 
Davies et al.69 demonstrated that BRAF was mutated in approximately 66% of 
melanomas and at lower frequency in other cancer types. Other cancer types 
with significant levels of BRAF mutation are papillary thyroid cancer (36%-
53%) and colorectal cancer (5%-22%)69. In melanoma mutations all fell in the 
kinase domain of BRAF, the most common mutation being BRAFV600E 70. 
BRAFV600E mutants are 500 times more activate in vitro71 and in NIH3T3 cells 
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stimulated proliferation and transformation through constitutive activation of 
ERK72. This highlighted tissue specific EGF signaling mutation.  
 
In vivo BRAFV600E mutations are commonly found in benign skin lesions 
known as naevi and in premalignant polyps in the colon73. Using a knock-in 
BRAFV600E mouse, which was expressed from one of the endogenous allele, 
the Marais lab demonstrated that conditional expression BRAFV600E induced 
the formation of naevi and induced melanocyte senescence73. This study 
established BRAF mutation as a founder event in the development of 
melanoma. Mice expressing BRAFV600E developed melanoma more quickly 
than mice expressing H-RASG12V after 6 months. 3% of H-RASG12V expressing 
mice versus 11% of BRAFV600E expressing mice, developed melanoma by 6 
months. After 14months 64% of mice expressing BRAFV600E had developed 
melanoma 73. The study suggested a model were BRAFV600E could induce the 
formation of naevi and melanocyte senescence, however another gene 
mutation would then be needed to overcome the senescence. 	  
BRAF emerged as an oncogene in melanoma with had 
pharmacological potential. Work studying the molecular biology and structure 
of BRAF in the last decade has led to the development of BRAF kinase 
inhibitors to treat melanoma that are proving successful in the clinic, for a 
disease which there has been little pharmacological success74. This work also 
provides a paradigm for how studying the molecular biology of EGF signaling 
cascade, has unveiled drug targets in tissue specific cancers.  
 
1.1.9. The development of tyrosine kinase inhibitors: New opportunities and 
challenges.  
 
During the late 80s and 90s there was overwhelming evidence for the 
importance of kinases in the regulation of cancer-associated pathways. 
However there was resistance from many to the notion of kinase inhibitors 
largely because a perceived notion that it would be difficult to achieve 
sufficient specificity75. Secondly because the intracellular concentration of 
ATP was very high (mM range) raising questions over whether drugs could by 
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developed with sufficient affinity to overcome this. Although are still very real 
challenges, however both of these problems have been overcome through 
exploiting additional hydrophobic pockets that exist around the ATP binding 
pocket75. 
 
 In 1988 Yaish et al.76 synthesized the first tyrosine kinase inhibitors.  
They were able to develop a number of compounds showing specificity 
towards EGFR with three orders of magnitude compared to the insulin 
receptor.  Importantly a number of the compounds effectively retarded EGF 
dependent cell proliferation in A431 cells. This study provided a proof of 
principle, that small molecule inhibitors of tyrosine kinases could be an 
effective way of inhibiting EGF dependent proliferation.  
 
 Exploiting the known structure of EGFR, Ward et al. (1994)77 
developed new classes of tyrosine kinase inhibitor. It had been found that 
EGFR formed a ternary complex with ATP and the substrate proteins. EGFR 
interacts with the protein substrate at Arg817 through a carboxylate group 
which deprotonates the tyrosine hydroxyl of the substrate, activating it as a 
nucleophile. The activated tyrosine group is then able to attack the ϒ-
phosphorus of ATP. Ward et al. (1994)77 devised a strategy to search 
compound libraries for structures that would mimic ATP ϒ-phosphate, tyrosyl 
hydroxyl and tyrosyl aromatic ring, which all interact tightly with the enzyme 
during catalysis. Using this strategy 4-(3-chloroanilino) quinazoline (CAQ) was 
identified as a competitive inhibitor of ATP binding to EGFR. This strategy of 
targeting the ATP binding pocket of kinases has since become a favored 
strategy by many pharmaceutical companies when designing kinase 
inhibitors75.   
 
 Imatinib was the first tyrosine kinase demonstrated to be clinically 
effective. Imatinib was designed as a treatment chronic myeloid leukaemia 
(CML) a disease characterised by a translocation between the long arms of 
chromosomes 9 and 22. This results in a fusion protein of BCR-ABL a 
constitutively active tyrosine kinase receptor that is able to drive CML and is 
dependent on the tyrosine kinase activity of the BCR-ABL. The first phase 1 
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trial for Imatinib in patients with CML reported potent antileukemic effects. 
Kinase inhibitors have now been produced against several target kinases and 
have been improved for the treatment of various cancers.  
 
Gefitinib another tyrosine kinase inhibitor that targets EGFR, has been 
developed and approved for the treatment of non-small cell lung cancer and 
colon cancer. Vemurafenib another competitive ATP antagonist has been 
developed and was approved by the FDA in 2011 for treatment of 
unresectable or metastatic melanoma were the patient is harbouring a 
BRAFV600E mutation. The development of these inhibitors has demonstrated 
that rational design and application of tyrosine kinases could be used to treat 
cancer. However a trait seen with many kinase inhibitors is the emergence of 
resistance after prolonged treatment and intrinsic resistance in caused by 
different genetic backgrounds. These challenges represent some of the 
biggest hurdles today in developing effective drugs to treat cancer.  
 
1.1.10. Overcoming resistance 
 
 There are multiple mechanisms underpinning resistance to inhibitors. 
They can be split into intrinsic mechanisms, where different genetic 
backgrounds produce unanticipated effects and acquired mechanisms. An 
acquired mechanism is were cells gain new mutations to develop resistance.  
A common mutation seen in kinases is the mutation of the gatekeeper 
threonine residue, which has been exploited by many kinase inhibitors for 
specific binding in the ATP binding pocket78. One of the disappointing features 
of BRAF and MEK kinase inhibitors has been the rapid onset of resistance79. 
Detailed molecular studies have addressed why some patients and cancers 
types with activating BRAF mutations, do not respond well to BRAF inhibitor.   
 
 BRAF activating mutations are also common in colon cancer but 
patients are largely unresponsive to BRAF inhibitors. Using a siRNA screen to 
identify secondary targets that could sensitize colon cancer cells lines to 
BRAF inhibitors Prahallad et al. (2012)80 identified EGFR as target. With 
further investigation the authors found that BRAF inhibition was causing a 
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feedback loop by driving the suppression of CDC25C, a phosphatase that 
negatively regulates EGFR. This in turn caused an increase in the activity of 
EGFR and downstream signaling through the AKT signaling pathway. This 
mechanism of resistance is not seen with melanoma cells due to the 
differences in expression levels of EGFR, colon cells express EGFR at high 
levels while melanocytes express EGFR at relatively low levels80. This study 
provides another example of the benefits of dual therapy in overcoming 
resistance to kinase inhibitors.  
 
 Probably the best-characterized example of resistance to BRAF 
inhibitors is the so-called BRAF inhibitor paradox. The underlying principle to 
this resistance is attributed to the mechanism of activation of the RAF 
kinases. RAF kinases are activated through dimerization; this can be through 
heterodimers that are combinations of ARAF, BRAF, CRAF and the RAF like 
pseudo-kinase KSR81. Activation is not driven through trans-phosphorylation 
but rather dimerization cause RAF kinases to adopt an active confirmation 
that is then stabilized by phosphorylation81. This effect is highlighted by the 
oncogenic BRAFE558K mutation that falls outside the kinase domain. Instead 
functioning by promoting dimerization with, and activation of CRAF.   
 
In Melanoma cell lines that harbor mutations in NRAS (20%) or KRAS 
(2%) inhibition of BRAF results in a paradoxical activation of MAPK signaling. 
A raft of papers in 2010 detailed the molecular mechanism that underlies this 
paradoxically activation82-84. In the presence of oncogenic RAS, BRAF is 
maintained in an inactive confirmation in the cytosol through an auto-
phosphorylation event. When the kinase activity of BRAF is inhibited, 
oncogenic RAS now promotes its recruitment to the plasma membrane where 
it can form heterodimers with CRAF and act as a scaffold promoting MAPK 
signaling through CRAF84. 
 
 Dysregulation of the EGF signaling pathway is major factor in the 
pathogenesis of many cancers. Pharmaceuticals have been developed to 
modulate the EGF signaling pathway, which are now having success in the 
clinic. However, as with many anti-cancer therapies, drugs resistance is a 
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major issue, the strategy of dual therapy is one potential avenue to overcome 
resistance. Future therapeutic strategies will rely on understanding the 
mechanisms of modulators of pathways and cross-talk between pathways.  
 
1.2. Control of EGFR endocytic trafficking and signaling by reversible 
ubiquitylation. 	  
1.2.1 Ubiquitin  
 
 Ubiquitin is a 76 amino acid polypeptide that is attached to a substrate 
through the sequential action of E1, E2, E3 cascade. Ubiquitin moieties are 
covalently attached to a substrate via an isopepide bond, between a lysine 
molecule of the substrate and the COOH terminus of ubiquitin85. Ubiquitin is 
conjugated to a substrate in a three step process, first ubiquitin in adenylated 
and conjugated to an E1 enzyme via a thioester bond to the catalytic cysteine 
residue. The ubiquitin is then transferred onto an E2 enzyme that binds the 
ubiquitin via a second thioester bond. The ubiquitin molecule can then be 
either directly transferred onto a substrate with the aid of a RING E3 ligase86 
or transfer the ubiquitin onto a HECT E3ligase, which then transfers the 
ubiquitin onto the substrate (figure 1.2)87. E3 ligases are the more numerous 
than the E1 or E2 components and form the substrate-recognizing component 
of the system.  	  
A single ubiquitin molecule can be extended to a chains of ubiquitin 
built from any of the 7 internal lysines of ubiquitin. This allows chains with 
different topologies to be built. The nature of these chains means that they 
adopt different steric distributions producing additional levels of complexity88. 
Building chains of ubiquitin has two major advantages over mono-
ubiquitylation; it increases the avidity between the ubiquitylated protein and 
the ubiquitin interacting protein. Secondly, it adds an additional layer of 
specificity, as each chain linkage can encode different signals, the complexity 
of ubiquitin chains can be further complicated by the existence of mixed and 
branched chains89. For this reason ubiquitylation can be thought of as a more 
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complex signal than phosphorylation. Quantitative mass spectrometry studies 
in Hek293t cells have demonstrated that Lys48 (52%) and Lys63 (38%) are 
the most abundant chains in the cells. While Lys29 (8%), Lys11 (2%) account 
for significant populations, Lys6, Lys27, Lys33 and linear ubiquitin represent 
0.5% or less of the total population of chains90.  However, it should be noted 
that abundance of chains is not necessarily linked to importance, for example 
linear chains play an important role in regulating the NfKB pathway91, 92. 
 
1.2.2. The Function of proteasomal DUBs 
 
  The proteasome is a major site for degradation of proteins in the cell93. 
It primarily recognizes substrates via ubiquitin chain linkages and has a 
preference to bind mutli-ubiquitinylated proteins94. It is a large multimeric 
complex composed of a regulator 19s particle and a core 20s particle formed 
from a stack of ATPase ring complexes in a barrel shape. Substrate proteins 
are captured by the regulatory protein and translocated into the central pore of 
the regulatory core where they are hydrolysed94. In order for substrate 
proteins to be transferred into the 20s core particle proteins need to be 
unfolded to enable them to pass through tight pores between the stacks of 
ATPases. Unfolding is generally performed within the 20s particle and 
translocation and unfolding are generally considered coupled events94.  
 
In eukaryotes there are 3 DUBs that are associated with proteasome, 
UCHL5, RPN11 and USP14. The DUBs perform 2 major functions to regulate 
the substrate-proteasome interaction and to maintain the cellular levels of 
ubiquitin94. In S. Cerevisiae deletion of Ubp6 the ortholog of USP14 causes 
pleiotorpically stress-sensitive as a consequence of ubiquitin depletion95. The 
proteasomal DUBs each belong to separate families (UCH, JAMM and USP 
respectively) and have distinct evolutionary origins. The deubiquitylating 
activity of RPN11 promotes degradation of substrates96, ubiquitin is a very 
stable proteins and retains its structure even with large fluctuations in pH and 
heat, therefore ubiquitin chains need to be removed before the substrate can 
pass through the central pore and be hydrolyzed97. In contrast to RPN11, 
siRNA mediated depletion of UCHL5 and USP14 increases the rate 
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degradation of substrates98, 99. The activity of RPN11 is thought to occur once 
a substrate has been committed to degradation while the activity of USP14 
and UCHL5 is thought to occur once the substrate is docked onto the 19s 
regulatory particle94. The second distinction is that RPN11 differs for the other 
two in that it is able to cleave at the base of ubiquitin chain where UCHL5 and 
USP14 trim from the distal end of the chain. Increased chain length increase 
the affinity between the chain, it has been proposed that by trimming the 
length of the chain from the distal end, UCHL5 and USP14 can fine tune the 
life-time of the proteasome-substrate interaction100. USP14 and UCHL5 also 
have non-catalytic activities at the proteasome. Binding of ubiquitin to USP14 
and UCHl5 can open the gate of the 20s particle101 and can stimulates the 
activity of ATPase activity of the proteasome102.  
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Figure 1.3. The ubiquitylation cycle.  
Ubiquitin is encoded by 4 separate genes ubiquitin is transcribed as a fusion protein and 
needs to be processed by deubiquitylases (DUBs) to produce free ubiquitin. Ubiquitin is 
conjugated to a substrate by the sequential action of E1, E2, E3 cascade. This is apposed by 
the action of DUBs.  
	   	   	  	  
	   40 
1.2.3 Endocytosis of EGFR 	  
 The surface expression of many plasma membrane proteins such as 
EGFR is regulated through the endo-lysosomal pathway. It has been known 
since the 1970s that activated EGFR is internalized and degraded via the 
lysosome12. This couples the control of plasma membrane levels of EGFR to 
the extracellular concentration of EGF and prevents excessive signaling. 
Reversible ubiquitylation is an important mediator of EGFR trafficking. 
Ubiquitylation is a reversible post-translational modification that can regulate 
the degradation of proteins at all the major sites degradation in the cell93.   
 
Activated EGFR is ubiquitylated and internalized either via clathrin-
coated vesicles or through clathrin independent mechanism103. The route of 
internalization appears to be dependent on the concentration of the EGF the 
cells are exposed to103. Upon receptor activation c-Cbl an E3 ligase is 
recruited and ubiquitylates EGFR. The receptor is then internalized and 
delivered to the sorting endosome via direct fusion of the transporting 
vesicles. Where mono-ubiquitylation can mediate the internalization of the 
receptor, Lys63 linked chains are required for the sorting of cargo at the 
endosome104. Once EGFR reaches the sorting endosome, there are two fates 
that are possible, either the receptor is trafficked back to the plasma 
membrane via the recycling endosomes or it is internalized in the intra-luminal 
vesicles (ILV) in the multi-vesicular body (MVB). Internalization into ILV is 
mediated through the ESCRT complex105. ESCRT0 component recognize 
ubiquitylated proteins via ubiquitin interacting motifs and through sequential 
action of the ESCRT machinery, trans-membrane proteins are internalized 
into ILV. Internalization of cargo into ILV is often seen as the point of no 
return. MVBs are then able to fuse with lysosome releasing their contents into 
the lumen of the lysosome (figure 1.2)105.   
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Figure 1.4. The endocytic pathway.  
Activated EGFR is internalized into the endocytic compartment. Once EGFR reaches the 
sorting endosome there are two outcomes, either the receptor is recycled back to the plasma 
membrane or the receptor is recognized by the ESCRT complex and internalized into intra 
luminal vesicles of the multi-vesicular body (MVB). The MVB can then fuse with the lysosome 
transferring its contents. The receptor is degraded in the lysosome by lysosomal proteases. 
The DUB ASHM removes Lys63 ubiquitin chain from EGFR rescuing it from lysosomal 
degradation. The ESCRT machinery recognizes and internalizes ubiquitylated EGFR in ILVs, 
this process is aided by USP8.  
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Conjugation of a single molecule of ubiquitin to a membrane protein is 
sufficient to induce internalization and targeting to the MVB. However, Lys63 
linked chains can more efficiently sort proteins89. Mass spectrometry studies 
have implicated all chain configurations to some extent in targeting proteins 
for degradation by the proteasome, except for Lys63 chains, which are 
generally thought to implicated in non-proteasomal functions of ubiquitin and 
Lys63 are not accumulated after proteasomal inhibition90. Comparisons of 
Lys63 versus mono ubiquitylation on the trafficking of GAP1 permase reveled 
that mono-ubiquitylation is sufficient to trigger internalization but Lys63 
ubiquitylation was required for sorting at the MVB106. Furthermore, Huang et 
al. (2013)104 generated chimeras of EGFR and AMSH (Lys63 specific 
deubiquitinases) which had depletion in the levels of conjugated Lys63 chains 
and a modest increase in mono-ubiquitylation and Lys48 chains compared to 
the wild type EGFR. The chimera could still undergo internalization but there 
was delay in receptor degradation and an increase in MAPK signaling, 
providing direct evidence for the importance of Lys63 chains in endosomal 
trafficking of EGFR104.   
 
1.2.4 ESCRT pathway 
 
 The formation of MVBs is a key step in the sorting of cargo into 
lysosomes. George Palade and Keith Porter first reported the existence of 
MVB, describing them as “two large vesicles with smaller vesicles inside”107, 
108. Later work, described previously in this chapter by Stanley Choen and 
colleagues described how stimulated EGFR receptor was internalized into 
MVBs but it wasn’t until 2001 that the Endosomal Sorting Complex Required 
for Transport (ESCRT) were determined109. First ESCRT complex to be 
identified was ESCRT-I109 and a year later two papers were published 
describing ESCRT-II and ESCRT-III110, 111.  
 
In total there are there are 5 ESCRTs, which have two major functions 
first to recognize and sort cargo into the ILVs and secondly to form ILVs 
through the deformation of lipid membranes. The ESCRT complexes can be 
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broadly split into three steps112. ESCRT-0 is the cargo recognition component, 
ESCRT-II brings ESCRT-III is involved in the maturation of the ILV and 
recruitment of DUBs to deubiquitylate cargo and finally VPS4 disassembles 
the complex from the membrane112.  
  
Ubiquitin is an important signal for the sorting of cargo into MVB and to 
this end multiple components of the ESCRT machinery (ESCRT0, I and II but 
not ESCRT III) contains distinct ubiquitin interacting motifs113. The Ubiquitin 
interacting motifs are low affinity ranging from 100µM-500µM, ESCRT0 
posses multiple ubiquitin interacting motifs which facilitates it’s function as a 
cargo recognition complex113. ESCRT0 is composed of two subunits in 
eukaryotes, HRS and STAM1/2, HRS contains UIM domain composed of a 
single alpha-helix that can interact with two molecules of ubiquitin. ESCRT-I 
binds Ubiquitin through an ubiquitin E2 variant (UEV) domain which has a 
similar structure to E2-ubiquitin conjugating enzyme114, 115. Most ubiquitin 
binding domains recognize the Lle44 hydrophobic patch of ubiquitin, UEV 
domain however can recognize an additional hydrophilic patch based around 
Gln62 of ubiquitin115. ESCRT-II is able to recognize ubiquitin via a GLUE 
domain that binds ubiquitin along the edge of beta sandwich motif. ESCRT 
proteins also contain domains that allow them to bind with clathrin which aids 
in cargo recognition116.  
 
1.2.5. Ubiquitin interacting domains 
 
 The ubiquitin conjugating system can be thought of as the writer. The 
reader in which decodes ubiquitin signals are ubiquitin interacting motifs 
(UIM). Most UIM-ubiquitin interactions are mediated through the hydrophobic 
patch on ubiquitin Leu8, Ile44 and Val70 in the beta sheet of ubiquitin. As 
most UIM target the same surface of ubiquitin the specificity is defined by the 
chain topology117. In solution different ubiquitin chains topologies can adopt 
different states with and chains can fluctuate between different states. The 
equilibrium between different states can be driven in a specific different 
direction by UIM motifs, which trap ubiquitin chains in different states118. For 
example linear and Lys63 linked chains adopt an open confirmation while 
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Lys48 chains adopt a closed confirmation. This provides a rational for 
understanding how different chain topologies can generate different signalling 
outcomes.  
 Hrs (Hepatocyte receptor substrate) is a member of the ESCRT 0 
complex. Hrs recognizes ubiquitylated cargo entering the sorting endosome 
through an UIM. Hrs concentrates ubiquitylated material on the limiting 
membrane of the sorting endosome via its UIM and engages ubiquitylated 
cargo with the ESCRT machinery. Deletion of the UIM in HRS and depletion 
of HRS prevents the internalization of EGFR and into the lumen of MVBs119.  
 
 
 
Figure 1.5. SH2 and UIM interacting domains  
 
SRC homology 2 (SH2) domains mediate interactions between tyrosine-phosphorylated 
proteins and their interactors. Ubiquitin interacting motifs (UIM) mediate interactions with 
ubiquitylated proteins and their interactors; avidity of the ubiquitin:interactor binding can be 
increased by additional UIM domains that can bind to chains of Ubiquitin. 
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1.2.6. The importance of endocytosis for EGFR signaling. 
   
 The signaling function of EGFR internalization has been the subject of 
intense debate since its discovery in the 1970s. The topology of the receptor 
means that the kinase domain will face the cytosol during the internalization 
and can bind downstream signaling molecules until it is internalized into intra-
luminal vesicles of MVBs and the kinase domain is finally sequestered away 
from the cytosol. Experiments to elucidate the relationship between 
endocytosis and signaling have been complicated by the fact that receptor 
activation effects endocytosis and that many signaling proteins also have 
endocytic functions. This makes it difficult to design experiments that perturb 
one system and not the other120.  
 
 Endocytosis can attenuate EGFR signaling in a number of ways. By 
regulating the abundance of EGFR at the plasma membrane, endo-lysosomal 
pathway can directly influence the strength and duration of EGFR signaling. 
Receptor down regulation may not determine the maximal signaling but can 
shift the dose response curves so that a higher concentration of ligand is 
required to reach achieve a maximal response. Endocytosis can also remove 
the EGFR away from its downstream effectors120. PI3K signaling is increased 
through disruption of endocytosis because the components of the PI3K are 
localized to the plasma membrane; internalization of EGFR physically 
removes EGFR and decrease EGFR signaling121. Counter this MAPK 
scaffolds are recruited on the endosomes and can maintain signaling from this 
compartment122, 123.   
 
  The consequence of endosomal signaling is not fully understood. 
Studies analyzing gene transcription downstream of EGFR, found little 
difference on the transcription profile in cells depleted of Hrs to retain EGFR 
on the limiting membrane of MVBs. Conversely depletion clathrin heavy chain 
and dynamin 2 to prevent internalization of the receptor internalization caused 
an increase in the transcriptional out put of EGF pathway124. Using phospho 
proteomics Omerovic et al. (2013)125 found that 40% of EGF responsive 
phospho site were sensitive to inhibition of endocytosis, however, this means 
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that the majority of sites were unaffected by inhibition of endocytosis126. After 
decades of research on this question the true significance of EGFR signaling 
from the endocytic compartment is still not fully understood due to limitations 
in technology.  
 
1.2.7. DUBs in EGFR trafficking.  
 
Ubiquitylation is apposed by the action of group of enzymes known as 
deubiquitylase (DUB) that catalyze the removal of ubiquitin from a substrate. 
Deubiquitylase perform 3 major functions in the cell, the first is to process 
ubiquitin that is transcribed as linear fusion protein with multiple copies of 
ubiquitin or fused to a ribosomal protein. The second is to maintain cellular 
pools of ubiquitin by removing ubiquitin from proteins committed to lysosomal 
or proteasomal degradation. Finally, DUBs function to rescue proteins from 
degradation by removing ubiquitin before a commitment to degradation (figure 
1.3)127.  
 
There are approximately 90 DUBs encoded in the genome that are split 
across 5 families, Ubiquitin specific proteases (USP), ovarian tumour 
proteases (OTUs), Ubiquitin carboxy hydrolases (UCH), Josephins (JOS), and 
the JAB1/MPN/MOV34 family (JAMM). The first four are cysteine proteases 
while the JAMM family are metalloproteases and they differ in there 
mechanism of action, see Clague et al. 2013128 for a review addressing this. A 
number of DUBs have been implicated in the trafficking of plasma membrane 
proteins, traversing the endo-lysosomal pathway. The two best characterised 
endosomal DUBs are AMSH and USP8105.  
 
AMSH is a Lys63 specific DUB belonging to the JAMM family. A 
proportion of AMSH is localised on the endosome, with pools in the cytosol 
and nucleus129. However, only endosomal functions of AMSH have been 
reported to date. Depletion of AMSH via siRNA leads to an increase in the 
rate of degradation of EGFR129. AMSH has been proposed as a mechanism 
for rescuing incoming ubiquitylated proteins into the sorting endosome and 
owing to its specificity, it is unlikely that AMSH plays a role rescuing proteins 
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from proteasomal degradation. AMSH knockout mice die after 3 weeks, and 
display a loss of hippocampal neurons and atrophy in the cerebral cortex 
reminiscent of EGFR knockout mice130. A homolog to AMSH, AMSH-lp, also 
has an endosomal localisation and like AMSH has specificity for K63 chains. 
Endosomal functions of AMSH-lp are relatively unexplored with early studies 
suggesting that AMSH and AMSH-lp will have separate roles on the 
endosome131. 
 
USP8 belongs to the USP family of DUBs and shows no preference for 
any chain linkage. USP8 has an endosomal localisation that shows a 
dependency on the activation of EGFR; under serum starvation conditions 
USP8 is largely cytosolic and is recruited onto endosomes with EGF 
stimulation132.  Depletion of USP8 causes an accumulation of cellular levels of 
ubiquitin and predominantly on endosomes as judged by 
immunofluorescence133. However, there is conflicting evidence on the 
phenotype of depletion of USP8 on the rate of degradation of EGFR is 
dependent on the degree of and time of depletion. Some researchers 
reporting an increase in EGFR degradation with USP8 depletion134, while 
other researchers, including work from our laboratory132, 135, 136, have shown a 
delay in EGFR degradation with USP8 depletion. This delay in degradation is 
coupled with a loss of the ESCRT0 complex and ultrastructural studies have 
indicated there is a delay in the sorting of EGFR into ILV with USP8 knock 
down. This effect appears to be a delay in sorting and after a longer time most 
EGFR is trafficked to the lysosome137. USP8 has been identified as a drug 
target to overcome Gefitinib resistance in lung cancer138. But there still remain 
questions about how USP8 affects EGFR trafficking and this can how best 
this can be exploited pharmacologically.  
 
USP2a is another DUB that has been localised to the early endosomal 
compartment using immunofluorescence and cell fractionation. 
Overexpression studies of USP2a indicate that USP2a prevents the recycling 
of EGFR in Rab11 positive endosomes139. Other DUBs that have not been 
reported as endosomal can also influence EGFR trafficking. In a family wide 
siRNA screen to identify DUBs that increase the rate of EGFR degradation. 
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Cezanne was identified; Cezanne specifically regulates the degradation of 
EGFR and not another RTK c-MET and depletion of Cezanne leads to a 
decrease in the ubiquitylated species of EGFR140. However, the localisation of 
this interaction is unclear, as Cezanne has been reported to have a non-
restricted localisation. USP12 and USP46 are two highly related DUBs that 
have both been implicated in the trafficking of plasma membrane proteins, 
Notch receptor141 and GluR1 respectively142, through the endo- lysosomal 
pathway. What is not clear is if USP12 and USP46 specifically regulate notch 
and GluR1 trafficking respectively or if they play more general roles in 
endocytic trafficking.  
 
Ubiquitylation is an important mediator of endocytic trafficking of 
EGFR. While endo-lysosomal trafficking of EGFR is crucial to regulate the 
plasma membrane levels of EGFR, it is still not clear what is the signalling 
significance of EGFR trafficking. Several DUBs have now been identified as 
regulator of plasma membrane trafficking. However, there are still questions 
over the specificity and mechanisms of action.  
 
1.3. Retrograde trafficking. 
 
 Internalisation in the ILV of the MVB is often viewed as the point of no 
return before degradation in the lysosome89. Recycling of proteins via 
retrograde transport from the MVB to the TGN, provides one mechanism to 
prevent lysosomal degradation143. Retrograde transport has been implicated 
in various pathologies and the pathway is utilised by pathogens such as HIV 
and toxins such as Shiga, cholera and ricin144. Components of the pathway 
are mutated in a subset of Parkinson’s disease and diabetes patients145 146. 
One of the best-characterised physiological roles for retrograde transport is 
the delivery of newly synthesised acid hydrolases from the TGN to endo-
lysosomal pathway. Acid hydrolases are actively sorted at the TGN by the 
mannose 6-phosphate receptors (M6PR) and delivered to the endosomes via 
clathrin-coated vesicles. The receptor is then trafficked back the TGN through 
the retrograde pathway allowing it to pick up more cargo, if the retrograde 
trafficking pathway is disrupted then there is no longer active sorting at the 
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TGN and the acid hydrolases are secreted into the extracellular environment 
via bulk flow147. 
 
The components that are required for the different aspects of 
retrograde trafficking are beginning to be identified. For retrograde transport to 
occur there needs to be several steps, cargo recognition, tubulation of the 
membrane, scission of the membrane and endosomal budding (figure 1.4.)148. 
The cargo recognition components of the retrograde pathway were identified 
through genetic screens in Saccharomyces cerevisae, characterising vaculor 
protein sorting mutants (VPS).  Through these studies VPS10 was identified 
as a receptor delivering newly synthesised vacuolar hydrolases from the TGN 
to the vacuole, VPS10 mutants were characterised by secretion of vaculor 
hydrolase in to the extracellular environment. Although there is little sequence 
similarity, VPS10 functions as the Saccharomyces cerevisae equivalent to the 
mammalian M6PR. Genetic studies revealed that VPS35, VPS29 and VPS26 
exhibited the same defect in vacuolar hydrolases sorting, and subsequent 
work has shown that they form the cargo recognition complex of the 
retromer149. Through crosslinking experiments VPS5 and VPS17 were 
identified as part of the complex150. They are SNX-Bar proteins also called 
SNX1 and SNX2, which function to sense membrane curvature and help 
deform membranes of the endosome151, 152.   
 
The WASH complex is necessary for the tubulation of membranes from 
the MVB153. WASH is a member of the Wiskott-Aldrich syndrome protein 
(WASP) family. WASP proteins bind actin and Arp2/3 complex to stimulate 
the nucleation of actin153. WASH is recruited on to endosomes in a complex 
with at least 5 other co-factors, CCDC53, FAM21, SWIP and Stumpellin, 
collectively called the WASH regulatory complex (SHRC)153-155. Though the 
WASH complex, F-actin is nucleated on the endosome providing the force 
required for the formation of tubules. WASH activation can be promoted by 
several signalling molecules among them is SRC kinase156, although WASH 
is thought to be dispensable for EGFR trafficking153. In 2013 Hao et al.157 
established the MAGE-L2-TRIM27 E3 ligase complex, localises to 
endosomes and stimulates retrograde transport through the Lys63 
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ubiquitylation of WASH. Disruption of WASH ubiquitylation inhibited 
retrograde transport but as of yet no DUB has been identified to regulate 
retrograde transport.  
 
          
 
Figure 1.6. Endosomal budding.  
Retrograde transport from the MVB is achieved through the sequential processing steps. First 
there is a cargo recognition phase with VPS26/VPS35/VPS29 complex binding to cargo and 
recruiting SNX1/SNX2. Next is membrane remodelling achieved through the action of 
SNX1/SNX2 and the WASH complex that nucleates F-Actin and providing force to remodel 
the membrane. Finally there is a scission step and endosomal budding.  
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1.4. Aims of this project 
 
Previous work in the lab has established USP15 as a regulator of the 
E3 ligase BRAP. BRAP can in turn regulate the action of the MAPK scaffold 
KSR. One aim of this project is to understand if and how USP15 is regulating 
the MAPK signaling pathway.  
 
 In order to identify novel DUBs as effectors of the EGFR we will 
perform a screen using GFP-DUB to assess DUB that exhibit EGF 
localizations.  
 
 The final part of this project will be to establish if any of the known 
endocytic DUBs play a role in the regulation of retrograde transport.  
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Chapter 2   Materials and methods	  	  
2.1. Molecular biology.	  
 
2.1.1. Reagents. 
 
The following items were sourced from Invitrogen (Paisley, UK). SOC 
media (#15544-034), TOP10 competent cells (#C4040-30), DH5α subcloning 
efficiency competent cells (#18265-017), electrophoresis grade agarose 
(#15510-019), pEF-FRT-V5 TOPO cloning kit (#45-0226). Nuclease free 
water was obtained from Sigma (#W4502). Luria Bertani (LB) agar and broth 
(LAB-168 and LAB-191 respectively) was purchased from LAB M limited 
(Bury, UK). The following items were sourced from Agilent Technologies 
(Santa Clara, USA), XL-1 Blue ultra competent cells (#200314), Pfu Hot start 
Ultra (#600390) Deoxynucleotide mix (100mM, #200415).  
 
50x TAE buffer (#B9-0030) was purchased from National Diagnostics 
(Hull, UK). Gel extraction kit (#28706), Miniprep Kit (#27106), HiSpeed 
Maxiprep kit (#12663) from QiaGEN (Crawley, UK). All restriction 
endonucleases, 1kb Hyper-ladder (#NO468), 100bp Hyper-ladder (#NO467), 
were sourced from New England Biolabs (Herts, UK). Pfu Hot start Ultra 
(Stratagene, #600390), Taq polymerase (Bioline, #BIO-21040). All other 
chemicals were obtained from Sigma Aldrich (Poole, UK) unless otherwise 
stated. 
 
2.1.2. Agarose gel electrophoresis 
 
 Agarose gels (between 0.8-1%) were prepared from electrophoresis 
grade agarose dissolved in 1x TAE buffer (40mM Tris Acetate, 1mM 
Na2EDTA) by heating the mixture in a microwave. Once the mixture had 
cooled, ethidium bromide was added to agarose solution to a final 
concentration of 0.5µg/ml and allowed to set in a gel mold. DNA samples 
were loaded in 1x sample buffer (5%w/v glycerol, 0.1mM EDTA, 0.005% 
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bromophenol blue) at volumes typically between 10-15µl and DNA standard 
ladder was loaded as a comparison (NEB, Hyper-ladder 1kb). Bands were 
resolved in TAE buffer in a horizontal midi electrophoresis tank (Fisher 
Scientific) at 90V for 1hour. Bands were visualized using a UV gel dock (Uvi-
dock).  
 
2.1.3. Bacterial transformation 
 
 TOP10 (Invitrogen), DH5α (Invitrogen) and XL-Blue (Agilent) cells were 
transformed according to the manufactures’ instructions. Typically 50µl of 
competent cells were incubated with less than 100ng of DNA on ice for 
20mins. The bacteria were then heat shocked at 42˚C for 42secs, followed by 
2mins rest period on ice.  200µl of SOC media was added to the cells and the 
mixture was incubated at 37˚C (rotating shaker at 225rpm) for 1 hour. 
Bacterial cells were streaked on to antibiotic supplemented LB agar plates 
and incubated at 37˚C overnight.  
 
2.1.4.  Polymerase Chain reaction (PCR) 
 
 To sub-clone GFP-USP46* and GFP-USP46*-C44S into the pEF-FRT 
vector, PCR products were generated to produce a blunt end DNA product 
with an introduced 5’-CACC and a blunt 3’ end required for directional TOPO 
cloning. Pfu Hot start Ultra (Stratagene) was used in all the reactions, and the 
PCR reactions were prepared in 0.65ml Thermowell (Corning) at 4˚C. Recipes 
for PCR reactions and thermal cycle program are detailed in Table 2.1 and 
2.2. Primers and template were pre diluted to 125ng/µl and 10ng/µl 
respectively. Primers used in this study are detailed in table 2.3; all primers 
were custom made from Eurofins MWG operon.  
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Stage No Cycles Temp (˚C) Duration (min:sec) 
1 1 95 2:00 
2 25 
95 0:30 
55 0:30 
72 2:42 
3 1 72 30:00 
 
Table 2.1 Thermocycler settings to amplify GFP-USP46 
 
 Positive PCR Negative PCR 
H2O 40.5µl 41.5µl 
10x Pfu-Buffer 5µl 5µl 
dNTPs (25mM each) 0.5µl 0.5µl 
Primer-F (125ng) 1µl 1µl 
Primer-R (125ng) 1µl 1µl 
10ng Template 1µl - 
Pfu Hot Start Ultra 
(2.5U/µl) 
1µl 1µl 
Total 50µl 50µl 
 
Table 2.2. Typical PCR recipes. 
 
Primer name Sequence TM(˚C) 
GFP_general_forward 5’-CACCATGGTGAGCAAGGCG 61.5 
USP46_rev 5’-GTTGGGTATTATCTTGACTGATAGAATA 59.3 
 
Table 2.3. Primers used in this study. 
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2.1.5. Gel Extraction.  
 
 Bands of interest were extracted from the agarose gel using a scalpel. 
DNA was extracted using QiaGEN gel extraction kit to the manufacturers 
instructions.  
 
2.1.6. TOPO subcloning into pEF-FRT-V5 plasmid. 
 
 8ng of purified PCR product was subcloned into TOPO- pEF-FRT 
vector. Reagents were mixed in a thermowell tube (Table 2.4) and incubated 
at 22˚C for 30mins. 2µl and 4µl of the reaction mixture was transformed into 
TOP10 competent cells (Invitrogen) according to the manufacturers protocol.  
 
 
 Volume (µl) 
PCR product (8ng/µl) 1µl 
Salt Soln 1µl 
H2O 3µl 
TOPO Vector 1µl 
Total 6µl 
 
Table 2.4 Recipe for TOPO cloning into pEF-FRT vector. 
 
  
	   	   	  	  
	   56 
 
2.1.7. Site directed Mutagenesis. 
 
 Mutagenesis was performed on USP46 and USP15 to render them 
resistant to siRNA, and to mutate the active cysteine residue to a serine in 
USP46 only. Mutagenesis was performed using the Quick-change 
mutagenesis kit (Agilent Technologies) and Pfu Hot start Ultra (Stratagene). 
pDONR223-USP46 and pDONR223-USP15 were used as templates; primers 
were designed to be complementary to the sequence surrounding the desired 
base changes (primers are shown in table 2.5, changes are highlighted in 
yellow). A comparison to the original sequence and mutated sequence are 
detailed in Table 2.6. Primers were typically designed to introduce silent 
mutations that modified restriction endonuclease sites so that the mutant 
peptide could be identified by restriction endonuclease digest. 
 
PCR reactions were prepared in 0.65ml Thermowell (Corning) tubes; 
recipes and cycle times are documented in table 2.7 and 2.8 respectively. 
Following the PCR reaction, DPN1 was added to the reaction mixture to 
digest methylated DNA from bacterial origin, leaving the unmethylated 
mutated DNA. 1-2µl of mutated plasmid was then transformed in to XL-Blue 
ultra competent cells to the manufacturers instructions.  
 
Target Primer name Primer Sequence 
USP15 
USP15*_F GCATACATGAAGAAGGGAGCCCAAGTGAAATGG 
USP15*_R CCATTTCACTTGGGCTCCCTTCTTCATFTATGC 
USP46 
USP46*_F 
GTCCGAAACATAGCCAGCATTTGTAATATGGGAA
CCAATGCCTC 
USP46*_R 
GAGGCATTGGTTCCCATATTACAAATGCTGGCTAT
GTTTCGGAC 
USP46 
USP46_C44S_F GGAAACACATCCTACTGTAACTCCGTGCTTCA 
USP46_C44S_F TGAAGCACGGAGTTACAGTAGGATGTGTTTCC 
 
Table 2.5. Primers used for mutagenesis in this study. 
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 Base change AA change Construct name 
WT 
ggC TCA 
 - pDONR223-USP15siRES1 
Mutant ggG AGC 
WT 
atc gcc tcc atc 
tgt aat atg ggc 
 
- pDONR223-USP46siRES8 
Mutant 
atA gcc AGC atT 
tgt aat atg ggA 
 
WT 
tGc 
 C44S pDONR223-USP46-C44S 
Mutant tCc 
 
Table 2.6. Base and amino acid changes introduced in this study. 
 
 Positive PCR Negative PCR 
H2O 40.5µl 41.5µl 
10x Pfu-Buffer 5µl 5µl 
dNTPs (25mM each) 0.5µl 0.5µl 
Primer-F (125ng) 1µl 1µl 
Primer-R (125ng) 1µl 1µl 
10ng Template 1µl - 
Pfu Hot Start Ultra 
(2.5U/µl) 
1µl 1µl 
Total 50µl 50µl 
 
Table 2.7. Typical PCR reaction recipes for site directed mutagenesis. 
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Stage No Cycles Temp (˚C) Duration (min:sec) 
1 1 95 2:00 
2 18 
95 0:30 
68 0:30 
72 4:00 
3 1 72 10:00 
 
Table 2.8. Typical thermo cycle setting for site directed mutagenesis. 
 
2.1.8. LR Gateway cloning in expression vector. 
 
 LR cloning was used to shuttle constructs from the destination plasmid 
into a mammalian expression plasmid. This was performed using the LR- 
Clonase ii (Invitrogen) mix to the manufactures’ instructions.  
 
2.1.9. Bacterial Colony PCR. 
 
 Bacterial colony PCR was used to screen for colonies that had been 
successfully transformed with the pEF-FRT-GFP-USP46* and pEF-FRT-GFP-
USP46*-C44S. A master mix was prepared using the recipe described in table 
2.10. Bacterial colonies were picked with a sterile pipette tip and dipped in to 
the 1x master mix. The same colony was then used to seed 5ml of LB culture 
supplemented with Ampicillin, grown for 16 hours at 37˚C (on rotating shaker 
at 225rpm), for DNA amplification and extraction. T7 and BGH primer 
(Invitrogen) (Table 2.11) sequence flanked the gene of interest and were used 
to screen for positive colonies by the size of the PCR product.  Typical 
program for the thermocycler is shown in table 2.9. 
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Stage No Cycles Temp (˚C) Duration (min:sec) 
1 1 95 5:00 
2 35 
95 1:00 
55 1:00 
72 3:00 
3 1 72 5:00 
 
Table 2.9. Typical thermo cycle setting for bacterial colony PCR. 
 
 1x 
H2O 6.9µl 
10x Pfu-Buffer 1µl 
MgCl2 0.4µl 
DNTPs (25mM each) 0.25µl 
Primer-F (125ng) 0.7µl 
Primer-R (125ng) 0.7µl 
Bioline Taq 1µl 
Total 10µl 
 
Table 2.10. Typical recipe setting for bacterial colony PCR. 
 
Primer name Sequence TM(˚C) 
T7_F 5’-TAATACGACTCACTATAGGG  48.0 
BGH_R 5’-TAGAAGGCACAGTCGAGG  
54.8 
 
  
Table 2.11. Primers used for bacterial colony PCR in this study. 
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2.1.10. Restriction endonuclease analysis. 
 
 Restriction endonuclease testing was routinely carried out to test the 
identity of constructs. Depending on the optimal conditions for the enzyme, 
typically 500ng of DNA would be subjected to restriction digestion for 1 hour 
at 37˚C. Table 2.12 details a typical recipe for restriction digest.  
 
 Volm (µl) 
500ng of DNA 1µl 
Restriction endonuclease 0.8µl (x2 0.4µl for double digestion) 
Reaction Buffer 1µl 
10x BSA 1µl 
H2O 6.2µl 
Total Volm 10µl 
 
Table 2.12. Typical recipe for restriction endonuclease digestion. 
 
2.1.11. Glycerol stock. 
 
 Glycerol stocks were produced from 5ml of overnight culture inoculated 
from a single colony. The culture was spun down at 1000g for 10mins, the 
pellet was resuspended in a solution of 40% Glycerol and 60% LB medium. 
Glycerol stocks were frozen at -80˚C.  
 
2.1.12. Plasmid sequencing. 
 
 Plasmid sequencing was performed by Dundee Sequencing services. 
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2.2. Protein Biochemistry. 
 
2.2.1. Reagents. 
 
 Tween-20 (#EC-407), 20% SDS solution (#EC-894), Resolving buffer 
(#EC-893), Stacking Buffer (#EC-870), Protogel (#EC-890) was obtained from 
National Diagnostics (Hull, UK). NuPage gels, NuPage MOPs running buffer 
(#NP-001-02), NuPage Antioxidant (#NP0005) were purchased from 
Invitrogen (Paisley, UK). Protran nitrocellulose membrane (#B3-0059) was 
bought from Geneflow (Litchfield ,UK). Pierce BCA assay kit (#23225) was 
sourced from Thermo scientific (Rockford, Il). All other chemicals were 
sourced from Sigma Aldrich (Poole, UK) unless otherwise stated. 
 
2.2.2. Cell lysis. 
 
 A confluent mono-layer of cells were washed twice in ice cold PBS and 
lysed in either NP40 buffer (0.5% NP40, 25mM Tris pH 7.5, 100mM NaCl) or 
RIPA (10mM Tris-HCl pH 7.5. 150mM NaCl, 1% Triton X-100, 0.1% SDS, 1% 
Sodium deoxycholate) buffer supplemented with mammalian protease 
inhibitors (1:250) and where appropriate Phos-Stop tablets (1 tablet in 10ml, 
Roche) on ice for 10mins with rocking. Lysates were then spun at 16,200g for 
10mins (4˚C) to remove the insoluble faction. 
 
2.2.3. BCA protein assay. 
 
 Protein concentrations of cell lysates were determined using BCA 
protein assay kit (#23225, Pierce) to the manufacturers instructions.  
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2.2.4. SDS polyacrylamide gel electrophoresis. 
 
 SDS polyacrylamide gel electrophoresis was performed using either 
custom made using the BioRAD system or the Invitrogen precast NuPage gel 
system. The recipes detailed in Table 2.13. and 2.14. were used according to 
need to make BioRAD gels.  
 
 8% 10% 
Protogel 5.34ml 6.66ml 
Protogel 
Resolving Buffer 
5.2ml 5.2ml 
Water 9.24ml 7.92ml 
APS 0.2ml 0.2ml 
TEMED 20µl 20µl 
 
Table 2.13. Recipe for 2x resolving mini-gel. 
 
 
Stacking 
Gel 
Protogel 0.65ml 
Protogel Stacking 
Buffer 
1.25ml 
Water 3.05ml 
APS 25µl 
TEMED 5µl 
 
Table 2.14. Recipe for 1x 4% stacking gel. 
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2.2.5. Western Blotting. 
 
  Western blotting was performed to transfer proteins resolved by SDS 
page onto 0.45µm nitrocellulose membrane for immuno detection of proteins. 
Protein transfer was performed using a genie blotter full submersion 
apparatus (Idea scientific) at 0.9A for an hour. Nitrocellulose was then stained 
with Ponceau-S stain to visualize bands and removed by washing in PBS. 
The membrane was blocked using either 5% Milk in TBS-T (20mM Tris, 
137mM NaCl, pH 7.5, 0.1% Tween20) or 5% BSA/ TBS-T for 1 hour. Primary 
antibodies were incubated according to the conditions required. After 
incubation in the primary antibody the membrane was then washed in TBS-T 
0.1% for 3x 5min. Fluorescent secondary antibodies raised against the 
primary antibody host species, were incubated in 5% milk TBS-T for 1 hour. 
The membrane was washed again 3x in TBS-T before detection of bands an 
Odyssey Licor system. Primary antibodies used in this study for western 
blotting are detailed in table 2.15 and secondary antibodies are detailed in 
table 2.16. 
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Table 2.15. Primary antibodies used in this study for western blotting. 
Description Target Species Source Blocking Dilution 
ERK #4695 ERK Rabbit Cell Signaling BSA 1;1000 
pERK 
(Thr202/Tyr204)  
#4370 
ERK Rabbit Cell Signaling BSA 1;500 
AKT AKT Mouse Cell Signaling BSA 1;500 
pAKT (Ser473) 
#9271 AKT Mouse Cell Signaling BSA 1;500 
MEK 
(Ser217/221) 
#9122 
MEK Mouse Cell Signaling BSA 1:500 
pMEK #9154 
 MEK Mouse Cell Signaling BSA 1:500 
pEGFR  
(Tyr845) 
#2231 
EGFR Rabbit Cell Signaling BSA 1:1000 
EGFR #sc-03 EGFR Sheep Santa Cruz Milk 1:500 
CRAF   
#A301-519A CRAF Rabbit Santa Cruz Milk 1:1000 
CI-M6PR CI-M6PR Rabbit Paul Luzio Milk 1:500 
VPS35 
#ab10099 VPS35 Goat AbCam Milk 1:1000 
Cathepsin D 
#219361 Cathepsin D 
Millipore/ 
Calbiochem Millipore Milk 1:2000 
HRS #864/3 HRS Rabbit Sylvie Urbe Milk 1:1000 
USP4   
#A300-830A 
 
USP4 Rabbit Bethyl Milk 1:1000 
USP8  
#HA004869 
 
USP8 Rabbit Sigma Milk 1:1000 
USP15  
#H00009958-
M01 
 
USP15 Mouse Abnova Milk 1:1000 
USP46  
#HPA007288 
 
USP46 Rabbit Sigma Milk 1:250 
BRAP   
#A302-682A BRAP Rabbit Bethyl Milk 1:1000 
KSR  #2234-1 KSR Rabbit Epitomics BSA 1:1000 
PHLLP1   
#A300-660A PHLLP1 Rabbit Bethyl Milk 1:200 
PHLLP2  
 #A300-661A PHLLP2 Rabbit Bethyl Milk 1:200 
Actin  #Ab6276 Actin Mouse AbCam Milk 1:10,000 
Tubulin  #T5168 Tubulin Mouse Bethyl Milk 1:10,000 
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Secondary Antibody Manufacturer Dilution 
Donkey anti-mouse IRDye 800cw #926-32212 Licor Biosciences 1:15,000 
Donkey anti-mouse IRDye 680cw #926-32222 Licor Biosciences 1:15,000 
Donkey anti-rabbit IRDye 800cw #926-32213 Licor Biosciences 1:15,000 
Donkey anti-rabbit IRDye 680cw #926-32223 Licor Biosciences 1:15,000 
Donkey anti-sheep IRDye 800cw #926-32214 Licor Biosciences 1:15,000 
Donkey anti-sheep IRDye 680cw #926-32224 Licor Biosciences 1:15,000 
 
Table 2.16. Secondary antibodies used in this study for western blotting. 
 
 
 
2.3. Cell Biology 	  
2.3.1. Reagents. 	  
The following products were purchased from Invitrogen (Paisley, UK), 
Oligofectamine transfection reagent (#12252-011), RNAi Max transfection 
reagent (#13778-075). Genejuice transfection reagent was obtained from 
(#70967, Merck Chemicals, Millipore, Darmstadt, Germany). Gefitinib 
(#51025) and AZD6244 (#142886). PI-1O3 (#528100), PDGF (#521225) and 
moviol (F017), epoxomicin (#324800) was purchased from Calbiochem 
(Merck, Millipore, Darmstadt, Germany). 16% PFA (#F017) was obtained from 
TAAB (Reading, UK). All other chemicals were obtained from Sigma Aldrich 
(Poole, UK) unless otherwise stated. EGF was a kind gift from Dr. J. Smith 
(University of Liverpool). All plastic ware was sourced from Corning Inc. (NY, 
USA). All other cell culture reagents were obtained from Invitrogen (Paisley, 
UK) unless otherwise stated. 	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2.3.2. Cell culture. 
 
HeLa, U2OS, HEK293t and HCT116 cells were cultured at 37˚C in a 
5% CO2 atmosphere in Dulbecco’s Modified Eagles’ Medium (DMEM) 
supplemented with 10% FBS, 1% non-essential amino acids and 
1%penicillin/streptomycin sulphate. HeLa (Human cervical cancer), U2OS 
(Human osteosarcoma), HEK293t (Human embryonic kidney cells) and 
HCT116 (Human Colon cancer cells) cells reached confluence after 2-3 days. 
HeLa, U2OS and HCT116 cells maintained by splitting a confluent dishes 1:5 
while HEK293t were split 1:10.  	  
2.3.3. Culture of CD8-CI-M6PR and CD8-FURIN cell lines. 
 
CD8-CI-M6PR-HeLaM and CD8-CI-Furin-HeLaM cells (a gift from Dr. 
Matthew Seamen, Cambridge Research Institute) stably express a chimera of 
the luminal domain of CD8 fused to the tail of CI-M6PR and Furin158. Cells 
were maintained in DMEM media supplemented with 0.5mg/ml G418. Cells 
were maintained by splitting a confluent dish every 2-3 days at a ratio of 1:5. 
 
2.3.4. SILAC cell culture. 
 
 Stably transfected HeLa S3 cells (G7, WT2, CS3) were grown in 
DMEM media lacking Arg and Lys (Dundee cell products), 10% Dialyzed FBS 
(Dundee cell products) and 1% penicillin/streptomycin sulphate. G7 cells were 
grown in media supplemented with light amino acids (Arg0/Lys0/Pro0), CS3 in 
medium amino acids GFP-USP46-C44S (CS3) (Arg6/Lys4/Pro0) and WT2 in 
heavy amino acids GFP-USP46-C44S (WT2) (Arg10/Lys8/Pro0). 
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2.3.5. Transient transfection of tissue culture cells. 
 
 For transient transfection of mammalian expression constructs, all cells 
were transfected with Genejuice (Merck Millipore). Typically, cells were grown 
on 22mm2 coverslips in 6 well plates. Plasmids were incubated with 
Genejuice in a 1:3 ratio between µg DNA/µl Genejuice, for a 6 well plate 1µg 
of DNA was incubated with 3µl Genejuice in serum free OptiMEM for 15mins. 
The mixture was then added directly to the cells in complete DMEM media for 
16-24 hours.  
 
2.3.6. siRNA transfection of tissue culture cells. 
 
 HeLa cells were transfected with 40nM of siRNA using Oligofectamine 
(Invitrogen), U2OS and HCT116 cells were transfected with 20nM and 40nM 
siRNA respectively using RNAi max (Invitrogen). Typically for a 72hour 
transfection, cells would be seeded in a 6 well plate a density of 1.2x105 cells 
and allowed to adhere to the plate, the next day the medium would be 
exchanged for serum free medium and treated with siRNA transfection 
reagent complex to the manufactures instructions. FBS was added 4 hours 
later to a final concentration of 10% and the media was exchanged the day 
after. All siRNA was obtained from Dharmacon Inc. (Lafayette, CO, USA), 
details of siRNA oligonucleotides used in this study are outlined in table 2.17. 
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Target Brand Cat number Target Sequence 
USP4-8 On-Target Plus J-004974-08 AAACUCAACUCUCGAUCUA 
USP8-1 siGENOME D-005203-02 UGAAAUACGUGACUGUUUAUU 
USP8-2 siGENOME D-005203-03 GGACAGGACAGUAGAUAUU 
USP15-1 siGENOME D-006066-01 GAAGAAGGCUCACCAAGUG 
USP15-2 siGENOME D-006066-02 GAACGCACCUUGGAAGUUU 
USP46-6 On-Target Plus J-006092-06 GAACGAACCUGCGGAAAAU 
USP46-7 On-Target Plus J-006092-07 GAAACUCGAUGCUUGAACU 
USP46-8 On-Target Plus J-006092-08 AAACAUCGCCUCCAUCUGU 
USP46-9 On-Target Plus J-006092-09 CCGCAUGUAUGACUUGGUU 
AMSH-3 On-Target Plus D-012202-02 GAGAAGCCCUCCUUAGAUGUU 
BRAP On-Target Plus 
Smart Pool 
L-006597-00 GGUAUUAUGCACCUAUAUA 
UGAGAAGUGUGAUAAUCUA 
CGACGUAAUUGAACAAAUG 
GGAGAGAAAGUAGCGAUUA 
RAF1 On-Target Plus 
Smart Pool 
L-003601-00 ACAGAGAGAUUCAAGCUAU 
AUUCAAAGAUGCCGUGUUU 
CAAAGAACAUCAUCCAUAG 
GUAAAUGGCACGGAGAUGU 
VPS35 On-Target Plus 
Smart Pool 
L-010894-00 GAACAUAUUGCUACCAGUA 
GAAAGAGCAUGAGUUGUUA 
GUUGUAAACUGUAGGGAUG 
GAACAAAUUUGGUGCGCCU 
NT1 On-Target Plus D-001810-01 UGGUUUACAUGUCGACUAA 
  
Table 2.17. siRNA Oligonucleotides used in this study. 
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Table 2.18. Primary antibodies used in this study for immunofluorescence. 
 
2.3.7. Immunofluorescence. 
 
 Cells were typically washed 2x in PBS then fixed in 3-4% PFA (16% 
w/v stock solution) for 10mins immediately after the experiment (or following a 
3min incubation in 0.02% Saponin/PIPES-MTSB, to remove cytosolic 
staining). Cells were subsequently quenched in 50mM NH4Cl for 20mins. 
Some antibodies were not compatible with PFA fixation and were fixed in -
20˚C Methanol on ice for 5mins (Primary antibodies used in this study are 
detailed in table 2.18). Cells were then generally blocked in 10% Goat serum 
in 0.2% Triton X-100 for one hour. Primary were typically incubated in 5% 
goat serum in 0.2% triton-X100 facedown on a 100µl drop for 1 hour. 
Coverslips were then washed 5x in PBS, 3x short 1min washes and 2x 5min 
wash. Secondary antibodies (detailed in Table 2.19) were incubated in 5% 
Goat serum in 0.2%Triton X-100/PBS. Cover slips were then washed again 
and mounted on 40µl drop of moviol (Calbiochem) on a microscope slide, 
Name Target Species Source Blocking Incubation Fixation Dilution 
HRS 
958/3 HRS Rabbit 
Sylvie 
Urbe 10% GS 5%  GS Methanol 1;1000 
VPS26 VPS26 Rabbit Abcam 10%  GS 5%  GS PFA 1;500 
EEA1 
243/3 EEA-1 Mouse Ian Mills 10%  GS 5%  GS PFA 1;500 
EEA1 EEA-1 Mouse BD  10%  GS 5%  GS PFA 1;500 
CD8 CD8 Mouse Matthew Seaman DHB DHB PFA 1:500 
P230 P230 Mouse BD 10%  GS 5%  GS PFA 1:500 
CI-
M6PR CI-M6PR Rabbit 
Paul 
Luzio 10%  GS 5%  GS PFA 1:200 
FK2 Ubiquitin Mouse Millipore 10%  GS 5%  GS PFA 1:1000 
ERK 
4695 ERK Rabbit 
Cell 
signaling 10%  GS 5%  GS Methanol 1;100 
pERK 
4370 pERK Rabbit 
Cell 
signaling 10%  GS 5%  GS Methanol 1;200 
GFP GFP Sheep Ian Prior 2%  BSA 2%  BSA Methanol 1;200 
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were necessary 4’,6-diamidino-2-phenylindole (DAPI) stain was added to the 
moviol at 1:10,000. Cell were imaged either SP2 aobs (lecia; 63.0 x 1.4 oil 
objective) confocal microscope or a Nikon Ti-E (60x Oil N2 N.A. 1x4, 
W.D.0.13mm) widefield microscope. 
 	  
 
 
 
 
 
 
 
Table 2.19. Secondary antibodies used in this study for immunofluorescence. 
 
2.3.8. Generation of Flp-in cell lines. 
 
 Flp-in cells were generated by co-transfection of pEF-FRT vector 
containing the gene of interest along with pOG44 plasmid encoding the Flp 
recombinase. Parental HeLa S3 cells containing the FRT recombination sites 
(generated by Maria Hernández) were seeded into 6 well plates and 
transfected using Genejuice with the method described in section 2.3.5. with a 
ratio of 1:9; 100ng of pEF-FRT plasmid and 900ng of pOG44 plasmid. 24 
hours after transfection the cells were re-seeded onto 10cm2 dishes at a 
density of 1:2 and 1:4. The cells were cultured in the presence of 150µg/ml 
Hygromycin B to select for positive clones; media was exchanged every 3 
days. After 14days colonies were visible colonies formed which were picked 
and transferred into a 24 well plate. Once the cells had formed large islands 
(approximately 1 week later) the cells were transferred into a 6 well plate and 
then into 25cm2 flasks for 2 passages before freezing down clones. Positive 
clones were identified through western blotting and immunofluorescence. 
  
Ab name Species Source Dilution 
Anti-Mouse AF350 #A10035 Donkey Invitrogen 1;500 
Anti-Mouse AF488 #A21202 Donkey Invitrogen 1;1000 
Anti-Mouse AF594 #A21203 Donkey Invitrogen 1;1000 
Anti-Rabbit AF488 #A21206 Donkey Invitrogen 1;1000 
Anti-Rabbit AF594 #A21207 Donkey Invitrogen 1;1000 
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2.3.9. Growth factor stimulation and lysis. 
 
 Cells were serum starved for 16hours before stimulation with serum 
free DMEM supplemented with the appropriate concentration of growth factor. 
Cell are washed 2x in Ice cold PBS and lysed in RIPA buffer (10mM Tris-HCl 
pH 7.5., 150mM NaCl, 1% Triton X-100, 0.1% SDS, 1% Sodium 
deoxycholate) supplemented with mammalian protease inhibitors 
(1:250)(Sigma) and PhosSTOP inhibitors (1 tablet per 10ml)(Roche). 
Application of growth factor is staggered so that all cells are lysed 
concurrently. Or alternatively cells were washed x2 in PBS and fixed in 4% 
PFA or -20˚C methanol. 
 
2.3.10. USP8 rescue experiments. 
 
HeLa cells were transfected 2x with 40nM of siRNA using 
oligofectamine (Invitrogen) over 96 hours at 0 and 48 hour time point. The 
cells were transfected with GFP constructs for 66hours using Genejuice 
(Merck Millipore). After 72 hours cells were seeded 0.4 x 106 cells per 22mm2 
or at 6.7x105 cells per 6well plate. The cells were then either fixed in 3% PFA 
or lysed in NP40 buffer.  
 
2.3.11. Epoxomicin treatment. 
 
Cells pretreated with siRNA were incubated with DMEM supplemented 
with 0.5µM Epoxomicin or 2µl DMSO, for 8hours before and lysis in NP40 
buffer on ice for 10mins on ice.  
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2.3.12. Kinase inhibitor treatment. 
 
HeLa cells were serum starved overnight before incubation in serum 
free DMEM supplemented with kinase inhibitors (300nM Gefitinib, 150nM PI 
103, 300nM AZD6244)	   for 15mins. Media was then exchanged to serum free 
DMEM containing the appropriate kinase inhibitor or DMSO and 20ng/ml 
EGF. Cells were then washed 2x in ice cold PBS before fixation in 4% PFA or 
lysis in RIPA buffer.	  	  
2.3.13. Immuno-precipitation using GFP Nano-Trap. 
 
Stably transfected HeLaS3 cells were lysed in NP40 buffer (0.5% 
NP40, 25mM Tris pH7.5, 100mM NaCl) and centrifuged at 16,200g (4˚C) to 
pellet cell debris. Lysates were adjusted to equal concentration using lysis 
buffer. GFP Nano-Trap antibody159 was pre-coupled to sepharose beads 
(Maria Hernández). Beads were incubated with the lysate for 2 hours at 4˚C 
(5µl beads per 100µg of lysate), the beads were then washed 3x in YP buffer 
(1%NP40, 25mM Tris pH 7.5, 150mM NaCl, 4˚C) and then 1x in 25mM Tris 
(4˚C). Proteins were eluted for the beads by incubation in either 1x SDS 
running buffer at 98˚C for 10mins or for large volumes in 1%SDS at 98˚C for 
10mins, the elute was the dried in a speed-vac (RVC 2-25, Christ, Osterode 
am Harz, Germany) for 16hours at 40˚C and the subsequent pellet was 
resuspended in 1x SDS running buffer. 
 
2.3.14. CD8 uptake assay. 
 
CD8-CI-M6PR and CD8-Furin cells were either treated with 40nM 
siRNA twice over a 96-hour time period at 0 and 48 hours. CD8-CI-M6PR and 
CD8-Furin cells were seeded onto 22mm2 coverslips at a dilution of 1:4, after 
72 hours siRNA treatment. After 96 hours cells were incubated for 15mins on 
ice cold DHB (serum free DMEM, 25mM HEPES, 0.2% Fatty acid free BSA), 
then subsequently incubated on a spot of 1µg/ml anti-CD8 antibody in 100µl 
DHB for 1 hour in the dark. The coverslips were then washed twice in ice-cold 
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PBS and transferred into 37˚C DMEM. The cells were fixed in 3% PFA at the 
indicated time points and processed for immunofluorescence. 
 
2.3.15. Cathepsin D secretion assay. 
 
HeLa cells were treated for 96 hours with 40nM siRNA against their 
respective targets. Cells were seeded at 72 hours cells were seeded into 6 
well plates at a density of 6.7x105 cells. 16 hours before the end of the 
experiment media was exchanged to 1ml serum free OptiMEM. The 
conditioned media was removed and underlying cells were washed twice in 
ice-cold PBS and lysed in NP40 buffer. SDS was added to the conditioned 
media to a final concentration of 0.02% and incubated on ice for 30mins. The 
media was centrifuged at 16,200g for 30min (4˚C) to remove cell debris. TCA 
(Trichloroacetic acid) was added to the supernatant to a final volume of 10% 
and incubated on ice for 1 hour after which it was centrifuged for 30mins at 
16,200g (4˚C). The resulting pellet was washed in ethanol:ether (1:1) and 
resuspended in 1x unbuffered SDS running buffer. Equal loading was 
determined by Ponceau staining.  
 
2.4. Mass spectrometry 
 
2.4.1. Reagents. 
 
 Trypsin Gold (#V5280) was sourced from Promega (Southampton, 
UK). HPLC grade Acetonitrile (#20060320) and Water (#23595328) were 
purchased from VWR (Lutterworth, UK). LoBind Eppendorf tubes 
(#022431081) were sourced from Eppendorf (Hamburg, Germany). All other 
chemicals were obtained from Sigma Aldrich (Poole, UK) unless otherwise 
stated. 
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2.4.2. In-gel digestion. 
 
 Immuno-precipitated samples were run in a single lane of a NuPage 4-
12% SDS polyacrylamide gel at 190v for 1 hour. The gel was stained with 
colloidal blue, used to the manufacturers instructions to visualize the bands. 
Bands were cut from the gel using a scalpel and de-stained in 50mM 
Ammonium Bicarbonate (Ambic)/ 50% Acetonitrile (ACN). Gel slices were 
reduced and alkylated by incubating gel slices at 37˚C in 10mM Dithiothreitol 
for 30mins followed by incubation in 50mM Chloroacetamide for 30mins at 
room temperature in the dark. Gel slice were then incubated in 100% ACN to 
dehydrate the gel piece at 37˚C. 20µl of 50mM trypsin was added to the gel 
slices and incubated for 16hours at 37˚C. 1% formic acid was added to 
quench the reaction and 100% ACN was added to extract the peptides. The 
eluted was spun at 16,200g for 10mins to pellet any gel pieces; the 
supernatant was transferred into fresh tubes and dried in a speed-vac (RVC 
2-25, Christ, Osterode am Harz, Germany) at 45˚C for 6 hours. The pellet was 
resuspended in 0.05% TFA and loaded on LC-MS/MS.  
 
2.4.3. Detection and identification of peptides. 
 
5µl of each sample was loaded on high performance liquid 
chromatography column coupled to an LTQ-Orbitrap XL (Thermo Fisher) fitted 
with a Proxeon nanoelectrospray source. Samples were run on a 1-62.5% 
linear ACN gradient over 21mins. MS spectra were acquired by the Orbitrap 
at a resolution of 30,000 and MS/MS was performed on the TOP 6 ions in the 
LTQ ion trap. All spectra were acquired using Xcalibur software (version 2.0.7; 
Thermo Fisher Scientific). Raw MS spectra were searched against 
human.ipi.library and analyzed using MaxQuant software 1.3.0.5160.  
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Chapter 3 USP15 regulates the MAPK pathway through                  
CRAF. 
 
3.2. Introduction. 
 
Reversible ubiquitylation can govern many signaling processes by 
regulating the stability of substrate proteins, enzymatic activity and protein-
protein interactions. The NFkB pathway is a model for the action of reversible 
ubiquitylation in the regulation of signaling pathways161. However, the role of 
ubiquitylation had not been as extensively explored in as a regulator of the 
MAPK pathway. Several components of the MAPK pathway notably, the RAS 
family of GTPase have been shown to be directly ubiquitylated, which 
influences localization162, activity163 and degradation164. The role of 
deubiquitylases (DUBs) as direct regulators of MAPK pathway components, 
downstream of the RTKs had been relatively understudied. USP17 has been 
described as determining the localization of N-RAS through RCE1165. While 
another DUB CYLD has recently been shown to regulate the activity of AKT, 
by maintaining it’s plasma membrane localization and opposing the action of 
E3 ligases that ubiquitylate AKT166. Ubiquitylation prevents the translocation 
of AKT into the cytosol and it’s subsequent inactivation.  
 
One feature of DUBs is that they are often found in complexes together 
with E3 ligases. This allows for dynamic interplay between E3 ligases and 
DUBs166. One explanation for these associations is that DUBs are required to 
deubiquitylate E3 ligases that have a tendency to auto-ubiquitylate167. 
Sebastian Hayes performed a directed Yeast two-hybrid screen to look at the 
interactions between 55 DUBs and 133 RING E3 ligases, to identify E3 ligase 
DUB partners that could influence signaling pathways. An interaction between 
BRAP and USP15 was observed, which was of interest because of the 
described function of BRAP167.  
 
BRAP is also annotated in the literature as IMP standing for Impedes 
Mitogenic Propagation. It was identified in a yeast two-hybrid (Y2H) screen 
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with active H-RAS168. Further analysis reveled that BRAP has an inhibitory 
role in MAPK signaling through a non-catalytic action on the MAPK scaffold 
KSR169. BRAP removes KSR from a complex with the RAF and MEK kinases 
were it would facilitate their activation170, 171. In the presence of activated 
RASG12V, BRAP becomes auto-ubiquitylated and is sequestered into Triton-
X100 insoluble complexes169. This in turn frees KSR allowing it to act as a 
scaffold increasing signaling through the pathway by enhancing the activation 
of the RAF/MEK kinases. The effect seen with BRAP was not restricted to 
EGF activation. Matheny al. (2004)169 were able to observe a KSR dependent 
inhibition in MAPK signaling, when over expressing BRAP in KSR-/- MEFs 
stimulated with PDGF168.  
 
Following USP15 knockdown, we would predict an increase in 
signaling with USP15 depletion due to a reduction in the levels of BRAP. 
However, when the activation of the MAPK pathway was tested with 
knockdown of USP15 by siRNA, a paradoxical decrease in MAPK activation 
was observed. To investigate this problem further, U2OS cells were employed 
as a model to study PDGF signaling. By testing USP15 function in PDGF 
signaling, it allowed us to test whether this effect was a conserved regulatory 
step in the MAPK cascade.  
 
3.2. Results.  
 
3.2.1. Establishing Knock down conditions in U2OS cells.  
 
In order to establish conditions to use U2OS cells as a model system to 
study the effects of USP15 on PDGF signaling. We first sought to assess the 
knockdown efficiency using RNAi max transfection reagent. As a control A549 
cells were included, which had been previously used in the lab and produced 
efficient depletion by siRNA. Two different concentrations of oligonucleotides 
were tested, 20nM and 40nM with two individual oligonucleotides. Individual 
oligonucleotides had been previously verified by deconvolution from the pool 
of oligonucleotides targeting USP15. We aimed to reduce the amount of 
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siRNA needed for each knockdown experiment, cutting both cost and off 
target effects associated with siRNA transfection (Figure 3.1).  
Both concentrations of oligonucleotides produced knock down 
efficiency of over 90% after 72hours, with the higher concentration being 
marginally more effective in U2OS cells (Figure 3.1.) Interestingly the Scr 
(scrambled) control caused a slight decrease in the expression levels of 
USP15 and was omitted as a control for later experiments. The levels of 
expression were quantitated using the odyssey software and values for 
USP15 band were normalized to the Actin control.  
 
         
Figure 3.1 Testing knockdown efficiency of USP15 in U2OS cells 
U2OS and A549 cells were depleted of USP15 with varying concentration of siRNA for 72 
hour using RNAi MAX. The cells were lysed in RIPA buffer and lysates were probed for 
USP15 and Actin, quantification was performed using Odyssey software. USP15 values were 
normalised to actin and expressed as relative abundance of no oligo control (%). 
Representative blot shown. 
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3.2.2. Titration of the concentration of growth factor required to activate 
MAPK pathway. 
 
Next we produced dose response curves for PDGF on U2OS cells. In 
addition to U2OS cells, dose response curves were performed for HeLa and 
HEK293t cells with EGF for comparison. pMEK (Ser217/221) was used as a 
readout of MAPK pathway activation. This was preferred to pERK because it 
is less influenced by cross talk from other signaling pathways than MEK. 
 
Performing a titration ensured that any perturbation of the MAPK 
pathway would be seen as either an increase or decrease in signal. For 
example, if you were to stimulate with too high a concentration of growth 
factor and saturate the system, then the pathway would be already maximally 
stimulated and no increase in signal would be observed. Equally if the 
perturbation caused a decrease in signal and you were stimulating the cells in 
the low end of the activation profile. Then this would reduce the dynamic 
range of the assay and underestimate any effect seen.  For this reason we 
chose to use a concentration in our experiments at approximately the EC50 for 
a given growth factor (10ng/ml PDGF). 
 
In figure 3.2, HeLa, U2OS and HEK293t cells were grown to 
confluency on the day of lysis. The cells were serum starved in DMEM for 16 
hours before stimulation with the indicated concentration of growth factor for 
5mins. Each growth factor reached saturation of the pMEK signal at 20ng/ml 
while PDGF had a shallower activation curve compared to EGF on HeLa and 
HEK293t. Interestingly in HEK293t cells, inhibition was observed at 100ng/ml 
relative to 20ng/ml of EGF. Also of note across the different cell lines tested 
there was differential activation of MEK isoforms. In Hek293t cells only one 
band was observed, in U2OS cells and HeLa cells two bands were seen for 
each. However, in HeLa cells both bands are activated equally whilst in U2OS 
cells the lower band is stronger than the upper.  
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Figure 3.2. Titration of Growth factor for MEK activation. 
Hek293t, HeLa and U2OS cells were serum starved overnight before stimulation with 
increasing concentrations of growth factor (indicated) for 5min. Cells were lysed in RIPA 
buffer and lysates were probed with antibodies against pMEK and actin. Quantification was 
performed Image J with values normalized to actin. Representative blot shown. 
 
3.2.3. Time course of MAPK activation. 
 
We next wanted to establish the time course of MAPK activation. Again 
this was performed in U2OS, HEK293t and HeLa cells. Cells were serum 
starved in DMEM for 16 hours before stimulation with the concentration 
growth factor indicated, for a time course between 0 and 60 mins. This would 
allow us to pick the optimal time point to assess changes in MAPK activation.  
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All cell lines showed pMEK rising sharply to peak at 5 mins and then 
declining. U2OS cells had the most sustained activation profile of those 
tested, consistent with previous reports172 (Figure 3.3). In contrast to U2OS 
cells activation, HEK293t cells rapidly declined after 5mins of stimulation.  
 
 
ggghhhhhhh  
 
Figure 3.3 Time course of pMEK activation with growth factor stimulation. 
Hek293t, HeLa and U2OS cells were serum starved overnight before stimulation with growth 
factor indicated for a time course between 0 and 60min. Cells were lysed in RIPA buffer and 
lysates were probed with antibodies against pMEK and actin. Quantification was performed 
with image J with values normalized to actin. Representative blot shown. 
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3.2.4. EGF titration against time in HeLa cells.  
 
To further investigate the regulation of the MAPK pathway by EGF. We 
generated activation profiles for 3 different concentrations of EGF (1ng/ml, 
5ng/ml and 20ng/ml) over a time course of 0-60 mins. This was performed on 
HeLa cells, a commonly used model to study EGF signaling. Lysates were run 
on the same gel and probed for pAKT and pMEK as readouts of the PI3K and 
MAPK signaling pathways respectively (Figure 3.4).  
 
By increasing the concentration of EGF there is acceleration in the 
phosphorylation of MEK and AKT, demonstrated by an increasing signal at 
the 2min time point. The slope of decay for AKT phosphorylation seems 
unaffected by the increase in concentration of EGF, which suggests that there 
is an overriding dephosphorylating activity for AKT even concentration that 
produces maximal activation of the pathway. However, there is more 
sustained signaling for MEK activation with increasing EGF. A second peak of 
MEK activation is observed, which is more evident with the lower doses of 
EGF and most apparent at 5ng/ml. It is likely at 20ng/ml the second peak is 
masked by sustained activation.  
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Figure 3.4. The effect of increasing EGF concentration over time on downstream 
effectors.  
HeLa cells were serum starved overnight before stimulation with increasing concentrations of 
EGF over a time course between 0 and 60 min. Cells were lysed in RIPA buffer and lysates 
were probed with antibodies against pMEK and pAKT as a measure of activation of 
downstream effectors. Quantification was performed with Image J with values normalised to 
actin. Representative blot shown. 
 
3.2.5. USP15 regulates PDGF stimulated MAPK pathway through CRAF.  
 
U2OS cells were treated with siRNA targeting USP15, and BRAP for 
72 hours. Control cells were mock treated with RNAi max alone or with siRNA 
targeting USP4. USP4 is a closely related DUB, also identified in the Y2H 
screen as binding to BRAP, which has no effect on the stability of BRAP167. 
Cells were serum starved overnight before stimulation with 10ng/ml PDGF for 
5 mins (figure 3.5).  
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We observed a significant decrease in the levels of pMEK (U15-1= 
39.8% SE=5.3, student t-test 0.008; U15-2 = 49.8%, SE= 1.9, student t-test 
p= 0.001, n=3) with USP15 knockdown with 2 individual oligonucleotides. To 
decipher the mechanism of this inhibition we probed for the critical upstream 
kinases, CRAF and BRAF. There was a significant decrease in the levels of 
the CRAF kinase (U15-1= 43%, SE=2, student t-test p= 0.001; U15-2 = 48.6% 
SE= 3.6, student t-test p= 0.004, n=3) but not the in the levels of the BRAF 
kinase with USP15 depletion. The decrease in CRAF could be observed with 
two individual oligonucleotides that corresponded to the decrease in pMEK.  
 
    
 
Figure 3.5. siRNA depletion of USP15 causes a decrease in MEK activation and the 
levels of CRAF. 
Depletion of USP15 leads to a reduction MEK activation and concomitant reduction in the 
levels of CRAF. U2OS cells, treated with siRNA for 72 hours, serum starved overnight then 
stimulated with 10ng/ml PDGF for 5 mins. Bands were quantified using Image J and bars 
represent standard error (n=3) 
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3.2.6. Treatment with epoxomicin fails to rescue loss of CRAF with USP15 
depletion.  
 
To investigate whether the loss of CRAF in USP15 depleted cells was 
due to changes in the ubiquitylation status of CRAF. We employed 
epoxomicin to inhibit the proteasome, if knock down of USP15 was causing 
an accumulation of CRAF in an ubiquitylated form. One hypothesis would be 
that this would lead to its degradation via the proteasome. Inhibition of the 
proteasome would therefore rescue the levels of CRAF. 
 
U2OS cells were treated with siRNA for 72 hours to deplete USP15 or 
USP4 as a control. The cells were then treated for 8 hours with 0.5µM 
epoxomicin before lysis. The intensity of bands was determined using image J 
software and normalized to the actin control.  
 
There was a loss of CRAF in the USP15 depleted cells but not in the 
no oligo control or in cells where USP4 has been depleted. Treatment with 
epoxomicin failed to recue the levels of CRAF in USP15 depleted cells. This 
indicated that the loss of CRAF in U2OS cells was not due to increased 
ubiquitylation leading to its degradation via the proteasome.  
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Figure 3.6. Inhibition of the proteasome fails to rescue CRAF levels. 
U20S cells transfected with siRNA for 72hours before treatment with 0.5µM epoxomicin. Cells 
were lysed in RIPA buffer and lysates were immuno-blotted with CRAF, USP15 and Tubulin 
antibodies. Bands were quantitated using image j and normalised to tubulin, expressed as 
relative abundance to no oligo control. Representative blot shown. 
 
3.2.7. Knockdown of CRAF phenocopies depletion of USP15.  
 
To investigate what the consequences of CRAF loss are in the MAPK 
pathway. We depleted CRAF in U2OS cells with USP15 as a comparison. 
U2OS cells were treated with either a pool of oligonucleotides against CRAF 
or with individual oligonucleotides targeting USP15. Cells were serum starved 
overnight before stimulation with 10ng/ml PDGF for the time course indicated. 
There was a similar reduction in the levels of pMEK with both CRAF and 
USP15 depletion. Knockdown of CRAF is phenocopying the depletion of 
USP15.  
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Figure 3.7 USP15 knock down phenocopies knock down of CRAF.  
U2OS cells were transfected with siRNA for 72hours, serum starved overnight then 
stimulated with 10ng/ml of PDGF for a time course between 0min and 30min. Lysates were 
probed with antibodies against pMEK and CRAF. 
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3.2.8. Rescue attempt of CRAF levels.  
 
We next asked whether the loss of CRAF was dependent on the 
catalytic activity of USP15. In order to answer this question I generated siRNA 
resistant forms (resistant to USP15 Oligo-1) of GFP-USP15* and catalytically 
inactive form GFP-USP15*-C269S (star denotes siRNA resistance). USP15 
constructs were rendered siRNA resistant by introducing silent point 
mutations into the target sequence of oligonucleotide 1. Mutations were 
introduced using Quick-change kit (Stratagene), the primers are documented 
in the materials and methods section 2.5. and 2.6. We made the constructs 
with the aim of expressing these exogenous forms of USP15 and rescuing the 
levels of CRAF seen with USP15 depletion. The same loss of CRAF was 
observed following USP15 depletion in HeLa cells and due to technical 
difficulties performing rescue experiments in U2OS cells; we concentrated on 
rescuing USP15 in HeLa cells.  
 
HeLa cells were treated either with USP15 oligo 1, USP4 as a control 
or mock treated with no oligo for 72 hours. 24 hours prior to lysis cells were 
transfected with GFP, GFP-USP15* or GFP-USP15*-c269s. The constructs 
were expressed constructs had the correct molecular weight and a second 
upper band was observed for GFP-USP15*-c269s that had been previously 
demonstrated to be an ubiquitylated form of USP15. However, in cells treated 
with USP15 oligo1 none of the constructs were expressed, indicative that 
knockdown of USP15 prevented the re-expression of plasmid DNA. 
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Figure 3.8 siRNA Resistant constructs fail to express in USP15 depleted cells. 
HeLa cells were treated with siRNA targeting USP15, USP4 or left as a No Oligo control for 
72 hours. 24 hours prior to lysis cells were transfected with siRNA resistant constructs GFP-
USP15*, GFP-USP15*C269S or GFP.  
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3.3. Discussion. 
 
We originally hypothesized that USP15 would have a positive effect on 
the regulation of the MAPK pathway. This was based on the findings that 
USP15 depletion led to the destabilization of BRAP, an E3 ligase that had 
been previously identified as a negative regulator of the pathway. BRAP 
functions by inhibiting the action of KSR, a scaffold for the RAF/MEK kinases 
facilitating their activation168, 170, 171, 173. The work presented here, together 
with other data published in Hayes et al. (2012)167, demonstrated that USP15 
has a dual role in the regulation of the MAPK pathway through direct and 
indirect mechanisms.  
 
We also monitored the signaling kinetics of EGFR with varying 
concentrations EGF. We analyzed the activation of MAPK and AKT signaling 
pathways using phospho-specific antibodies. The results indicate that there is 
acceleration in the activation of AKT signaling with increasing concentration of 
EGF. While increasing the concentration of EGF delayed the inactivation of 
MAPK signaling. This fit with a model that AKT signaling is primarily occurring 
at the plasma membrane while MEK signaling can be sustained from the 
endosome. EGFR is endocytosed by either clathrin dependent routes with low 
concentrations of EGF (1ng/ml) or clathrin independent routes with high 
concentrations of EGF (100ng/ml)103. Clathrin mediated endocytosis has been 
reported to be dispensable in the degradation of EGFR, however is required 
the prolonged signaling of AKT an MAPK past peak (5mins) stimulation with 
EGF. Inhibition of non-clathrin dependent endocytosis causes increased post 
peak stimulation of AKT and MAPK pathways174. This would suggest that in at 
least HEK293t cells stimulated with EGF the predominant route of entry for 
EGFR is through non clathrin dependent endocytosis. 
 
The effect of EGF concentration on the kinetics of EGF signaling is that 
well understood. However, one study addressing this issue used micro-
western arrays to probe for multiple substrates of EGFR in A549 cells175. 
However, the authors were unable to see the same changes in AKT and 
MAPK we report here. There are two possible explanations for this, first, that 
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there are a cell specific effects of EGF activation that can depend on the 
multiple factors, such as EGFR concentration on the plasma membrane. 
Secondly, the sensitivity of their assay may not as great as our own due to the 
nature of micro-western arrays.  
 
It would be interesting to explore which features of EGF signaling 
kinetics depended on the endosomal localization of EGFR. The activation and 
termination of the AKT signaling pathway is relatively quick and one could 
image that this is a mainly dependent signaling complex being localized 
plasma membrane. However in the case of MAPK pathway, it would be worth 
exploring the role of endocytosis on late acute signaling. Is the second peak 
of MAPK activation dependent on the endosomal localization of EGFR, as 
after 60min acute stimulation one would expect the majority of EGFR to be 
internalized into intra luminal vesicle (ILV) of the multi vesicular body (MVB). 
To test this hypothesis one could perform the same experiment with and 
without perturbation of endocytosis, using for example a dynamin inhibitor.  
 
 By using U2OS cells as a model system we have established that 
USP15 depletion caused a decrease in PDGF stimulated MAPK signaling. 
This was supported by evidence from HeLa cells and suggested that the 
effect was a conserved form of regulation167, as USP15 depletion reduced 
MAPK signaling, in both EGF and PDGF stimulated cells. This led us to 
hypothesis that USP15 was regulating a core component of the MAPK 
pathway. By probing kinases in the pathway, we were able to confirm that this 
hypothesis held true. There was a reduction in the levels of the CRAF kinase, 
which was a specific effect as the BRAF kinase levels remained unaffected. 
Furthermore, the reduction of pMEK seen with USP15 depletion was 
phenocopied by knock down of CRAF.   
 
 This study suggests that USP15 is acting through CRAF to modulate 
the MAPK pathway. This is supported by additional experiments in W266-4 
cells that harbor an activating BRAFV600D mutation. In this genetic background 
the knockdown of USP15 no longer has an effect as downstream signaling to 
MEK, as downstream signaling is now dependent on BRAF by passing 
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CRAF167. In contrast, in this context BRAP loss would be expected to have an 
effect.  
 
Two questions remain outstanding. First, why is BRAP not having an 
affect on the MAPK pathway? This is partially answered in HeLa cells where it 
has been observed that serum starvation ablates the action of BRAP. 
Depleting BRAP in cells grown in full media caused an effect on MAPK 
signaling, which is abolished by serum starvation before stimulation167. In 
U2OS cells however, we didn’t observe this effect. Secondly, are there 
additional targets for USP15 in the MAPK pathway? Knockdown of CRAF 
caused over a 90% drop in CRAF levels, which elicited the same response as 
partial (around 50%) loss with USP15. This raises the possibility that there are 
other targets for USP15 in the MAPK pathway that we are yet to uncover.  
 
 The mechanism of action USP15 on BRAP is direct as it is a bone fide 
substrate of USP15167. The mechanism of action of USP15 remains more 
obscure. Data from our lab indicate that USP15 is acting at a pre-translational, 
level influencing the stability of CRAF mRNA, which is dependent on the 
3’UTR of CRAF167. Although this form of regulation was unexpected for 
USP15 on CRAF, ubiquitylation has been demonstrated to regulate mRNA 
stability176. From the literature it is also apparent that USP15 can regulate 
protein levels by multiple mechanisms. A portion of USP15 has been shown 
to be associated with polysomes and influences the generation of newly 
synthesized proteins177. It has also interacts with multiple components of the 
spliceosome, where it is possibly influencing the splicing of gene products178, 
179.  
 
 This work has helped establish USP15 as modulator of the MAPK 
pathway. It builds on growing evidence of the importance of ubiquitylation as a 
regulator of MAPK signaling events, both directly and indirectly. USP15 has 
now also been established as a mediator of other cancer associated 
pathways, notably, the TGF-β and BMP signaling pathways180, 181.  
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So could USP15 be a viable drug target to treat cancer? With a 
complex involvement in different signaling pathways it is not clear whether 
USP15 would make a suitable drug target. Detailed understanding of the 
signaling functions of USP15 within different genetic backgrounds would need 
to be explored to confirm this hypothesis.  
 
    
 
 
Figure 3.9. Model for the role of USP15 in MAPK signaling cascade. 
USP15  has both positive and negative roles in the regulation of the MAPK cascade. Positive 
by maintaining the levels of the CRAF kinase and negative by deubiquitinating BRAP leading 
to it’s proteasomal degradation. In systems tested in the dominant signaling function of 
USP15 is through CRAF however, in models where MAPK is not dependent of CRAF, the 
dominant signaling function of USP15 may signal through BRAP.   
 
3.4. Conclusions 
 
1. USP15 is a positive regulator of MAPK signaling.  
2. USP15 maintains the levels of the CRAF kinase.  
3. The dominant signaling effect of USP15 in U2OS cells is consistent with 
CRAF modulation.  
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Chapter 4 USP46 is a potential effector of EGFR. 
 
4.1. Introduction 
 
EGFR activation occurs at the plasma membrane19 and the activated 
receptor if internalized into the endo-	  lysosomal pathway13, 182. The topology of 
EGFR means that the cytosolic kinase domain remains in the cytosol until it’s 
is enveloped into multi vesicular bodies (MVB). This allows both the plasma 
and endosomal membranes act as platforms to build EGFR dependent 
signaling complexes122, 123. However, activation of EGFR regulates processes 
in locations distinct from the receptor. To achieve this downstream signaling, 
effector proteins can be recruited to separate compartments. The prototypic 
example of this recruitment is the MAPK (ERK1/2), which translocates from 
the cytoplasm to the nucleus upon EGFR activation. Translocation allows 
ERK to activate downstream transcription factors such as ELK1 and through it 
regulate gene transcription35.  
 
Phosphorylation is a key mediator of signaling pathways downstream 
of EGFR. The role of other post-translational modifications, such as 
ubiquitylation in the EGF signaling pathway is less understood.  In 2011 
Argenzio et al.183 identified 285 proteins that changed ubiquitylation status in 
response to EGF application. This work suggested that ubiquitylation was 
playing a greater role in EGF signal transduction than previously thought. 
Ubiquitin is thought to be able to build signaling networks through interactions 
between ubiquitylated proteins and ubiquitin interacting motifs (UIM), 
comparable to those built between pTyr and SH2 domains. One may expect, 
as proteins are becoming ubiquitylated in response to EGF stimulation, that 
ubiquitylation is involved EGF signal propagation. Because of the dynamic 
nature of signal transduction, one would also expect DUBs to oppose the 
action of ubiquitin dependent signaling complexes. 
 
It has been previously shown that USP8, is recruited onto endosomes 
with EGF application and is cytosolic when cells are serum starved132. USP8 
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regulates the degradation of EGFR through the endo-lysosomal pathway and 
is an effector of EGF signaling cascade132, 135. We devised an assay to 
identify other DUBs which exhibited EGF dependent localizations, utilizing a 
GFP-DUB library previously established in the laboratory184. We hypothesized 
that any DUB that changed its localization with EGF stimulation would 
potentially be an effector of the EGF signaling cascade. 
 
4.2. Results  
 
4.2.1. Identification of DUBs that are post-translationally modified in response 
to EGFR activation 
 
We wanted to mine the literature for DUBs that are post-translationally 
modified with EGF stimulation, to guide our own studies.  We curated data 
from 4 separate mass spectrometry experiments, which had identified post-
translationally modified proteins with EGF stimulation. The first source was 
Olsen et al. (2006)185  who used phospho-peptide enrichment from HeLa cells 
to create a global picture of proteins that are phosphorylated, in response to 
EGF. BAP1 was the highest confidence DUB hit in this screen with FLJ14981, 
A20 and USP54 also having some fluctuations in the phosphorylation status 
with EGF application.  
 
The second source was Hammond et al. (2010)186, the experiment 
sought to identify differences between EGF and HGF signaling in A549 cells. 
The authors used pTyr antibodies to enrich phosphorylated proteins after 
EGF/HGF stimulation, 3 DUBs were identified in the EGF IP, CYLD, USP6 
and USP9x. The third source was Argenzio et al. (2011)183 who enriched for 
ubiquitylated and ubiquitin bound proteins with EGF stimulation from HeLa 
cells. A number of DUB were identified in that study, ATXN3, JOSD1, USP5, 
USP11, USP15 and USP34. The final source was from Blagoev et 
al.(2004)187 using a similar strategy to Hammond et al. (2010)186 enriched 
pTyr pull down with EGF application at 0, 1 and 10min time points from HeLa 
cells. CYLD was the only DUB identified in this experiment and the only DUB 
seen in more than one experiment.  
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Gene 
Phospho Peptide enrichment 
pTyr IP  
EGF/HGF 
Ub IP  
With 
EGF  
pTyr IP 
EGF 
Increasing Decreasing 
BAP1 Y - - - - 
FLJ14981 Y - - - - 
A20 Y - - - - 
USP54 - Y - - - 
CYLD - - Y - Y 
USP6 - -  Y - - 
USP9X Y - Y - - 
ATXN3 - - - Y - 
JOSD1 - - - Y - 
USP5 -  - - Y - 
USP11 - - - Y - 
USP15 - - - Y - 
USP34 - - - Y - 	  	  
Table 4.1 PTM-DUB identified in large-scale proteomic screens. 
Data collected from 4 different sources on post-translational modification of DUBs in response 
to EGF signaling. Column 1 is sourced from Olsen et al.(2006) 185, Column 2 is sourced from 
Hammond et al.(2010) 186, Column 3 is sourced from Argenzio et al.(2011) 183, Column 4 is 
sourced from Blagoev et al.(2004) 187. 	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4.2.2. Validation of model system	  
 
We sought to validate HeLa cells as a model by demonstrating that 
changes in localization could be observed with saturating dose of EGF and 
that those changes could be visualized following fixation in 4% PFA. As a 
readout we used the ERK1/2 as it is a prototypic model for protein 
translocation after EGF stimulation. HeLa cells were serum starved for 16 
hours before stimulation with 20ng/ml EGF for 10 mins. Cells were fixed in 4% 
PFA and stained using antibodies against ERK1/2 and the phospho specific 
antibodies that target the activated form of ERK1/2 (Thr202/Tyr204). ERK1/2 
translocates into the nucleus after 10 mins of stimulation with 20ng/ml EGF 
stimulation in its activated form (Figure 4.1). 
 
 
 
 
 
Figure 4.1 Positive controls for EGF dependent translocation. 
 
Validation of model, HeLa cells were serum starved for 16hours before application of 20ng/ml 
EGF for 10mins and fixed in PFA. Cells were stained with antibodies against the 
phosphorylated and total ERK.  
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4.2.3. DUB-EGF screen  
 
We chose to perform the screen in HeLa cells, as the GFP-DUB library 
had been previously used in this system to assess the basal localization of 
each construct184. This provides an added reference point to assess changes 
in localization seen with EGF application. Cells were serum starved before 
stimulation to remove the effect of any other factors present in the serum. 3 
time points were used, 0 min representing serum starved conditions, 10 min 
to capture post-peak stimulation and 30 mins for late signaling events. 
 
HeLa cells were transfected with individual members from the GFP-
DUB library. 63 individual DUBs were included in the screen; a break down of 
the coverage across the families of DUBs is shown in figure 4.2.B. Following 
detailed visual inspection, changes in distribution were noted for USP8, 
USP46 and UCHL5. Figure 4.2.A shows representative images for these 
proteins taken from the screen. USP8 was observed being recruited onto 
punctate structures in the cytoplasm. This served as a positive control for the 
screen as the endosomal recruitment of USP8 with EGF stimulation has been 
previously reported132. USP46 was also observed on similar punctate 
structures in the cytoplasm with EGF stimulation, reminiscent of those 
changes seen with USP8. UCHL5 was seen in punctate structures in the 
nucleus under starvation conditions that disappeared with EGF stimulation. 
The changes seen were all subtle; therefore quantification was performed on 
USP46 and UCHL5 to increase confidence. As USP8 translocation has been 
previously reported132 we didn’t follow this up.  
 
 Full results are shown in supplementary figures S.1-6. Results are split 
into DUB sub-families groups with representative images shown for each 
DUB. Notes from the screen are documented in supplementary table S.1. 
Some DUBs displayed dual distributions that were not dependent on EGF 
when further analyzed; this data is summarized in table S.1.  
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Figure 4.2. Overview of DUB-EGF screen. 
A) GFP-DUB library was transfected into HeLa cells, cells were stimulated with 20ng/ml of 
EGF for a time course of 0min, 10min and 30min. Cells were then imaged using fluorescence 
microscopy to judge changes in subcellular localization. Representative images shown in 
panel A. Scale = 10µm. 
B) A graphic representation of the coverage of the screen across the different families of 
DUBs.  
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4.2.4. Quantification of UCHL5 distribution 
 
There was an enrichment of UCHL5 into punctate structures within the 
nucleus in serum-starved conditions, which disappeared following EGF 
stimulation. This observation was quantified by stratifying cells into different 
bins were there was no punctae (C; red), observable punctae (B; yellow) and 
prominent punctae (A; green). Each experiment was performed 3 times and 
approximately 200 cells were counted per condition, cells were counted by 
eye under the microscope from random fields of view, error bars represent 
standard deviation. There was a significant dissipation of the punctate 
structures following EGF stimulation (Figure 4.3).  
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Figure 4.3 Quantification of GFP-UCHL5 nuclear punctae. 
HeLa cells were transfected with 1µg GFP-UCHL5, serum starved for 16 hours and then 
stimulated with 20ng/ml EGF for a time course of 0, 10 and 30 mins before fixation in 4% 
PFA. A) Represents criteria for stratification A, prominent nuclear punctae B, observable 
punctae C, No nuclear punctae. Images taken from fig. 4.21. scale bar = 20µm B) Graph 
showing the results of quantification, results were grouped into 3 bins. Approx. 200 cells were 
counted per condition, n=3. Bars represent standard deviation. 
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4.2.5. Quantification of USP46 punctate distribution in HeLa and U2OS cells. 
 
Quantification of USP46 enrichment into cytosolic punctate structures 
was performed on GFP-USP46 transfected cells. Cells were stratified into 2 
categories (i) observable punctae (ii) diffuse cytosolic distribution. Each 
experiment was performed 3 times and approximately 100 cells were counted 
per condition, cells were counted by eye under the microscope from random 
fields of view. Under serum starved conditions 13%±3 of transfected cells 
displayed punctae, after 10mins 20ng/ml EGF stimulation this increased to 
60±11% and fell to 48±11% after 30mins of EGF stimulation (Figure 4.4).  
 
To test whether this effect was specific to EGF stimulation we tested 
the effect of PDGF stimulation on U2OS cells transfected with the same 
plasmids. Under serum starvation conditions, 14±6% of transfected cells had 
a punctae distribution, this rose to 55±4% after 10min stimulation with 20ng/ml 
PDGF. Representative images from U2OS cells are shown in figure 4.4.B.  
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Figure 4.4. Quantification of Punctate Phenotype. 
 
A) Images taken from DUB-EGF screen, images A and G are taken from figure 4.3.1.A. 
HeLa cells were transfected with GFP-USP46 and stimulated with 20ng/ml EGFR. 
Scale = 10µm. Cells were stratified as either (i) observable punctae (ii) diffuse 
cytosolic distribution. Error bars = Std dev. n= approx. 100 per condition.  
B) B) U2OS cells were transfected with GFP-USP46, cells were serum starved overnight 
before stimulation with 20ng/ml PDGF. (i) Observable punctae (ii) diffuse cytosolic 
distribution. Error bars = Std dev. n= approx. 100 per condition. 
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4.2.6. Blockade of the EGF receptor activation prevents USP46 translocation. 
 
 We next wanted to test if either of the MEK/ERK or PI3K/AKT 
pathways is required for the translocation to occur. To do this we used a panel 
of kinase inhibitors, which would block the canonical signaling cascades 
downstream of the EGFR receptor. Gefitinib that blocks activation of the 
receptor itself188, PI103 that inhibits class 1α PI3K189 and AZD6244 that 
inhibits MEK190. We titrated the concentration of the kinase inhibitors and 
tested the efficacy using HeLa cells which were incubated for 15 mins with the 
kinase inhibitors before the media was exchanged for medium containing 
20ng/ml EGF + the respective concentration of kinase inhibitor. Cells were 
then lysed in RIPA buffer and lysates were probed with phospho specific 
antibodies against the EGFR receptor, AKT and ERK kinases, which identify 
the active form of each kinase. We noted that with increasing concentrations 
of the MEK inhibitor we observed a paradoxical increase in the levels of AKT 
phosphorylation (figure 4.5.A). Gefitinib and AZD6244 were used at a 
concentration of 300ng/ml and PI103 were used at 150ng/ml. 
 
When the translocation of GFP-USP46 was assessed in the presence 
of the kinase inhibitors there was a block of the translocation seen with 
treatment with Gefitinib to similar levels observed (10%±4%) in serum starved 
cells indicating that the translocation was dependent upon tyrosine kinase 
activation. There was no effect observed with inhibition of the PI3K signaling 
pathway (47±1%) compared to the DMSO control (45±5%) and blockade of 
the MAPK pathway (21±13%) showed a partial blockade of the translocation 
(figure 4.5.B). This indicated that the translocation effect was downstream of 
the EGFR receptor regulated, by the MAPK pathway, which corroborates with 
the observations that PDGF stimulation can also induce the translocation as 
the PDGF can also activate the MAPK pathway.  
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Figure 4.5. Recruitment to punctae is blocked by inhibition of EGFR/ERK pathway. 
A) Titration of inhibitors on HeLa cells. HeLa cells were serum starved for 16hours then they 
were then pretreated for 15mins with the inhibitor at the concentration indicated, then 
stimulated with 20ng/ml EGF in the presence of the inhibitor. Cells were lysed in RIPA buffer 
and probed using phospho-specific antibodies.  
B) HeLa cells were transfected with GFP-USP46 for 24hours. Cells were serum starved 
overnight then pretreated with DMSO, 300ng/ml Gefitinib, 150ng/ml PI 103 or 300ng/ml 
AZD6244. 20ng/ml was then added in the presence of the inhibitor. Transfected cells were 
stratified into either having punctae or not with approx. 100 cells counted per condition. n=3, 
error bars represent standard deviation. 
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4.2.7. USP46 is localized to HRS positive endosomes. 
 
We next sought to identify the punctate structures using confocal 
microscopy to assess co-localization with a panel of markers for various 
endocytic compartments. U2OS cells were stimulated with 20ng/ml PDGF and 
either fixed in methanol or 4%PFA depending on the requirement of the 
antibodies. There was co-localization with HRS, a protein that decorates the 
MVB compartment191. Concomitant with HRS there was also some overlap 
with the retromer component VPS26 that is involved in cargo recognition for 
retrograde transport from the late endosome to the trans Golgi network 
(Figure 4.6). 
 
 
 
 
 
Figure 4.6. USP46 is recruited to HRS positive endosomes. 
U2OS cells were transfected with GFP-USP46 for 24 hours then serum starved overnight 
before stimulation with 20ng/ml PDGF for 10min then subsequently fixed in 4% PFA or 100% 
methanol. Cells were then labeled with antibodies indicated. Cells were imaged using 
confocal microscopy. Scale = 20µm. 
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4.2.8. Knock down of USP46 has no effect on the trafficking of EGFR but 
causes a delay in the inactivation of EGF signaling. 
 
Given the response to EGF and localization of GFP-USP46 on the 
multi-vesicular body compartment we wanted to test if knockdown of USP46 
had an effect on the degradation of EGFR and downstream signaling. USP46 
was depleted using a pool of siRNA oligonucleotides against USP46, using a 
double hit protocol over a period of 120 hours. Cells were serum starved for 
16hours before stimulation with either 1ng/ml or 100ng/ml EGF over a time-
course of 0 to 120 mins.  
 
Depletion of USP46 had no effect on the rate of degradation of EGFR 
was observed (Figure 4.7.A and C). There is a characteristic upshift of the 
EGFR band with EGF stimulation consistent with hyperphosphorylation of the 
receptor. At 5 mins hyperphosphorylation is such that it partially prevents the 
ability of the antibody to recognize EGFR, as the epitope is located in the 
intracellular domain of EGFR. To better image the later time-points when 
EGFR is not hyper-phosphorylated, 30µg of sample were run on a gel 
confirming that there was no effect on EGFR degradation for the time points 
0, 30, 60 and 120mins.  
 
Samples stimulated with 1ng/ml EGF were probed with pAKT (Ser473) 
and pMEK (Ser217/221) as readouts for activation of the two canonical 
signaling pathways downstream of EGFR (Figure 4.7.B). There was little 
change in the peak phosphorylation of either pathway, however there was a 
delay in the inactivation for both pathways seen by increased phosphorylation 
at the 60 and 120 min time-points.  
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Figure 4.7. USP46 depletion has no effect on the degradation of USP46 but delays 
pMEK and pAKT inactivation. 
HeLa cells were treated with a pool of oligonucleotides targeting USP46 or a Non-targeting 
oligo for 120 hours. Cells were serum starved for 16hours before stimulation with either 
100ng/ml EGF (A and C) or 1ng/ml EGF (B). A and C are the same experiment with lysates 
run at 15µg and 30µg to improve visualization of EGFR band. * Denotes non-specific band.  
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4.2.9. Knock down of USP46 delays AKT inactivation. 
 
Next we wanted to test if the signaling phenotype seen with depletion 
of USP46 was a specific effect of the siRNA. We therefore depleted USP46 
using individual oligonucleotides from the pool used in previous experiments. 
We also tested if the stability of PHLPP1/2 was affected by USP46 depletion. 
PHLPP1/2 are phosphatases that have been identified as interactors with 
USP46, and are described as regulating the activity of AKT58, 178. A delay in 
the inactivation of MAPK/AKT pathways was observed when USP46 was 
depleted, to identify a possible mechanism for this regulation we tested if the 
depletion of USP46 affected the stability of PHLPP1/2 (figure 4.8).  
 
HeLa cells were treated with siRNA for 72 hours in order to deplete 
USP46. Non-targeting oligonucleotide (NT1) and No Oligonucleotide mock 
transfection (NO) was used as controls. Cells were serum starved for 16 
hours before treatment with 1ng/ml EGF (approximately the EC50 defined in 
chapter 3) for 5 mins to look at the peak activation and 60mins to look later 
time point. Of the 4 oligonucleotides, 6, 7 and 8 generated efficient 
knockdowns while 9 only partially depleted USP46. An increase in pAKT 
signaling and to a lesser extent with pMEK was seen with oligonucleotides 6 
and 7 but not with 8. No changes were seen in the stability of PHLLP1 and an 
increase in the levels of PHLLP2 was seen with oligonucleotide 6 (figure 4.8).  
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Figure 4.8. Deconvolution of USP46 depletion phenotype on activation of EGF 
signaling. 
HeLa cells were treated with individual oligonucleotides for 72hours. Cells were serum 
starved for 16hours before treatment with 1ng/ml EGF for 5 and 10mins before lysis in RIPA 
buffer.  
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4.2.10. Depletion of USP46 in HCT116 cells. 
 
 During the course of this study it was reported by Li et al. (2013)192 that 
USP46 was a DUB for PHLPP1. The authors demonstrated that USP46 
regulating PHLPP1/2 stability and the phosphorylation of AKT through 
PHLPP1, in the context of colon cancer cells (HCT116). In light of our results 
we wanted to use the same model system to look at the stability of PHLPP1 
and the attenuation of pAKT signaling. We performed the siRNA depletion 
experiment in HCT116 cells using oligonucleotides 6 and 7, which gave the 
greatest knockdown of USP46 in HeLa cells.  
 
 We first titrated the concentration of EGF using pMEK as a readout of 
EGFR activation as to be consistent with previous experiments. The EC50 for 
our EGF on HCT116 cells was approximately 5ng/ml, which was used, in 
subsequent experiments. The time course of pMEK activation in HCT116 cells 
displayed interesting kinetics, after peak stimulation there was a long 
refractory period were pMEK did not return to basal levels of stimulation 
(Figure 4.9.A).  
 
 HCT116 cells with depleted USP46 showed differential activation of the 
AKT pathway with the two oligonucleotides tested. Oligonucleotide 6 
produced a large increase in the levels of pAKT with stimulation over the NT1 
control. This effect however was not replicated with the oligonucleotide 7 
which had kinetics more similar to the NT1 control. No effects were observed 
on the stability of PHLPP1 with either oligonucleotide despite both produced 
efficient knockdowns (Figure 4.9.B). 
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Figure 4.9. Depletion of USP46 in HCT116 cells.  
A) HCT116 cells were serum starved for 16hours before treatment with EGF at the 
concentration and time indicated. Representative blot shown. 
B) HCT116 cells were treated with siRNA targeting with USP46 or with a non-targeting control 
oligonucleotide FOR 72 hours. Cells serum starved for 16hours before treatment with 5ng/ml 
EGF for the time indicated. Quantification was performed using Image J software; values are 
normalized to actin control. Representative blot shown. 
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4.3. Discussion 
 
We devised an assay to look for mobilization of DUBs with EGF 
stimulation, using a GFP tagged DUB library transiently expressed in HeLa 
cells. The assay was viable and the redistribution of USP8 could be observed, 
serving as a positive control that was consistent with reports in the 
literature132. From this screen, we identified a number of candidate DUBs that 
either changed localization or induced changes in cell shape when stimulated 
with EGF. 2 DUBs USP46 and UCHL5 were quantified and EGF dependent 
distributions were confirmed. USP46 was chosen for more detailed analysis, 
as the changes in distribution were reminiscent of those seen for the EGF 
effector USP8 and because of the availability of reagents. Using confocal 
microscopy USP46 was confirmed as an endocytic DUB partially, co-
localizing with HRS, a protein that decorates the sorting endosome. A number 
of DUBs have been associated with endosomes, AMSH129, AMSH-lp131, 
USP8132, USP2a193 and USP10194, all of the which have proposed roles in the 
trafficking of plasma membrane proteins. AMSH195, USP8132 and USP2a193 
have been demonstrated to directly influence the trafficking of EGFR. 
 
USP46 has been shown to play a role in the trafficking of the inotropic 
GluR1 channel in C.Elegans. Knockout worms show a decrease in the 
expression levels of GluR1 and an increase in the ubiquitylated form of the 
receptor142. This evidence is compounded in mice by a loss of function 
mutation in USP46 (deletion of Lys92 in mice), which significantly reduced 
immobile time during forced swimming test (FST) and tail suspension assays 
(TST)196. When animals are subjected to FST and TST they enter a state of 
behavioral despair, where the animal cannot escape the situation it is in and 
effectively gives up. This is commonly used to test for anti-depressive effects, 
as anti-depressive compounds reduce immobility time in these assays197. 
USP46 knockout mice mimic the effect of the mutation and agonists against 
GABAA neurons partially increased immobility time. However, these results 
suggest that USP46 is having multiple levels of action197, possibly through the 
regulation of plasma membrane receptors.  
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In our experiments USP46 didn’t regulate the trafficking of EGFR as 
judged by biochemical methods. These results are consistent with results 
from Parja et al.198 who performed a family wide siRNA DUB screen to identify 
DUBs altering EGFR degradation, using the same assay as here.  The non-
effect of USP46 depletion on the termination of EGF signaling in figure 4.8 
was reproduced with 2 oligonucleotides (figure 4.9) in HeLa cells. We tested 
the stability levels of PHLPP1/2 because it had been reported that USP46 
interacts with PHLPP phosphatases192,178. PHLPP1/2 are phosphatases that 
directly dephosphorylate AKT at Ser473 and have tumor-suppressing 
effects58. USP46 has also been reported to regulate the stability of the PHLPP 
phosphatases, and theoretically influences the activity of AKT in HCT116 
colon cancer cells192. However, the results here contradict those published by 
Li et al. (2013)192. Following efficient knockdown of USP46 no effect on 
PHLPP1 expression levels could be observed, which should reflect protein 
stability.  
 
We sought to clarify our results with regards to the activation of AKT 
and PHLPP1/2 by performing USP46 depletion experiments in HCT116 cells 
(the same used in Li et al. (2003)192 study). Oligonucleotide 6 produced a 
pronounced effect on the levels of pAKT while oligonucleotide 7 had no effect, 
nor did depletion of USP46 have an effect on the stability of PHLPP1. It is of 
note that the antibody used to detect PHLPP1 was from the same source of Li 
et al. (2003)192 and has been well characterized199. It is also worth noting that 
the antibody has also been reported to cross react with β-catenin, which casts 
further doubt on some of the data published by Li et al. (2013)192, 199. The 
results presented here directly contradict the conclusions in the Li et al.192 
study. There are two possible explanations for this, first, that our depletion 
was not as effective as that previously employed and the remaining pool of 
USP46 is sufficient to maintain PHLPP1 levels. In that case the effect seen 
with oligonucleotide 6 may occur because it has the most efficient depletion. 
Alternatively as only 1 oligonucleotide is having a significant effect across 2 
cell lines (HeLa and HCT116) then the effect seen is an off target effect of the 
siRNA.  
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This chapter describes USP46 as a new endosomal DUB responding 
to EGF activation although we failed to establish a specific endosomal 
function for USP46.  This work has directly contradicted published work 
describing USP46 as a regulator of EGF signaling through PHLPP1/2.  
 
4.4. Conclusions 
 
• USP46 is an endosomal DUB. 
• USP46 is a potential effector of the EGF signaling cascade. 
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Chapter 5 USP46 interactome 
 
5.1. Introduction 
 
USP46 is a deubiquitylase that has been implicated in the regulation of 
glutamate receptor (inotropic, GluR1) trafficking142 and has been identified as 
drug a target to treat depression196, 197. In the previous chapter we have 
identified USP46 as an endosomal deubiquitylase but could not identify any 
endosome specific functions of USP46. Interaction datasets have been 
generated for across the families of DUB including USP46 by Sowa et al. 
(2009)178 through immuno precipitation (IP) experiments coupled with LC-
MS/MS identification, however, no endosomal proteins were among the high 
confidence interactors178. WDR20 and WDR48 are the 2 best-characterized 
interactors of USP46200. WR20 and WDR48 belong to a family of proteins 
characterized by the inclusion of WD40 domains. These proteins are believed 
to behave as interaction hubs that facilitate interactions in protein complexes. 
Binding of WDR48 and WDR20 to USP46 is required for the deubiquitylating 
activity200 and the interaction is required for USP46 function as a histone 
deubiquitylase201.  
 
In addition to WDR20/WDR48, the AKT phosphatases PHLPP1/2 have 
been identified as interactors of USP46192, reported in 3 separate papers178, 
192, 200. However, none of these studies have seen this interaction with the 
endogenous USP46 raising the possibility that it requires overexpression of 
USP46 to be observed. In the previous chapter we were unable to see any 
effects on the stability of PHLLP1/2 with USP46 depletion and could not 
definitively prove an effect on AKT activity. To better understand the functions 
of USP46 we sought to identify interactors in an unbiased fashion. 
 
 We generated cell lines that stably expressed GFP-USP46 and 
catalytically inactive GFP-USP46-C44S using the Flp-in system. We could IP 
the exogenous plasmid using GFP Nano-trap antibody, from SILAC (stable 
isotopically labeled amino acids in culture) labeled cells. This allowed us to 
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directly compare interactors of GFP-USP46, GFP-USP46-C44S and GFP, in 
a quantitative manner by using the SILAC ratio to excluded non-specific 
interactors with GFP202. From this experiment we identified several candidate 
interactors, including FBXO11, a substrate-recognizing component of the 
SKP-CUL E3 ligase complex203.  
 
5.2. Results 
 
5.2.1. USP46 antibody is not applicable to IP. 
 
We wanted to establish a method to IP USP46 from cells. We tested 
the abundance across different cell lines to identify a cell line that expressed 
high levels of USP46 from which to IP from. 20µg of lysate from of a panel of 
cell lines was loaded onto a SDS page gel and probed with antibodies against 
USP46 and USP8, as a reference (Figure 5.1.1). The levels of USP46 varied 
more greatly across different cell lines, compared to USP8. HEK293t cells had 
the greatest expression of USP46, while HeLa cell had a relatively low 
abundance of USP46. We therefore used HEK293t cells to check the 
efficiency of the anti-USP46 antibody (Sigma) for IP. 
 
ggghhggg 
 
Figure 5.1.1. USP46 expression across a panel of cell lines.  
20µg of lysate of each cell line was loaded onto SDS page gel. Even loading was determined 
by Ponceau staining. Lysates were probed for USP8 and USP46.  
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 We sought to test the efficiency of our anti-USP46 antibody (Sigma) to 
IP endogenous USP46. HEK293t cells were lysed in NP40 buffer and 750µg 
of lysate with 0.75µg of antibody for 3 hours at 4˚C (Figure 5.1.2). There was 
little depletion of USP46 in the unbound fraction compared to both the input 
and the unbound fraction from the beads only IP. The experiment also 
highlighted another problem with this approach. There was contamination of 
the IP with the heavy and light chain of the antibody. As the bands for the 
heavy and light chain of the antibody were so strong, they would mask the 
detection any proteins of the same size. We adopted an alternative strategy to 
overcome these problems using GFP Nano-trap llama antibody that consists 
only of a 13kDa light chain159 in a system expressing GFP tagged USP46. 
The antibody can be produced in the laboratory cheaply and can be coupled 
to sepharose beads (documented in materials and methods section 2.3.13).  
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Figure 5.1.2. Endogenous USP46 IP from HEK293t cells. 
HEK293t cells were lysed in NP40 buffer. 750µg of lysate was subjected to immuno 
precipitation (IP) with 0.75µg of anti-USP46 antibody or just beads alone. Input, IP and 
unbound fractions were loaded onto a SDS page and probed with anti-USP46 antibody.  
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5.2.2. Generation of USP46 stable cell lines. 
 
In order take advantage of the GFP Nano-Trap system we developed 
two cell lines that expressed GFP-USP46 and GFP-USP46-C44S. We used 
the Flp-in system (Invitrogen) to generate the cell lines because it has a 
number of advantages. First, it has one integration site so each cell should 
express the plasmid at the same level across separate clones. This allows for 
direct comparisons of mutant cell lines without variations in expression levels 
and the artifacts they introduce. The second advantage was that our USP46 
cell lines expressed relatively low levels of GFP-USP46 compared to transient 
transfection; 5 times the levels of endogenous USP46 (figure 5.2.2.).  
 
The Flp-in system takes advantage of Flp Recombination Target sites 
that are introduced into the genome of the parental cell line. Dual transfection 
of plasmids containing the gene of interest flanked by FRT sites with pOG44 a 
plasmid that expresses Flp recombinase, stably introduces the plasmid of 
interest into the FRT sites in the parental cell genome. A Hygromycin B 
resistance cassette is included in the expression vector (figure 5.2.1). Once 
the recombination event has taken place this allows selection of positive 
clones.  
 
To generate constructs to establish our cell lines, point mutations were 
introduced into existing GFP-USP46 constructs rendering it inactive by 
mutating the catalytic cysteine to serine. Both constructs were also made 
siRNA resistant to oligonucleotide USP46-8 by introducing silent point 
mutations into the siRNA target sequence. A stop codon was also introduced 
to prevent the translation of the V5 tag into the open reading frame that is part 
of the Invitrogen vector. All Point mutations were introduced using the Quick-
Change kit (Agilent) and primers are documented in the materials and 
methods section (2.1.6). PCR derived, linear GFP-USP46 and GFP-USP46-
C44S were introduced into pEF-FRT-V5 vector by TOPO recombination. pEF-
FRT-V5-USP46 and pEF-FRT-V5-USP46 vectors were transiently transfected 
into HeLa S3 cells with pOG44 recombinase using Genejuice. The constructs 
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were incorporated into the genome HeLa S3 cells that had previously had a 
single FRT site introduced (Maria Hernandez) (Figure 5.2.1).  
 
 
 
 
 
Figure 5.2.1 Schematic for the generation of GFP-USP46  Flp-in Cell lines. 
pEF-FRT-GFP-USP46 and pEF-FRT-GFP-USP46-C44S vectors were transiently transfected 
into HeLa S3 cells with pOG44 recombinase. Through a recombination event the constructs 
were incorporated into the genome HeLa S3 cells that had previously had FRT site 
introduced. Figure adapted from Invitrogen handbook.  
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Colony Island Morphology 
WT1 ++ 
WT2 +++ 
WT3 + 
WT4 ++ 
WT5 ++ 
WT6 +++ 
WT7 Failed to grow 
CS1 ++1/2 
CS2 ++1/2 
CS3 +++ 
CS4 ++1/2 
CS5 + 
CS6 Failed to grow 
 
 
Table 5.1. Morphologies of USP46 cell line clones. 
 
GFP-USP46 (WT) cells are numbered 1-7 and GFP-USP46-C44S (CS) is numbered 1-6. 
Morphology was visually judged between + and +++ according to how similar the 
morphology was to parental cell lines. 
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Figure 5.2.2. Lysates from stable cell line clones. 
25µg of NP40 lysate were run of SDS-page gels. Cell lysates were probed with A) anti-
USP46 and B) anti-GFP. GFP-USPP46 predicted molecular weight = 69kDa GFP =27kDa 
and USP46=42kDa. Quantification of anti-USP46 blot was performed using Odyssey (Licor) 
software. C) Quantification of endogenous USP46 levels across cell lines. D) Quantification 
was expressed a % of the greatest band (WT2) to compare GFP-USP46 band to the 
endogenous band. Quantification was performed using the odyssey (Licor) software. 
Representative blots shown. 
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Transfected cells were maintained in Hygromycin B containing medium 
to select for positive clones. 7 colonies were picked for wild type cells and 6 
colonies were picked for catalytically inactive transfected cells, 2 colonies, 
WT7 and CS6 failed to grow. Colonies were scored out of 3 based on their 
morphology (Table 5.1) with WT2, WT6 and CS3 having the morphology most 
like the parental cells (+++). There was stable expression of the constructs 
across the different clones and a reduction in the levels of the endogenous 
protein relative to GFP control Flp-in cells (courtesy of Han Liu) (Figure 
5.2.1.C). There was approximately 5 times more GFP-USP46 and GFP-
USP46-C44S expressed in our cell lines, compared to the endogenous 
protein (Figure 5.2.1.D). This expression was within a normal physiological 
range as HEK293t cells express more that 5 times the levels of USP46 than 
HeLa cells (figure 5.1.1). 
 
 The expression levels of GFP-USP46 in the cell lines were relatively 
low making them difficult to image. Therefore we counter stained the GFP-
USP46 (WT2) and GFP-USP46-C44S (CS3) cell lines with anti-GFP antibody 
to increase the fluorescence signal (Figure 5.2.3). Cells were either stained 
under basal conditions or alternatively cells were serum starved for 16 hours 
and either stimulated with 20ng/ml for 10 mins before pre-permeabilization 
(pre-treatment) in 0.02% Saponin/MTSB (microtubule stabilizing buffer) for 3 
mins to extract cytosolic background before fixation in 100% methanol (-20˚C) 
before labeling with anti-GFP and anti-HRS antibodies to asses co-
localization. 
 
 GFP-USP46 and GFP-USP46-C44S had a fine punctate distribution 
that was resistant to Saponin permeabilization. The punctate structures 
displayed little co-localization with HRS and there was no change in the 
distribution of GFP-USP46 and GFP-USP46-C44S with EGF stimulation.  
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Figure 5.2.3. Images of GFP expressing cells. 
GFP-USP46-C44S (CS3) and GFP-USP46 (WT2) cells were fixed in 4% methanol and 
stained with anti-GFP and anti-HRS antibodies with and without pre-treatment with 0.02% 
Saponin to remove cytosolic background and +/- 20ng/ml EGF. Images were taken at the 
same exposure. Scale bar = 10. 
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5.2.3. Signaling response of USP46 stable cells to EGF.  
 
We next wanted to test the response of each of the stable cell lines to 
EGF stimulation. GFP (G7), GFP-USP46 (WT2) and GFP-USP46-C44S 
(CS3) cell lines were serum starved for 16 hours before stimulation with 
1ng/ml EGF over a time course between 0 and 60 mins. The cells were lysed 
in RIPA buffer and lysates were probed for pMEK and pAKT as readouts of 
activation of the MAPK and AKT signaling pathways respectively.  
 
Cell expressing GFP-USP46 (WT2) had greater levels of pAKT at all 
time points compared to the GFP expressing (G7) control cells. Cells 
expressing the catalytically active form of GFP-USP46-C44S (CS3) had a 
similar activation peak as WT2, but the increase late pAKT signaling in the 
WT2 was not observed in CS3 cells (figure 5.3). In WT2 and CS3 cells there 
was a decrease in the activation of the MAPK pathway compared to the G7 
cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   	   	  	  
	   125 
 
 
 
 
Figure 5.3. EGF signaling response of stable cell lines.  
GFP (G7), GFP-USP46 (WT2) and GFP-USP46-C44S (CS3) cells were serum starved 
overnight before stimulation with 1ng/ml EGF. Cells were lysed in RIPA buffer and probed 
with pAKT (Ser473) and pMEK (Ser217/221) antibodies as readouts for AKT and MAPK 
pathway activation respectively. Quantification was performed using Image J, pAKT levels 
were normalised to Actin control. Representative blots shown. 
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5.2.4. Optimizing IP conditions for GFP Nano-Trap antibody.  
 
We sought to determine the optimal conditions to use the GFP Nano-
trap antibody to IP GFP-USP46 from our cell lines. We wanted to establish 
conditions that had effective depletion of the GFP-USP46 constructs from 
cells, while having the minimal amount of antibody in the IP to reduce non-
specific binding of the antibody and the beads. The antibody was pre-coupled 
to the sepharose beads (Maria Hernandez). 5µl of antibody beads complex 
was added to increasing amounts of GFP-USP46 lysate. The most effective 
depletion observed was when 5µl of antibody:bead complex was incubated 
with 100µg of lysate. Depletion could be quantitated using densitometry, 
demonstrating that there was a 70% depletion compared to the input, when 
5µl of bead/antibody complex was incubated with 100µg of lysate (Figure 5.4). 
We chose not to use a higher concentration of antibody to minimize non-
specific binding.  
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Figure 5.4. Testing GFP Nano-trap antibody.  
GFP-USP46 (WT2) cells were lysed in NP40 buffer. GFP-USP46 was immuno-precipitated 
(IP) with 5µl of GFP-Nano trap coupled beads from a range lysate from 100µg-300µg, 30µg of 
lysates were loaded from the input and unbound fractions. Quantification was performed 
using Image J software. Representative blots shown. 
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5.2.5. Mass spectrometry identification of USP46 interactors. 
 
To identify interactors of USP46 we performed IP from USP46 stable 
cell lines cultured in SILAC media, using GFP expressing cells as a control. 
Cells were grown in media containing “heavy” amino acids l-Lysine-2H4 (Lys 
4, 4Da heavier), l-arginine-U-13C6 (Arg 6, 6Da heavier), l-Lysine-U-13C6-15N2 
(Lys 8, 8Da heavier) and l-Arganine-U-13C6-15N4 (Arg10, 10Da heavier). There 
will cause a shift in the molecular weight of the peptide, which has 
incorporated a heavy amino acid, which can then be identified by mass 
spectrometry. Producing the peptides using trypsin, which will cut at carboxyl 
side of Lys and Arg, can ensure the production of heavy peptides.  This 
strategy allows you to directly compare the abundance of proteins from 
different samples by comparing the peak intensity between “heavy” peptides 
to the “light”.  
 
Individual IPs were performed from 3mg of lysates derived from GFP, 
GFP-USP46 and GFP-USP46C44S cell lines. GFP cells were grown in “light” 
(Arg0/Lys0), GFP-USP46-C44S was grown in “medium” (Arg6/Lys4) and 
GFP-USP46 was grown in “heavy” (Arg10/Lys8) (Figure 5.5.1). The elute from 
each IP was mixed and dried in a speed-vac the resulting pellet was re-
suspended in sample buffer and run in a single lane on a Nu-page (Invitrogen) 
4-12% SDS gel, as the first phase of chromatography (Figure5.5.1). The gel 
was processed using in gel digestion on bands cut from the gel204. The 
subsequent samples were then loaded on a reverse phase liquid 
chromatography column, run on a 1-62.5% linear ACN gradient over 21 mins 
coupled to a LTQ-OrbitrapXL (Thermo Fisher) fitted with a Proxeon 
nanoelectrospray source. The top 6 most abundant peptides were selected for 
MS/MS identification and raw MS/S data was processed using MaxQuant 
software160. Sample peptide MS1 data for USP46 and FBXO11 peptides 
identified by MaxQuant are show in figure 5.5.2. Samples of MS/MS 
fragmentation data are shown in figure 5.5.3. Fragmentation peaks were 
checked by eye against a theoretical fragmentation for each peptide, 
generated by MS-product software.  
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Figure 5.5.1. SILAC configuration for large scale USP46 immuno-precipitation. 
A) SILAC labeled GFP (G7) (Arg0/Lys0/Pro0) GFP-USP46-C44S (CS3) (Arg6/Lys4/Pro0) and 
GFP-USP46-C44S (WT2) (Arg10/Lys8/Pro0) were lysed in NP40 buffer and were subjected 
to immuno-precipitated (IP) using GFP Nano-trap antibody. IP elute was mixed in a 1:1:1 ratio 
and run on a SDS page gel, the bands were cut from the gel (B) and subjected to in gel 
digestion. Peptides were detected by LC-MS/MS and identified using MAX-Quant software. 
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Figure 5.5.2. Sample MS1 spectra. 
Sample spectra derived from USP46 and FBXO11 with peaks labeled the medium (yellow) 
and heavy (red) condition.  
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Figure 5.5.3. Sample peptides from MS/MS identification.  
Peptides from MaxQuant identification, y and b fragments ions are indicated for each peptide 
and the corresponding raw peaks are labeled as such.  
	   	   	  	  
	   132 
150 proteins were identified in the experiment, 10 of which were known 
contaminants such as Keratin and were removed from further analysis. We 
then performed 2 levels of exclusion, first removing proteins that were part of 
the BEADome; known “sticky” proteins that are commonly seen in IP 
experiments established by Trinkle-Mulcahy et al. (2008)202, this included 
many histone proteins. Despite USP46 having been demonstrated to be a 
Histone deubiquitylase201 we removed them from our list as we did not have 
the expertise in the lab to follow them up and could not be sure of the 
reliability of these hits, as they are known “sticky” proteins. The second level 
of exclusion was to remove any proteins seen in IP experiments from our lab, 
using the same strategy of IPing GFP tagged constructs from Flp-in cells 
established from the same parental cell line. A full list of identified peptides 
including those expelled from either first or second exclusion is provided in 
supplementary table 2.  
 
In figure 5.5.2-3, graphs of residual proteins are plotted as intensity to 
LOG10 against LOG2 of ratio. In figure 5.5.2, graph A, ratios are calculated 
between GFP-USP46/GFP and in graph B, GFP-USP46-C44S/GFP. In figure 
5.5.3 ratios are calculated as GFP-USP46/GFP-USP46-C44S providing a 
comparison between the interactors of the wild type and catalytically inactive 
form of USP46. Data points were labeled in red for proteins that were 
enriched greater or equal to 1.5 fold in either GFP-USP46 or GFP-USP46-
C44S against GFP. WDR48 and WDR20 are known binding partners of 
USP46205 and are thought to regulate the deubiquitylase activity of USP46, 
and have been labeled in grey as a known protein complex. Neither WDR20 
nor WDR48 showed a significant preference for the wild type or catalytically 
inactive form.  
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Figure 5.5.4. Comparison of USP46 interactors compared to GFP control. 
SILAC ratios were generated between GFP and GFP-USP46/GFP-USP46-C44S using Max 
Quant. Ratios were transformed to a LOG2 scale and plotted against the LOG10 of the 
intensity of the peptide signal. Points that have a positive ratio represent proteins that are 
found more in the GFP-USP46/GFP-USP46-C44S IP. Grey circles denote USP46 complex.  
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GFP was enriched in the GFP IP compared with either GFP-USP46 or 
GFP-USP46-C44S presumably because of the higher expression of GFP 
compared to either USP46 construct. Ubiquitin (UBB) preferentially bound to 
the catalytically inactive mutant of USP46 over the wild type. It is not clear if 
the ubiquitin detected derives from USP46 itself and/or from substrate 
proteins. There was a bias in the experiment towards the catalytically inactive 
form of USP46 as more proteins were identified in the “medium” condition 
figure 5.5.4). This suggests that the catalytically inactive form may act as a 
substrate trap; further experiments would be needed to confirm this. Notably 
we did not detect PHLPP1/2 in our experiment. 
 
 
 
Figure 5.5.5. Comparison of USP46 interactors between wild type and catalytic inactive 
mutant. 
SILAC ratios were generated between GFP-USP46/GFP-USP46-C44S using Max Quant. 
Ratios were transformed to a LOG2 scale and plotted against the LOG10 of the intensity of the 
peptide signal. Points that have a positive ratio represent proteins that are found more in the 
GFP-USP46 IP while negative points represent proteins found in the GFP-USP46-C44S IP. 
Grey circles denote USP46 complex.  
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5.2.6. Confirmation FBXO11:USP46 interaction. 
 
We chose to selectively confirm interactions based on novelty and 
interest. DDAH1 was chosen as it was seen with in both the wild type and 
catalytically inactive IP and had a similar ratio and intensity to USP46 and 
WDR48. DDAH1 has also been described in the literature as a regulator of 
the AKT and NO signaling pathways and an effector RAS206. FBXO11 was 
chosen, as it is part of the Scf-E3 ligase complex207, given that DUBs and E3 
ligase are often found in complexes together we chose to follow this up. 3 
separate IPs were performed on 1mg of lysate derived from GFP, GFP-
USP46 and GFP-USP46-C44S cell lines using the GFP Nano-trap antibody 
for 3 hours at 4˚C. Verification of the interaction was confirmed using 
antibodies against the endogenous protein. No band could be detected for 
DDAH1 in any of the IP lanes (Figure 5.6).  
 
FBXO11 could be detected at the right molecular weight for FBXO11 in 
both the WT and CS IP and was not present in the GFP IP. Interestingly there 
is a second higher molecular weight band that is more highly enriched relative 
to the lower band, presumably another isoform of FBXO11.  
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Figure 5.6. Confirmation of USP46:FBXO11 interaction. 
GFP (G7), GFP-USP46 (WT2) and GFP-USP46-C44S (CS3) cells were lysed in NP40 buffer. 
1mg of lysate was subjected to immuno-precipitation with GFP Nano-trap, 25µg of the input 
and unbound fractions were run along side the IP fractions. Samples were probed with anti-
FBXO11, anti-DDAH1 and anti-MAOAB antibodies. 
 
 
 
 
 
 
 
 
 
	   	   	  	  
	   137 
5.2.7. Depletion of USP46. 
 
We next wanted to test whether the stability of FBXO11 and DDAH1 
was affected by USP46 depletion. Despite the interaction between USP46 
and DDAH1 not being confirmed, we wanted to test the possibility that USP46 
could still affect its stability. DUB substrate interactions are low affinity and it is 
possible that they could be difficult to detect with 1mg of lysate. USP46 was 
depleted in HeLa cells over 72hours with 4 individual oligonucleotides. The 
experiment was set up twice and lysed in NP40 to mimic the IP condition and 
in RIPA buffer in case USP46 affected a NP40 insoluble fraction.  
 
The levels of DDAH1 decreased with one oligonucleotide (USP46-6) 
but there was no effect with any of the other oligonucleotides. FBXO11 
showed a small decrease in the stability of FBXO11 with multiple 
oligonucleotides compared to the NT1 control but not compared to the no 
oligo control (NO) (Figure 5.7).  
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Figure 5.7. Depletion of USP46 causes a modest reduction in the levels of FBXO11 and 
DDAH1. 
HeLa cells were treated with individual oligonucleotides against USP46 for 72 hours. The 
cells were then lysed in either NP40 or RIPA buffer and run on an SDS-page gel. Samples 
were probed with anti-FBXO11, anti-DDAH1 and anti-MAOAB antibodies. 
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5.2.8. Epoxomicin rescue of FBXO11 and DDAH1. 
 
One would expect that if DUB interacts with protein and the protein 
levels decrease with depletion of said DUB, then this effect would be due to 
increased ubiquitylation of the protein leading to its proteasomal degradation. 
To test whether the possible effect on DDAH1 and FBXO11 stability were due 
to proteasomal degradation, we depleted USP46 in HeLa cells, then either 
treated the cells with 0.5µM epoxomicin for 8 hours to block proteasome 
activity or DMSO as a control. In cells treated with USP46-6 oligonucleotide 
there was a decrease in the levels of DDAH1, however there was no change 
in the levels of DDAH1 after epoxomicin treatment, suggesting that the effect 
is pre-translational and likely an off target effect of the oligonucleotide  (Figure 
5.8). In NT1 cells treated with epoxomicin there was a small increase in the 
levels of FBXO11. The increase in FBXO11 levels with epoxomicin was 
greater in cells treated with USP46-6 oligonucleotide. This suggests that 
FBXO11 protein levels are rapidly turned over via the proteasome; depletion 
of USP46 did caused a proportionate enhancement FBXO11 levels over the 
control.  
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Figure 5.8. Epoxomicin rescue of USP46 depleted cells. 
HeLa cells were treated with individual oligonucleotides against USP46 for 72 hours. Cells 
were treated for 8 hours with 0.5µM epoxomicin before lysis in NP40 buffer.  
Lysates were run on SDS-page gel and samples were probed with anti-FBXO11 and anti-
DDAH1. Representative blots shown. 
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5.3. Discussion 
 
We sought to identify interactors of USP46 in an unbiased fashion. To 
do this we generated two cell lines stably expressing GFP-USP46 and a 
catalytically inactive GFP-USP46-C44S. We identified a strategy to discover 
USP46 interactors by IPing the stably expressed constructs via their GFP tags 
using the GFP Nano-trap llama antibody, to identify proteins that co-
precipitated using LC-MS/MS. We selectively followed up hits from our 
interaction dataset based on interest, novelty and availability of reagents.  We 
were able to confirm an interaction between USP46 and FBXO11. A higher 
molecular weight isoform of FBXO11 showed increased affinity for USP46.  
 
Furthermore, there was differential activation of the AKT and MAPK 
signaling across our cell lines, suggesting that USP46 regulates these 
pathways. An effect on late AKT was observed, which was dependent on the 
catalytic activity, as neither USP46 nor the catalytically inactive mutant or the 
GFP expressing cells displayed the same phenotype. The reduction in MAPK 
signaling was not dependent on catalytic activity of USP46, suggesting that 
USP46 may be playing some scaffolding role in the formation of signaling 
complexes downstream of EGFR.  
 
The increase in late AKT signaling was reminiscent of the changes 
seen with USP46 depletion in HeLa cells (Figure 4.9) with both knockdown 
and overexpression displaying the same phenotype. One possibility is that 
USP46 is required for the formation of signaling complexes that terminate 
AKT signaling, were loss of USP46 would prevent assembly of this complex, 
while overexpression of USP46 has a dominant negative effect. The data 
presented here demonstrates that stable USP46 overexpression influences 
acute EGF signaling. In our cell lines there is an increase levels of AKT 
signaling in GFP-USP46 cells compared to the GFP control. These results are 
is contradictory to results published in Li et al. (2013)192 were the authors 
demonstrated that there was a decrease in AKT signaling mediated through 
PHLPP1/2 when USP46 is overexpressed192. Taken at face value these 
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results suggest that USP46 is having multiple roles in the regulation of the 
pathway that we presently do not understand. Although it will be necessary to 
confirm that these results are not due to clonal variation by testing the EGF 
signaling of other clones.  
 
We were unable to confirm the localization experiment from Chapter 4. 
A proportion of USP46 was localized to punctate structures in the cytoplasm 
that had little co-localization with HRS. We were also unable to observe EGF 
stimulated recruitment onto these punctate structures. There are several 
possible reasons for this observation. The expression levels of GFP-USP46 
introduced through transient transfection are above physiological levels and 
vary from cell to cell. Overexpression of proteins can cause mislocalization 
and unanticipated artifacts. 
 
We were initially interested in the interaction between USP46 and 
FBXO11, as it is a F-Box protein that forms the substrate-recognizing 
component of the SCF E3 ligase complex203. One feature of SCF substrates 
is that they exhibit phosphodegron-dependent interaction with F-Box proteins, 
which facilitates their degradation through ubiquitylation. However this feature 
is not universal and in the case of FBXO11, recognition of one of its substrate, 
CDT1 is blocked by phosphorylation208, 209. FBXO11 mutations (E491L) have 
been identified in Jeff mice210, homozygous mice are lethal while 
heterozygous mice display abnormalities in epithelial development, being born 
with open eyes similar to mice injected with EGF210. Jeff mice display 
increased pSMAD2 activation and a low molecular weight isoform of FBXO11 
binds to pSMAD2210. The nature of the interaction is unclear and it is not 
understood how mutations in FBXO11 contribute to increased pSMAD2 
signaling. AKT and MAPK are parallel pathways to SMAD2 downstream of 
TGF-beta receptor. Further analysis is needed to understand how FBXO11 
mutations contribute to an increase in pSMAD2 and if USP46 counteracts the 
SCFFBXO11 complex.  
 
Another possibility is that USP46 is directly regulating the stability of 
FBXO11. There are now numerous examples of DUBs and E3 ligases being 
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found in complexes together167. One function of DUBs is to regulate the 
stability of E3 ligases, which can become auto-ubiquitylated, thus protecting 
them from degradation. However in this case, there was no dramatic 
decrease in the levels of FBXO11 with USP46 depletion. Although, it is 
possible that USP46 affects the FBXO11 under specific conditions such as 
during the cell cycle in a more dramatic fashion that we have not tested. 
USP46 may also function in tandem with FBXO11 to dynamically influence 
ubiquitylation status of substrates. Several substrates have been described 
for SCFFBXO11, notably CDT2209 and BCL6 that influence cell-cycle exit and 
apoptosis respectively. FBXO11 is beginning to emerge as a tumor 
suppressor207 and could potentially explain the anti-proliferative effects of 
overexpressing USP46192 by opposing the effects of FBXO11. 
 
FBXO11 has been reported as a nuclear localized protein. In our stable 
cell lines a proportion of GFP-USP46 was localized to the nucleus, making it 
unlikely that the USP46:FBXO11 interaction is taking place on the endosome. 
Co-localization studies using FRET probes would need to be preformed in 
order to confirm were this interaction is taking place. In Uniprot there are 6 
isoforms of FBXO11 annotated (as of September 2013) and there is relatively 
little information available on the functions of the different isoforms. Our 
results show that the higher molecular weight isoform of FBXO11 has a 
relatively increased binding preference to USP46 that the lower molecular 
weight isoform. It would be interesting to follow up which of the known 
FBXO11 functions depend on the higher molecular weight isoform and the 
sub cellular localization of the different isoforms.  
 
 Our dataset found overlapping interactors in WDR20 and WDR48. The 
interactions between USP46 and WDR20 and WDR48 seem to be 
fundamental to the action of USP46 but the mechanism of action is unclear200. 
It is thought that the WD40 containing proteins act as scaffolds for protein 
interactions possibly bringing USP46 into contact with the substrate200. Crystal 
structures of USP46 in a complex with WDR20 and WDR48 would be able to 
shed light on this mechanism. The detection of these proteins in our study 
provided a positive control for the experiment. Ubiquitin (UBB) preferentially 
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associated with the catalytically inactive form of USP46. It is unclear whether 
this is due to ubiquitylation of USP46 itself (which was not consistently seen) 
or that USP46 was bound to ubiquitylated substrates. If the latter is the case 
then performing IPs with catalytic inactive DUBs could be a successful 
strategy to identify new substrates. In our dataset there were more proteins 
identified in the catalytic mutant IP suggesting that GFP-USP46-C44S may 
act as a substrate trap. However, this would need to be verified through 
additional experiments. The identification of true substrates through this 
method will inevitably be limited by need to use traditional methods such as 
using antibodies that can be expensive and difficult to source. 
 
We were unable to confirm the interaction between USP46 and PHLPP 
phosphatases. The methodology used here differed from the Sowa at al. 
(2009)211 in that they purified HA-USP46 that was expressed by retroviral 
vector in HEK cells. The expression levels driven through the retroviral vector 
are likely to be higher and non-uniform across cells, different cells will express 
different levels of HA-USP46 depending on the multiplicity of infection by the 
virus. No interaction between USP46 and PHLPP1/2 has been demonstrated 
for endogenous USP46 raising the possibility that the interaction depends on 
high levels of USP46 to be seen. 
 
The results presented here have contributed to the USP46 interactome 
and confirmed a novel interaction with FBXO11. The work has also provided a 
provision of new tools to study USP46. Future work will focus on the function 
of the USP46:FBXO11 interaction.  
   
5.4. Conclusions 
 
• Generation of a new model to study USP46. 
• USP46 interacts with FBXO11. 
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Chapter 6  USP8 regulates retrograde trafficking of  
CI-M6PR.      
 
6.1. Introduction 
 
A proportion of trans-membrane proteins undergo retrograde transport 
from the endo-lysosomal system to the trans-golgi network (TGN)147. The 
archetypal cargo for retrograde transport is the cation-independent mannose 
6-phosphate receptor (CI-M6PR). The function of CI-M6PR is to bind newly 
synthesized lysosomal hydrolases in the TGN to be trafficked into the endo- 
lysosomal system147. Once in the endo-lysosomal compartment, the acid 
hydrolases dissociate from the receptor due to the acidic environment and 
then are trafficked into the lysosome by bulk flow147.  
 
Cathepsin D is a lysosomal hydrolase that is trafficked by CI-M6PR. It 
is synthesized on membrane bound ribosomes and translocates into the 
lumen of the ER. It becomes N-glycosylated in the ER and then subsequently 
phosphorylated in the cis-Golgi network. It is through these post-translational 
modifications that Cathepsin D associates with the receptor212. The ligand 
bound receptor is packaged in AP1 clathrin-coated vesicles, which then fuse 
with endosomes. A proportion of the receptor is trafficked to the plasma 
membrane via the secretory pathway and is retrieved through endocytosis213. 
Once the cargo bound receptor reaches the endo-lysosomal system, 
progressive acidification of the compartment through the v-ATPase pump, 
induces the maturation of the Cathepsin D into an active form. Cathepsin D 
maturation is achieved through limited proteolysis first from a 53kDa precursor 
protein into a 47-kDa intermediate form (also known as a Pro form) in the 
endo-lysosomal system through an autocatalytic mechanism. The 
intermediate protein is transferred into the lysosomes where it is processed 
into a 31kDa active hydrolase in the lysosome212 and processed through an 
unknown mechanism214. 
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CI-M6PR is then retrieved back to the TGN via the retrograde 
transport. This process is mediated by the retromer complex, a cargo 
recognizing trimer unit comprising VPS35, VPS26 and VPS29 and 
membrane-deforming unit composed of SNX1 and SNX2215. However, there 
are also other mechanisms for retrograde transport. Furin is a trans-
membrane endopeptidase that also undergoes retrograde transport passing 
through the late endocytic compartment. However, unlike CI-M6PR it does not 
require the retromer complex for retrieval to the TGN216. Additionally 
retrograde trafficking is dependent on the F-actin nucleating complex WASH, 
which assembles actin filaments required for the extraction of vesicles from 
the late endosomal membranes148.  
 
In 2013, Hao et al.157 identified an E3 ligase regulating retromer 
dependent retrograde transport, MAGE-L2-TRIM27. Mechanistic studies 
demonstrated that MAGE-L2-TRIM27 built K63 chains on WASH at K220, 
which were necessary for vesicle formation157. As ubiquitylation was required 
for normal retrograde trafficking we hypothesized that this would be a 
reversible process. We therefore screened for disruption of retrograde 
trafficking of CI-M6PR with depletion and over-expression of 4 endosomal 
DUBs, USP8, USP46, AMSH and AMSH-lp.  
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6.2. Results. 
 
6.2.1. Depletion of USP8 causes mislocalisations of CI-M6PR. 
 
We used CI-M6PR distribution as a readout for perturbed retrograde 
trafficking. Under steady-state conditions in HeLa cells, CI-M6PR is localized 
to the TGN. If there is a disruption of retrograde trafficking, then CI-M6PR will 
accumulate in the endo-lysosomal compartment, as it can no longer make the 
return journey to the TGN. HeLa cells were treated for 72 hours with single 
siRNA oligonucleotides that have been previously characterized in the lab and 
are targeting 3 endosomal DUBs, USP8, AMSH, and USP46. VPS35 the core 
component of the retromer was targeted using a pool of siRNA 
oligonucleotides and a non-targeting siRNA were used as controls.  
In figure 6.1, cells treated with NT1 control show an overlapping 
distribution between p230 (TGN marker) and CI-M6PR. In cells that were 
treated with AMSH and USP46 this distribution is unaltered. There was a 
change in distribution of CI-M6PR in cells depleted of USP8 with 2 individual 
oligonucleotides. CI-M6PR was trapped in a compartment distinct to p230. 
Cells treated with VPS35 also showed a change in distribution with the pattern 
of CI-M6PR distribution appearing more disperse.   
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Figure 6.1. Depletion of USP8 causes mislocalization of CI-M6PR. 
HeLa cells were treated with siRNA for 72 hours. Cells were fixed and labeled for p230 (TGN) 
and CI-M6PR. Under steady state conditions CI-M6PR is localized to the TGN. USP8 
depletion causes CI-M6PR to accumulate in a compartment separate to p230.  
Scale bar=10µm.  
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6.2.2. USP8 depletion causes an accumulation of CI-M6PR in aberrant 
endosomes.   
 
As USP8 depletion was causing a mislocalization of CI-M6PR from the 
TGN, one may predict that CI-M6PR is accumulating in the endosomal 
system. HeLa cells were depleted of USP8 with 2 individual oligonucleotides 
or treated with oligonucleotides targeting NT1, AMSH and VPS35 as a 
control. The cells were stained with EEA1 (early endosome antigen 1) as a 
marker of early endosomes and CI-M6PR. In figure 6.2.1.A, NT1 and AMSH 
siRNA treated control cells, show little overlap between EEA1 and CI-M6PR, 
with the majority of CI-M6PR accumulating in a peri-nuclear compartment. In 
USP8 knockdown cells, EEA1 positive endosomes show an altered 
distribution, they appear aggregated and contain CI-M6PR.  
 
Previous work has demonstrated that there is an accumulation of 
ubiquitin on aberrant endosomes in USP8 depleted cells132. To confirm this 
USP8 depleted cells were stained with anti-ubiquitin FK2 antibody that 
recognizes mono and poly-ubiquitylated proteins (Figure 6.2.1.B). There was 
an accumulation of ubiquitylated proteins on endosomes consistent with 
previously reported results132.  
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Figure 6.2.1. Depletion of USP8 leads to an accumulation of CI-M6PR in aberrant 
endosomes. 
HeLa cells were treated for 72hours with siRNA. Cells were fixed and labeled with antibodies 
against A) EEA1 (early endosomes) and CI-M6PR B) FK2 (poly- mono- conjugated ubiquitin) 
and EEA1. Depletion of USP8 causes an accumulation of CI-M6PR in an EEA1 positive 
compartment. Scale bar = 10µm. 
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Lysates from the knockdown samples were probed with antibodies 
against USP8 and VPS35 (Figure 6.2.3) confirming that the knockdown had 
been successful. There was no change in the stability of CI-M6PR upon 
depletion of USP8 or VPS35. 
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Figure 6.2.3. USP8 depletion dose not cause a change in levels of CI-M6PR. 
HeLa cells were treated with siRNA for 72hours. Cells were lysed in NP40 buffer and lysates 
were probed with antibodies against USP8, VP35, CI-M6PR and Actin. Cells treated with 
USP8 and VPS35 siRNA showed efficient depletion of their target proteins. Neither 
knockdown of VPS35 nor of USP8 had an effect on the levels of CI-M6PR. 
 
6.2.3. USP8 depletion causes a delay in CD8-CI-M6PR uptake. 
 
To confirm the disruption of CI-M6PR trafficking with USP8 depletion 
we employed an assay to look at the uptake of CI-M6PR from the plasma 
membrane. A proportion of CI-M6PR is lost via the secretory pathway to the 
plasma membrane. This can be exploited using a CD8-CI-M6PR chimera 
stable cell line. These cells can be labeled with an anti-CD8 antibody on ice 
for 1 hour, the cells are then warmed up to 37˚C to promote the internalization 
of the receptor-antibody complex. The trafficking of the receptor:antibody 
complex can then be visualized, by fixing the cells and then labeling with 
fluorescent secondary antibodies at different time points. The cells were 
counter-stained with EEA1 as a reference point for CD8-CI-M6PR transition 
through the endosomal compartments. In figure 6.3.1 CD8-CI-M6PR-HeLa 
cells were treated with siRNA over 96 hours. A delay in the retrograde 
transport of CD8-CI-M6PR is observed when cells were depleted with USP8 
and this effect was consistent using 2 individual oligonucleotides. This is in 
contrast to control NT1 treated cells where after 48mins at 37˚C, the majority 
of CD8-CI-M6PR has accumulated in a peri-nuclear compartment. 
Interestingly in USP8 depleted cells some of the CD8-CI-M6PR still reaches 
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the TGN indicating that USP8 depletion does not completely block, but rather 
delays retrograde transport.  
 
The assay failed in VPS35 knockdown cells. There were few cells 
labeled with the CD8 antibody possibly because VPS35 knockdown efficiently 
blocked retrograde transport of CI-M6PR, trapping it in the endosomal 
system. In figure 6.4.2 NP40 lysates from the experiment were probed with 
antibodies against USP8 and VPS35 demonstrating effective depletion.  
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Figure 6.3.1. Depletion of USP8 causes a delay in CD8-CI-M6PR uptake. 
CD8-CI-M6PR stably transfected HeLa cells were treated at 0 and 48 hours with siRNA over 
96hours. Plasma membrane CD8-CI-M6PR was labeled with an anti-CD8 monoclonal 
antibody for 1 hour on ice. Cells were subsequently warmed to 37˚C and fixed at various time 
points over 48mins.  The cells were then labeled with EEA1 and fluorescent secondary 
antibodies to visualize the internalization of CD8-CI-M6PR through the endosomal network. 
CD8-CI-M6PR trafficking is delayed in USP8 knockdown cells compared to NT1 control. 
Scale bar=10µm. 
 
 
 
 
 
Figure 6.3.2. siRNA treatment efficiently depletes respective targets in CD8-CI-M6PR 
stable cells.   
CD8-CI-M6PR cells from figure 6.4.1 were treated twice with siRNA over 96hours and 
subsequently lysed in NP40 buffer. Immuno blotting demonstrates efficient depletion of target 
proteins.  
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6.2.4. USP8 depletion causes a delay in CD8-Furin uptake. 
 
A delay in the uptake of CD-CI-M6PR was caused by depletion of 
USP8. To test the hypothesis that this effect was dependent on disruption of 
the retromer complex, we employed a CD8-Furin uptake assay. Furin is 
transported through the late endosomal compartment to the TGN, like CI-
M6PR, however it’s retrograde transport is not dependent on the retromer 
complex. Stably transfected CD8-Furin-HeLa cells were treated with siRNA 
twice over 96 hours. Using the same experimental procedure as in figure 
6.4.1, the transport of CD8-Furin to the TGN was monitored. Preliminary data 
had indicated that the transport of CD8-Furin was more or less completed by 
32 mins, so the 48min time point was dropped from the assay.  
 
In cells depleted of USP8 a delay in CD8-Furin transport to the TGN 
was observed with CD8-Furin accumulating in aberrant endosomes, 
reminiscent of the delay observed for CD8-CI-M6PR. VPS35 depletion had no 
effect on the retrograde transport of CD8-Furin with the majority of CD8-Furin 
reaching the peri-nuclear compartment after 32mins in both VPS35 and NT1 
treated cells.  
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Figure 6.4.1. Depletion of USP8 causes a delay in CD8-Furin uptake part 1.  
HeLa cells stably transfected with CD8-Furin were treated twice with siRNA over 96hours. 
Plasma membrane CD8-Furin was labeled with an anti-CD8 monoclonal antibody for 1 hour 
on ice. Cells were subsequently warmed to 37˚C and fixed at the indicated time points over 
48mins.  The cells were then labeled with EEA1 and fluorescent secondary’s antibodies to 
visualize the internalization of CD8-CI-M6PR through the endosomal network. CD8-Furin 
trafficking is delayed in USP8 knockdown cells compared to NT1 treated control cells. Scale 
bar=10µm. 
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Figure 6.4.2. Depletion of USP8 causes a delay in CD8-Furin uptake part 2.  
HeLa cells stably transfected with CD8-Furin were treated twice with siRNA over 96hours. 
Plasma membrane CD8-Furin was labeled with an anti-CD8 monoclonal antibody for 1 hour 
on ice. Cells were subsequently warmed to 37˚C and fixed at the indicated time points over 
48mins.  The cells were then labeled with EEA1 and fluorescent secondary’s antibodies to 
visualize the internalization of CD8-CI-M6PR through the endosomal network. CD8-Furin 
trafficking is delayed in USP8 knockdown cells compared to NT1 treated control cells. Scale 
bar=10µm. 
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6.2.5. Overexpression of exogenous USP8 does not increase CD8 uptake. 
 
USP8 depletion inhibited the uptake of USP8 we therefore wanted to 
test if overexpression of USP8 increases the rate of CD8-CI-M6PR transport 
to the TGN. The same assay as used in figure 6.4.1 was employed with 
transient expression of GFP-USP8, GFP-USP8-C786S or EGFP as a control 
for 24hours.  
 
In figure 6.5, GFP-USP8 was observed in both the cytosol and on 
endosomes while GFP-USP8-C786S accumulates on endosomes. There was 
no increase in the rate of CD8-CI-M6PR observed over the control GFP or to 
untransfected cells at 8min for either the GFP-USP8 or GFP-USP8-C786S. 
Nor could any effects been seen on the retrograde trafficking of CD-CI-M6PR 
at any other time points.  
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Figure 6.5. Overexpression of GFP-USP8 does not effect CD8-CI-M6PR uptake. 
HeLa cells stably transfected with CD8-CI-M6PR were transfected with GFP, GFP-USP8 and 
GFP-USP8-C786S for 24hours. Plasma membrane CD8-CI-M6PR was labeled with an anti-
CD8 monoclonal antibody for 1 hour on ice. Cells were subsequently warmed to 37˚C and 
fixed at indicated time points over a period of 48mins.  The cells were then labeled with EEA1 
and fluorescent secondary antibodies to visualize the internalization of CD8-CI-M6PR through 
the endosomal network. There is no effect on the trafficking of CD8-CI-M6PR with 
overexpression of GFP-USP8 over the GFP control however there is a delay in the trafficking 
with overexpression of GFP-USP8-C786S. Scale bar = 10µm. 
 
6.2.6. Overexpression of other endosomal DUBs has no effect of CD8-M6PR 
retrograde trafficking. 
 
Ubiquitylation of the WASH complex was a critical step for retrograde 
transport157. One would predict that overexpression of a DUB that targeted 
WASH would inhibit the action of WASH. Overexpression of USP8 was 
having no effect on retrograde trafficking; we therefore sought to identify other 
endosomal DUBs, which may disrupt this process. We overexpressed 3 other 
endosomal DUBs (AMSH, AMSH-lp, USP46) in the CD8-CI-M6PR HeLa-M 
cells. In figure 6.6 in cell transfected with GFP constructs there was no effect 
on the trafficking of CD8-CI-M6PR for any of the DUBs tested compared to 
untransfected cells. Co-localization between AMSH, AMSH-lp and CD8-CI-
M6PR is observed in a peri-nuclear compartment, which may correspond to 
the TGN, based on co-localization experiments previously conducted by 
Monika Chojnowska-Monga217.  
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Figure 6.6. Overexpression of endosomal DUBs, USP46, AMSH and ASMH-lp do not 
disrupt CD8-CI-M6PR retrograde trafficking. 
HeLa cells stably transfected with CD8-CI-M6PR were transfected with GFP, GFP-USP46, 
GFP-AMSH and GFP-AMSH-lp for 24hours. Plasma membrane CD8-CI-M6PR was labeled 
with an anti-CD8 monoclonal antibody for 1 hour on ice. Cells were subsequently warmed to 
37˚C and fixed at the indicated time points over 48mins.  The cells were then labeled with 
EEA1 and fluorescent secondary antibodies to visualize the retrieval of CD8-CI-M6PR to the 
TGN. Scale bar = 10µm. 
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6.2.7. Re-expression of GFP-USP8 rescues CI-M6PR mislocalization. 
 
In order to test if the mislocalization of CD8-CI-M6PR is a specific 
effect of USP8 knockdown or an off-target effect caused by the siRNA, we re-
expressed exogenous USP8 to rescue the effect of depletion. Three USP8 
constructs that are resistant to USP8-1 siRNA were expressed in either NT1 
or USP8-1 siRNA treated cells: wild type GFP-USP8, catalytically inactive 
GFP-USP8-C786S and GFP-USP∆MIT that lacks microtubule interacting 
transport domain (MIT) that allows USP8 to associate with endosomes135. 
HeLa cells were treated twice either with NT1 or USP8-1 siRNA over 96 hours 
with re-expression of exogenous USP8 constructs or pEGFP control for 
66hours. By comparing the overlap between p230 TGN marker and CI-M6PR 
judged mislocalization was assessed. 
 
In figure 6.7.1, NT1 siRNA treated cells displayed an overlapping 
distribution between CI-M6PR and p230 in all conditions. In USP8 depleted 
cells, CI-M6PR was mislocalized, consistent with previous results. The re-
expression of GFP-USP8 rescued the mislocalization whereas expression of 
GFP-USP8∆MIT and EGFP failed to rescue the phenotype and a similar 
distribution is observed in untransfected cells. In cells transfected with GFP-
USP8-C786S there is also no rescue of the CI-M6PR phenotype and CI-
M6PR accumulates in aberrant endosomes positive for GFP-USP8-C786S. 
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Figure 6.7.1. Re-expression of USP8 rescues CI-M6PR mislocalization. 
HeLa cells were treated twice over 96 hours and transfected with GFP, GFP-USP8, GFP-
USP8-C786S (CS) or GFP-USP8∆MIT for 66hours. Cells were subsequently fixed and 
labeled with CI-M6PR and p230 (TGN). Exogenous expression of GFP-USP8 rescues CI-
M6PR mislocalization caused by USP8 depletion while expression of GFP-USP8∆MIT does 
not. Expression of GFP-USP8-C786S accumulates in the same compartment as CI-M6PR 
and does not rescue the mislocalization phenotype. Merged images are a composite of CI-
M6PR (594) and p230 (350). Scale bar = 10µm.  
 
USP8 re-expression rescued the aberrant endosome phenotype of 
USP8 depletion (figure 6.7.2). In cells depleted of USP8 there was an 
increase in ubiquitylated substrates on aberrant endosomes consistent with 
the results in figure 6.22. In cells where GFP-USP8 had been re-expressed 
the depletion phenotype is rescued and there were reduced levels of 
ubiquitylated proteins compared to non-transfected proteins in the same field 
of view. This rescue was dependent on the endosomal localization of USP8 
as re-expression of GFP-USP8∆MIT failed to rescue this phenotype.  
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Figure 6.8.2. Re-expression of USP8 rescues aberrant endosome phenotype. 
HeLa cells were treated twice with U8-1 siRNA over 96 hours and transfected with GFP, 
GFP-USP8, GFP-USP8-C786S or GFP-USP8∆MIT for the last 66hours. Cells were 
subsequently fixed and labeled with the anti-Ubiquitin antibody FK2 and EEA1 (early 
endosome). Exogenous expression of GFP-USP8 rescues FK2 accumulation caused by 
USP8 depletion while expression of GFP-USP8∆MIT does not. Scale bar = 10µm. 
 
Lysates from the experiment shown in Figure 6.7.3. were run on a 
SDS-page gel confirming the knockdown of USP8 and the expression of 
siRES constructs (figure 6.7.3). The GFP-USP8 and GFP-USP8-C786S 
constructs were expressed at low levels compared with the endogenous 
USP8 however, this was sufficient to see a significant rescue of HRS, loss of 
HRS has been demonstrated previously with USP8 depletion135. Note that the 
transfection efficiency was estimated at 20% for this experiment.  
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Figure 6.8.3. Re-expression of USP8 rescues HRS loss. 
HeLa cells were treated twice with siRNA for 96 hours and transfected with GFP, GFP-USP8, 
GFP-USP8-C786S or GFP-USP8∆MIT for 66hours. Cells were lysed in NP40 buffer and 
probed for HRS, USP8 and Actin. Expression of WT GFP-USP8 rescues the loss of HRS 
despite low expression levels while GFP-USP46-C786S and GFP-USP8∆MIT do not. 
 
6.2.8. USP8 depletion causes secretion of Cathepsin D 
 
To test the disruption of CI-M6PR trafficking using a biochemical assay 
we employed an assay to look at the secretion of Cathepsin D. When CI-
M6PR retrograde trafficking is perturbed it can no longer reach the TGN to 
actively sort newly synthesized hydrolases such as Cathepsin D. In this 
situation Cathepsin D is missorted and follows the secretory pathway out of 
the cell into the extracellular environment. The secretion of Cathepsin D can 
be tested biochemically by TCA precipitating proteins from the media and 
Cathepsin D levels can then be detected using a conventional western blot.  
 
HeLa cells were treated twice with siRNA targeting USP8 at 0 hours 
and 48 hours over a 96hour time course. 16 hours before the end of the 
experiment the media as exchanged to Opti-MEM, after which it was collected 
and the proteins were TCA precipitated. The underlying cells were lysed in 
NP40 buffer to determine the cellular levels of Cathepsin D. I observed a 
marked increase in the levels of Cathepsin D in the media compared to 
control cells and a concomitant decrease in the mature form of Cathepsin D in 
cells.  
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Figure 6.9. Depletion of USP8 causes missorting of Cathepsin D. 
HeLa cells were treated twice with siRNA over 96 hours. Media was exchanged to Opti-MEM 
16 hours before the end of the experiment. The media was collected and subjected to TCA 
precipitation. The cells were lysed in NP40 lysis buffer and the samples were probed with 
Cathepsin D antibody.   
 
6.3. Discussion 
 
 Ubiquitylation mediates retrograde trafficking from the late endosomes 
to the TGN157. The work presented in this chapter aimed to identify DUBs that 
regulate this pathway, by employing a number of assays that monitor the 
trafficking of CI-M6PR, an archetypal substrate for retrograde transport. We 
identified USP8 as a novel regulator, which when depleted delayed the 
transport of CI-M6PR. Furthermore, depletion of USP8 caused a secretion of 
Cathepsin D, an enzyme trafficked by CI-M6PR to endosomes from the TGN. 
There was a concomitant decrease in the mature form of the enzyme in cells 
(Figure 6.10). USP8 required both catalytic function and an endosomal 
localization domain to mediate these effects as neither GFP-USP8-C786S nor 
GFP-USP8∆MIT could rescue CI-M6PR mislocalization. These results 
indicate that USP8 depletion causes the accumulation of CI-M6PR in aberrant 
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endosomes and delays trafficking to the TGN, which in turn disrupts lysosome 
biogenesis. 
 
 
 
 
Figure 6.10. Model for retrograde transport in USP8 depleted cells.  
USP8 is required for efficient retrograde transport of CI-M6PR and Furin. In USP8 depleted 
cells CI-M6P^ and Furin accumulate in aberrant endosomes that may prevent recycling from 
to the TGN. This in turn leads to secretion of newly synthesized acid hydrolases and as a 
consequence leads to a decrease in lysosome biogenesis. 
 
 The nature of the aberrant endosomes has also been addressed on an 
ultrastructural level. The clusters seen by light microscopy are MVBs that 
contain EEA1 antigen and are tethered to together by electron dense linkers. 
Depletion of USP8 produces a mixed phenotype on these endosomes, with 
some having a reduced number of internal vesicles while others have an 
increase and others are swollen132, 137. With USP8 depletion there is also a 
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delay in the sorting of EGFR into intra luminal vesicles of MVBs after 30mins. 
However, most EGFR eventually reached the lumen of late endosomes or 
lysosomes137.  
 
Both CI-M6PR and Furin trafficking are disrupted by USP8 depletion. It 
is also likely that other proteins passing through the late endosomal 
compartment en-route to the TGN will also be delayed. As such, it is unlikely 
that USP8 depletion directly disrupts the retromer, although that has not be 
formally tested and it is possible that USP8 depletion could disrupt retrograde 
trafficking thorough multiple mechanisms. There are two alternative 
mechanisms by which USP8 could function. The first is that USP8 depletion 
causes a loss of the ESCRT0 complex, STAM through proteasomal 
degradation132 and it’s partner protein HRS through an unknown 
mechanism132, 135. Recently two papers have identified a requirement of HRS 
for retrograde transport of amyloid beta precursor protein (APP)218 and Shiga 
toxin219. HRS has also been shown to interact with SNX1220, which is a 
component of the retromer complex. Taken together, these studies suggest 
that HRS may play a role in retromer mediated retrograde trafficking and that 
USP8 knockdown could disrupt trafficking by through the associated loss of 
HRS. However, as USP8 can also disrupt the trafficking of Furin this suggests 
that the mechanism is not retromer dependent. So either HRS could have an 
effect on multiple routes of retrograde trafficking or USP8 is functioning in 
another manner. USP8 depletion is partially phenocopied by depletion of HRS 
causing enlarged endosomes which have fewer internal vesicles221. 
 
An alternative explanation is that depletion of USP8 causes the 
formation of aberrant endosomes. An increase in such endosomes is coupled 
with an increase in ubiquitylated proteins on the endosomes and loss of 
ESCRT0 complex. Incoming ubiquitylated proteins to the endosome may not 
be efficiently sorted which could lead to a “traffic jam” of proteins on the 
limiting membrane of MVBs. Molecular crowding on the membrane of the 
sorting endosome could impact on other proteins transiting this compartment, 
whether or not they have been ubiquitylated. This would cause a build up of 
proteins waiting to be trafficked out of the MVB compartment, effectively 
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clogging up the system. One way to test this hypothesis would be to acutely 
inhibit USP8 using an inhibitor and then look at CD8-CI-M6PR retrograde 
trafficking. If this hypothesis holds true one would predict that acute inhibition 
would have little effect on a single pass of CI-M6PR trafficking. Supporting 
this idea is the observation that during the CD8-CI-M6PR trafficking assay 
there is not a complete blockade of CI-M6PR during a single pass of the 
endocytic system. However, when we monitor the steady state distribution of 
CI-M6PR in USP8 depleted cells, there is an altered distribution suggesting 
the equilibrium of CI-M6PR distribution has been shifted by this delay and that 
this takes time to establish. 
 
As a consequence of CI-M6PR mistrafficking in USP8 depleted cells 
there will be a knock-on effect on lysosome biogenesis due to missorting of 
newly synthesised acid hydrolases. USP8 has been implicated in the 
regulation of various trans-membrane proteins by preventing their lysosomal 
degradation. KCa3.1222, ENaC223, Fz224, MET135 receptor and EGFR132 are 
a few  well characterized examples. However, the reason why degradation 
of trans-membrane proteins is inhibited by USP8 depletion is currently 
unclear. Our results indicate that deficiencies in lysosomal biogenesis may 
be a contributory factor to inadequate lysosomal degradation of trans-
membrane proteins. This effect will be augmented by inefficient sorting into 
intra-luminal vesicles caused by the loss of ESCRT0 complex.  
 
USP8 has been also implicated in the recycling of the WNT receptor 
Fz224. WNT signaling is initiated by the binding of WNT proteins to the 
receptor Fz and its co-receptor LRP5/6/Arrow. WNT ligands are 
morphogens determining the differentiation of tissues; differentiation is 
controlled through the formation of WNT signaling gradients across 
tissues. These are maintained through the secretion of WNT proteins via 
the receptor Wntless and the availability Fz of the receptor on the plasma 
membrane. Both of these factors are controlled through the endocytic 
pathway: Fz is ubiquitylated, internalized and sorted at the MVB and USP8 
directly deubiquitylases Fz acting as a proofreading step that determines 
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whether the receptor is committed to degradation in the lysosome or 
recycled back to the plasma membrane224. The Wntless receptor is 
trafficked through the retrograde pathway, which is dependent on 
VPS35225-228. Recycling of the receptor is required to maintain gradients of 
secreted WNT ligands. In light of the results presented here, USP8 may 
have a dual regulatory role in regulating WNT signaling by determining the 
secretion of the ligand and the plasma membrane levels of the receptor, 
which would generate the same knockout phenotype.  
 
Inhibition of USP8 can overcome Gefitinib resistance exhibited in some 
lung cancer cell lines138 and USP8 has also been identified as a target for the 
treatment of multiple myeloma229. However, the mechanism for overcoming 
Gefitinib is not known and is presumed to be through defects in the trafficking 
of EGFR. Byun et al. (2013)138 found there was a down regulation of several 
RTK including EGFR with inhibition of USP8. However, siRNA mediated 
depletion of USP8 induces a delay in the degradation of EGFR. It could be 
that there are two phenotypes based on long-term depletion and acute 
inhibition. Long-term inhibition causes the formation of aberrant endosomes 
that delay EGFR degradation while acute inhibition could enhance 
degradation by preventing recycling of EGFR. These effects may need to be 
considerated for administration regimes of any drugs used in patients 
targeting USP8.  
 
The results presented in the chapter raises another possible 
explanation for the action of USP8 as an anti-cancer drug target. As USP8 
function is integral to MVB function, targeting USP8 may function as a de 
facto lysosome inhibitor, raising parallels to the use of proteasomal inhibitors. 
Another feature of USP8 biology that has potential anti-cancer effects is 
through its regulation of the cell cycle230. It would be interesting to explore 
how these effects are mediated through USP8 and if these effects are 
mediated through a general disruption of trafficking or via a specific disruption 
of EGFR trafficking.  
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6.4. Conclusions 
 
• USP8 regulates retrograde trafficking.  
• USP8 is required for lysosomal biogenesis.  
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Chapter 7 	  Discussion  	  
This chapter aims to summaries the findings of this thesis and discuss 
future directions for work.  
 
I found that there is a decrease in MAPK signaling in USP15 depleted 
cells that correlate with a decrease in the protein levels of CRAF kinase. Work 
presented here and published in Hayes et al. (2012)167, has shown that 
dominant signaling function of USP15 in MAPK signaling, at least in U2OS 
and HeLa cells, is consistent with the requirement for maintenance of CRAF 
levels. Future directions would address the suitability of USP15 as an anti-
cancer drug target, in disease states that are driven through hyperactivation of 
MAPK pathway. Despite a significant effect on the activation of MAPK there 
was relatively little effect on the activation of the downstream ERK kinase this 
is likely because there is extensive input from other signaling pathways to 
activate ERK. It would be worth exploring different cancer cell lines to 
establish what the effects of USP15 are on MAPK dependent proliferation. 
 
Translating our observation into in vivo model is not a straightforward 
issue. USP15 is playing a dual role in MAPK signaling influencing CRAF and 
BRAP and the extracellular environment dictates the extent of USP15s 
influence167. This effect was demonstrated in HeLa cells were no effect is 
seen for depletion of BRAP in serum-starved cells before growth factor 
application, whereas cells kept in complete media before growth factor 
stimulation exhibit BRAP influenced MAPK signaling167. It would be interesting 
to see how these effects are translated in vivo, were there will be considerable 
heterogeneity in the extracellular environment between different cancer types. 
Additionally, USP15 has been identified as a regulator of several cancer 
associated pathways177, 180, 181. Making it difficult to predict what the 
phenotypic output of USP15 inhibition will be In Vivo. Although, another 
viewpoint would be that if USP15 is regulator of many key processes in the 
cell, therefore inhibition may kill cancer cells, as they have higher metabolic 
stress than normal cells. The proteasomal inhibitor Bortezimib has been used 
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successfully in the treatment of cancer despite proteasomal inhibition having 
many cellular effects231.  
 
This study identified USP46 as an endosomal DUB. The consequences 
of this finding are not fully understood. There is an increase in late AKT 
signaling associated with depletion and overexpression of USP46 that was 
dependent on the catalytic activity of USP46. This would suggest that USP46 
is enhancing EGFR recycling and maintaining its plasma membrane levels. 
However when tested through biochemical means, we saw no effect on the 
degradation rate of EGFR. Previous work has identified USP46 as a regulator 
of AKT signaling by influencing the stability of PHLPP1/2192 but this study has 
not been able to recapitulate these findings neither through depletion 
experiments nor through an unbiased approach to identify interactors of 
USP46.  
 
We generated a new set of tools to study USP46 by establishing cell 
lines expressing GFP-USP46 and GFP-USP46-C44S. Using the GFP tag to 
IP the exogenous proteins from our cell lines, we generated a dataset of 
potential interactors for USP46. We were able to confirm one interaction 
between USP46 and FBXO11, but the significance of this interaction is not 
presently known. We were initially interested in FBXO11 because it is the 
substrate-recognizing component of SCF-E3 ligase complex203. E3 ligases 
are often found in complexes together with DUBs, a minimalistic view for this 
observation, is that E3 ligases form these complexes to maintain cellular 
levels of E3 ligases that have a tendency to auto-ubiquitylate. Preliminary 
experiments though, suggest that USP46 is not regulating the stability of 
FBXO11 in a significant way. Another possibility that we have not explored is 
that USP46 works in partnership with FBXO11 to dynamically regulate the 
ubiquitylation status of proteins.  
 
There have been several substrates identified for FBXO11 and through 
them FBXO11 regulates apoptosis203 and exit from cell cycle232. It would be 
worth investigating if USP46 could influence the ubiquitylation status of known 
substrates of FBXO11 and what if any role it plays in apoptosis203 and cell 
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cycle232. Because our cell lines expressed comparable levels of the wild type 
and catalytically inactive mutant of GFP-USP46, we were able to directly 
compare IPs from each cell line using SILAC. There was a bias in our dataset 
with interactors preferentially binding to the catalytically inactive mutant of 
USP46 over the wild type form, suggesting that it may act as a substrate trap.  
It has been technically difficult to identify substrates for DUBs using IP 
experiments coupled with mass spectrometry analysis, due to the transient 
nature of DUB substrate interactions. Therefore if the catalytically inactive 
mutant does acts a substrate trap it would be worth pursing this strategy 
further and expand it for other DUBs.  
 
USP46 has been identified as a drug target to overcome depression. 
This is thought to be through the regulation of GluR1, but our interaction 
dataset has raised another possibility that USP46 inhibition could overcome 
depression through an interaction with MAOB. MAOB is an enzyme involved 
in the generation of dopamine, which plays a central role in pathogenesis of 
depression and inhibitors targeting MAOB and another isoform MAOA can be 
used to treat clinical depression233. We were unable to confirm this interaction 
as we could not source a reliable antibody but these results may explain 
another way in which USP46 could overcome depression.   
 
The final section of the thesis has dealt with the role of established 
endocytic DUBs play in the regulation of retrograde transport. From this work, 
we identified USP8 as necessary for retrograde transport. When USP8 is 
depleted, it causes a missorting of newly synthesized lysosomal hydrolases 
into the secretory pathway and a decrease in the mature form of these 
enzymes. As both Furin and CI-M6PR trafficking are inhibited by USP8 
depletion, one would not expect this mechanism of action to be dependent on 
the retromer. Rather one possible explanation is that a “traffic jam” on the 
sorting endosome occurs when USP8 is depleted, as there is an increase in 
ubiquitylated proteins on the sorting endosome, preventing efficient 
ubiquitylation dependent sorting. The question that still needs addressing is if 
there is a decrease in lysosomal function. To test this we would need to use a 
model substrate for lysosomal degradation, however it is difficult to dissect out 
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USP8 dependent defects in lysosomal function from the sorting defects of 
USP8.  
 
USP8 has been identified as a drug target for over coming Gefitinib 
resistance in lung cancer and compounds have been developed to inhibit 
USP8138. Studying the early effects of USP8 inhibition may shed some light on 
the mechanism of action, as one would not expect a “traffic jam” of proteins to 
occur on the sorting endosome with acute inhibition. Long-term questions 
about USP8, should address whether the anti-cancer potential of USP8 
inhibition is due to effects on the trafficking of RTKs or if it is due to a more 
general disruption of endocytic trafficking. Questions about the targets of 
USP8 also remain, it is clear that depletion causes an increase in the cellular 
levels of ubiquitylated species230, largely on the endosome133. Exploring the 
binding partners of USP8 maybe a fruitful strategy to identifying substrates, 
using the same method presented in this thesis to identify interactors of 
USP46. An alternative strategy would be to isolate endosomes from cells, 
either depleted with USP8 or not, in SILAC configuration.  
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Supplementary Figures 
 
DUB Family Gene 
Name 
Subcellular localization Response Notes Ref 
Jamm/MPN+ AMSH Endosomal/ 
Nuclear/ 
Cytosolic 
No There is an 
apparent 
decrease in 
punctae but this 
is not a 
consistent effect. 
195, 
234 
AMSH-lp Endosomal/ 
Nuclear/ 
Cytosolic 
No -  
BRCC3 Predominantly nuclear/ 
Cytosolic 
No Peri-nucleclolar 
structures 
observed 
 
COPs5 Cytosolic/ nuclear No Dual localization 
observed not 
dependent of 
EGF. 
 
COPs6 Predominantly nuclear/ 
Cytosolic 
Yes Cells exhibit 
change in 
morphology, look 
stressed with 
EGF. 
 
EIF3s3 Predominantly nuclear/ 
Cytosolic/ PM 
No Aggregates   
EIF3s5 Punctate aggregates No Aggregates  
FLJ4981 Cytosolic No -  
MYSM Nuclear No Low expression 
levels some 
background 
fluorescence in 
pictures. 
 
PSMD7 Cytosolic/ PM No -  
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Otubain A20 Cytosolic aggregates No Aggregates  
Cezanne Nuclear/ Cytosolic/ PM No Regulates EGFR 
degradation 
 
OTUB1 Nuclear/ Cytosolic/ PM No Dual localization 
not dependent on 
EGF 
 
OTUB2 Nuclear/ Cytosolic No -  
OTUD3 Cytosolic  No Excluded from 
vacuolar type 
structures 
 
OTUD4 Cytosolic No Excluded from 
vacuolar type 
structures 
 
OTUD6a Cytosolic No Excluded from 
vacuolar type 
structures. Bright 
spot in 
cytoplasm. 
 
OTUD6b Cytosolic No Excluded from 
vacuolar type 
structures 
 
YOD1 Predominately Nuclear/ 
Cytosolic 
No  Fine punctae 
observed in 
cytoplasm 
 
TRABID Predominately Nuclear/ 
Cytosolic/ PM 
No -  
Ubiquitin 
carboxyl-
terminal 
hydrolase 
BAP1 Predominately Nuclear/ 
Nucleoli/ Cytoplasm 
No Dual localization 
not dependent of 
EGF 
 
UCHL1 Nuclear/ Cytoplasmic No -  
UCHL3 Nuclear/ Cytoplasmic No -  
UCHL5 Nuclear Yes Punctae 
structures occur 
at a higher 
frequency in 
serum starved 
conditions 
 
Josephin JOSD1 PM/ Cytosolic/ Nuclear No Partial co-
localization with 
Actin  
 
JOSD2 Cytoplasmic No -  
ATXN3 Predominantly Nuclear/ 
Cytoplasmic 
No -  
ATXN3l Cytoplasmic No -  
Ubiquitin 
Specific 
Protease 
USP2a Cytoplasmic Punctae No Reported as 
endosomal but 
we couldn’t 
repeat co-
localization 
139 
USP4 PM/ Cytosolic/ Nuclear Yes Less PM 
becoming 
enriched in 
nucleus 
235 
USP5 Nuclear No Found in EGF-
Ubome 
183 
USP6 PM No Found in pTyr IP  
USP7 Nuclear No No  
USP8 Cytoplasmic/ Endosomal Yes   
USP9x Predominantly Nuclear/ No No  
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Cytoplasmic 
USP10 Cytoplasmic/  No Excluded from 
vacuolar type 
structures 
 
USP11 Nuclear No Found in EGF-
Ub-ome 
183 
USP12 Cytoplasmic/  
Peri-nuclear 
No - 
 
 
USP13 Predominantly Nuclear/ 
Cytoplasmic 
No -  
USP14 Cytoplasmic No -  
USP15 Cytoplasmic No Found in EGF-
Ub-ome 
 
USP16 Cytoplasmic No -  
USP18 Cytoplasmic No -  
USP19 Endoplasmic Reticulum No - 236 
USP20 Cytoplasmic Peri-nuclear No -  
USP21 Cytoplasmic/Microtubules No - 184 
USP26 Nuclear No -  
USP29 Nuclear No -  
USP30 Mitochondria No - 237 
USP32 Perinuclear/Golgi No - 238 
USP33 Perinuclear/Golgi No - 239 
USP36 Nucleolar No - 240 
USP38 Nuclear No -  
USP39 Nuclear No Large structures 
present in 
nucleus 
 
USP42 Nuclear No Large speckles 
present in 
nucleus 
 
USP44 Nuclear No -  
USP45 Cytoplasmic/ Peri-nuclear No -  
USP46 Cytoplasmic/ Endosomal Yes Becoming more 
endosomal with 
EGF application 
 
USP49 Nuclear No -  
USP50 Cytoplasmic No -  
USP52 Cytoplasmic/ Peri-nuclear No -  
USP53 Cell-Cell Junctions No -  
CYLD Cytoplasmic/ Peri-nuclear No Found in 2 
independent pTyr 
IP 
 
 
Table S1. Summery of DUB screen  
Table 4.2 is a summary of GFP-DUB screen indicating the localization and changes or notes 
from the screen. Where a definitive localization is given the reference is indicated in final 
column.  
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Figure S1. JAMM/MPN+ family DUB-EGF screen. 
Representative images from JAMM/MPN+ family in the DUB EGF screen. HeLa cells were 
transfected with 1µg of GFP-DUB constructs for 24hours, serum starved for 16hours then 
subsequently stimulated with 20ng/ml of EGF for the time indicated before fixation in 4% PFA. 
Cells were then imaged using fluorescence microscopy to judge changes in subcellular 
localization. Representative images shown in panels. Scale bar = 10µm. 
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Figure S2. Otubain family DUB-EGF screen. 
Representative images from OTU family in the DUB EGF screen. HeLa cells were transfected 
with 1µg of GFP-DUB constructs for 24hours, serum starved for 16hours then subsequently 
stimulated with 20ng/ml of EGF for the time indicated before fixation in 4% PFA. Cells were 
then imaged using fluorescence microscopy to judge changes in subcellular localization. 
Representative images shown in panels. Scale bar =10µm. 
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Figure S3. Josephin family of enzymes, DUB-EGF screen. 
Representative images from Josephin family in the DUB EGF screen. HeLa cells were 
transfected with 1µg of GFP-DUB constructs for 24hours, serum starved for 16hours then 
subsequently stimulated with 20ng/ml of EGF for the time indicated before fixation in 4% PFA. 
Cells were then imaged using fluorescence microscopy to judge changes in subcellular 
localization. Representative images shown in panels. Scale bar =10µm. 
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Figure S4. UCH family of enzymes, DUB-EGF screen. 
Representative images from UCH family in the DUB EGF screen. HeLa cells were transfected 
with 1µg of GFP-DUB constructs for 24hours, serum starved for 16hours then subsequently 
stimulated with 20ng/ml of EGF for the time indicated before fixation in 4% PFA. Cells were 
then imaged using fluorescence microscopy to judge changes in subcellular localization. 
Representative images shown in panels. Scale bar =10µm. 
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Figure S5. USP family part 1, DUB-EGF screen. 
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Figure S6. USP family part 2, DUB-EGF screen. 
Representative images from USP family in the DUB EGF screen. HeLa cells were transfected 
with 1µg of GFP-DUB constructs for 24hours, serum starved for 16hours then subsequently 
stimulated with 20ng/ml of EGF for the time indicated before fixation in 4% PFA. Cells were 
then imaged using fluorescence microscopy to judge changes in subcellular localization. 
Representative images shown in panels. 
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Gene Name 
Peptides 
identified PEP 
Ratio 
M/L 
Ratio 
H/L 
Ratio 
H/M Intensity 
Intensity 
L 
Intensity 
M 
Intensity 
H 
LOG10  
Intensity 
Trinkle-
Mulcahy 
et al. 
 Blacklist 
Lab  
Blacklist 
LOG2  
M/L 
LOG2 
H/L 
LOG2 
H/M 
HSP90AB1 2 1.67E-12 4.3 0.5 0.1 730250 116840 552360 61052 5.9 + + 2.1 -1.0 -3.1 
PPIB 1 0.0080389 3.8 0.6 0.2 184320 46276 120340 17703 5.3   + 1.9 -0.8 -2.7 
EPRS 1 0.043386 1.5 0.6 0.4 50748 15724 24111 10913 4.7   + 0.6 -0.8 -1.3 
EEF2 4 7.80E-07 1.8 0.6 0.3 489890 147260 252900 89726 5.7   + 0.8 -0.8 -1.6 
RANP1 1 0.0093934 2.7 0.6 0.2 63190 11180 42913 9096.5 4.8   + 1.4 -0.7 -2.2 
RPL8 1 0.018819 1.9 0.6 0.3 52246 15653 27948 8644.8 4.7   + 0.9 -0.6 -1.6 
KRT18 3 9.33E-06 5.7 0.6 0.1 317690 31403 271670 14617 5.5   + 2.5 -0.6 -3.1 
RPL38 1 0.045945 2.5 0.7 0.3 143440 38551 77983 26904 5.2   + 1.3 -0.5 -1.8 
HNRNPH1 1 0.012469 3.3 0.8 0.2 156690 27558 106040 23093 5.2   + 1.7 -0.4 -2.1 
BASP1 2 6.54E-05 5.1 0.8 0.2 292550 41473 218990 32085 5.5   + 2.3 -0.3 -2.7 
HSPA9 2 0.00016069 3.1 0.8 0.2 315590 63064 198100 54433 5.5   + 1.6 -0.3 -2.0 
NONO 1 0.0041526 3.7 1.0 0.3 96725 19442 55837 21447 5.0 + + 1.9 0.0 -1.9 
XRCC6 2 5.48E-06 5.0 1.1 0.2 354360 55663 246150 52544 5.5   + 2.3 0.2 -2.1 
HNRNPC 2 0.00054434 10.7 3.3 0.2 172940 7087.3 153820 12036 5.2   + 3.4 1.7 -2.6 
BANF1 1 0.0025215 8.6 0.7 0.1 196410 21228 161960 13218 5.3   + 3.1 -0.6 -3.7 
SCHIP1 1 0.043109 0.0 0.1 1.4 243210 206860 13529 22821 5.4 +   -4.6 -4.1 0.5 
GAPDH  2 0.00010579 1.8 0.3 0.2 371110 117920 215330 37861 5.6 +   0.8 -1.7 -2.6 
SLC25A5 2 0.00013144 2.3 0.4 0.2 164480 51068 96672 16737 5.2 +   1.2 -1.2 -2.2 
PPIA 3 2.15E-09 2.0 0.5 0.2 467510 134040 265920 67553 5.7 +   1.0 -1.0 -2.2 
PRDX1 7 4.63E-19 1.3 0.5 0.4 3925300 1414500 1792800 717980 6.6 +   0.4 -1.0 -1.3 
RPS7 1 0.0060346 2.2 0.5 0.3 87995 27266 47071 13658 4.9 +   1.1 -0.9 -2.0 
RPS3 1 0.017099 2.1 0.6 0.3 153980 48190 79686 26109 5.2 +   1.1 -0.9 -1.9 
RPLP0 1 0.010098 1.9 0.6 0.3 130450 42995 66703 20753 5.1 +   1.0 -0.8 -1.8 
FLJ51435 3 1.89E-16 0.9 0.6 0.6 3131900 1255800 1108800 767230 6.5 +   -0.1 -0.8 -0.6 
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TMPO 2 0.0004823 2.6 0.6 0.2 424190 104030 262950 57214 5.6 +   1.4 -0.8 -2.2 
RPS12 1 0.016268 2.1 0.6 0.3 186120 63761 99400 22961 5.3 +   1.0 -0.8 -1.7 
RPS5 1 0.039788 2.1 0.6 0.3 144960 42443 76112 26408 5.2 +   1.1 -0.8 -1.8 
RPS24 1 0.062951 2.3 0.6 0.3 73425 19780 40960 12685 4.9 +   1.2 -0.8 -2.0 
RPS19 1 0.010769 1.3 0.6 0.5 165490 50800 73754 40933 5.2 +   0.3 -0.7 -1.1 
SERBP1 1 7.62E-15 1.5 0.6 0.4 347150 114920 161530 70695 5.5 +   0.6 -0.6 -1.2 
RPS23 1 0.027323 2.5 0.7 0.3 91781 21366 57127 13289 5.0 +   1.3 -0.6 -1.9 
PHGDH 3 8.82E-06 2.2 0.7 0.3 1012200 276870 552030 183290 6.0 +   1.2 -0.6 -1.8 
RPL11 2 3.84E-05 2.7 0.7 0.3 546640 134360 319700 92584 5.7 +   1.4 -0.6 -2.0 
EEF1E1 1 0.027264 1.5 0.7 0.5 55763 21343 22115 12305 4.7 +   0.6 -0.5 -1.1 
HSP90AA1 2 3.85E-11 3.2 0.7 0.2 60816 18461 32327 10027 4.8 +   1.7 -0.5 -2.2 
EIF4A3 1 0.010326 4.2 0.7 0.2 65087 11657 44346 9084.2 4.8 +   2.1 -0.5 -2.5 
RPS14 2 0.00036884 3.3 0.8 0.2 255860 51486 163270 41099 5.4 +   1.7 -0.4 -2.1 
HSPA8 12 3.21E-53 2.0 0.8 0.4 8188100 2212700 4347500 1627900 6.9 +   1.0 -0.3 -1.4 
MIF 3 2.83E-16 1.1 0.8 0.7 41736000 13754000 14419000 13562000 7.6 +   0.1 -0.3 -0.4 
HSPA5 2 0.00018146 2.4 0.8 0.3 616590 179930 319290 117370 5.8 +   1.3 -0.3 -1.6 
PARP1 2 0.0022195 3.0 0.8 0.3 33872 6877.7 23767 3227.5 4.5 +   1.6 -0.3 -1.9 
HIST1H4A 8 4.58E-26 24.6 0.8 0.0 6985300 250150 6566900 168330 6.8 +   4.6 -0.3 -4.9 
RPLP1 1 1.30E-06 2.2 0.8 0.4 153340 39859 79576 33903 5.2 +   1.1 -0.3 -1.4 
LMNA 19 7.22E-61 4.6 0.8 0.2 5557000 936900 3813400 806660 6.7 +   2.2 -0.3 -2.5 
HSPA6 5 7.66E-20 2.1 0.8 0.4 823590 217060 447870 158660 5.9 +   1.1 -0.3 -1.4 
CPS1 5 8.75E-07 4.3 0.8 0.3 312460 53554 209910 49001 5.5 +   2.1 -0.3 -1.9 
PDIA6 3 4.57E-11 1.3 0.8 0.7 830400 266670 334540 229190 5.9 +   0.4 -0.3 -0.5 
TUBB 11 6.27E-44 2.4 0.9 0.4 8858700 2211800 4711200 1935600 6.9 +   1.2 -0.2 -1.4 
HSPD1 1 0.010423 3.0 0.9 0.3 201220 45496 119730 36001 5.3 +   1.6 -0.2 -1.8 
NPM1 1 0.015871 7.2 0.9 0.1 270720 35767 202440 32512 5.4 +   2.8 -0.1 -3.0 
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PKM2 13 2.58E-50 1.2 0.9 0.8 9519900 3007200 3609000 2903600 7.0 +   0.2 -0.1 -0.4 
VIM 8 3.43E-16 9.7 1.0 0.1 1725000 189680 1407500 127800 6.2 +   3.3 0.1 -3.2 
TXN 1 0.0020187 1.6 1.1 0.7 403640 125200 152080 126360 5.6 +   0.7 0.1 -0.6 
HIST1H1B 2 0.00014319 6.3 1.1 0.2 213700 3972.1 188710 21015 5.3 +   2.6 0.1 -2.6 
PCBP1 2 3.59E-07 1.8 1.1 0.6 559430 144080 268050 147310 5.7 +   0.8 0.1 -0.7 
HSPA1B 9 4.09E-25 2.6 1.1 0.5 2170200 484620 1123500 562020 6.3 +   1.4 0.2 -1.1 
HIST1H2AB 1 0.0026064 23.7 1.5 0.1 445430 9188.6 419890 16361 5.6 +   4.6 0.6 -4.0 
HIST2H2BE 4 5.54E-64 18.0 1.8 0.1 9155800 264500 8463900 427390 7.0 +   4.2 0.8 -3.8 
POTEA 1 0.014786 63.6 2.0 0.0 732040 11048 716060 4932.8 5.9 +   6.0 1.0 -5.0 
HDAC6 1 0.019708 NaN NaN NaN 0 0 0 0 NaN +   NaN NaN NaN 
ASH1L 1 0.050074 NaN NaN NaN 0 0 0 0 NaN +   NaN NaN NaN 
EIF4A2 1 0.015196 3.5 NaN NaN 87473 20117 60368 6987.8 4.9 +   1.8 NaN NaN 
YBX1 1 0.0089051 NaN NaN NaN 0 0 0 0 NaN +   NaN NaN NaN 
SERPINH1 1 0.024439 NaN NaN NaN 0 0 0 0 NaN +   NaN NaN NaN 
HIST1H1C 1 0.0019972 4.3 NaN NaN 73654 9816 59295 4543.1 4.9 +   2.1 NaN NaN 
HIST1H1E 1 0.011273 5.5 NaN NaN 160010 25408 130080 4526.6 5.2 +   2.5 NaN NaN 
RPL27 1 0.029382 NaN NaN NaN 0 0 0 0 NaN +   NaN NaN NaN 
CCT3 2 1.17E-05 NaN NaN NaN 0 0 0 0 NaN +   NaN NaN NaN 
HSP90AB2P 2 5.42E-12 NaN NaN NaN 0 0 0 0 NaN +   NaN NaN NaN 
RPL27A 1 0.0097477 NaN NaN NaN 0 0 0 0 NaN +   NaN NaN NaN 
GFP 10 5.29E-24 0.1 0.1 0.7 5016000 3639100 816840 560050 6.7     -3.0 -4.1 -0.4 
LOC100290710 1 0.022291 0.1 0.1 0.9 184280 163890 10160 10225 5.3     -3.2 -3.3 -0.2 
PGAP2 1 0.058921 12.6 0.2 0.0 132090 6823.9 123360 1907.1 5.1     3.7 -2.1 -5.8 
KIAA0748 1 0.021891 3.9 0.4 0.1 105280 22137 75423 7716.2 5.0     2.0 -1.4 -3.4 
FBXO11 1 0.034421 3.7 0.4 0.1 176380 38321 116370 21690 5.2     1.9 -1.2 -3.1 
PRSS35 1 0.022805 2.1 0.5 0.2 331720 96594 185470 49655 5.5     1.1 -1.0 -2.1 
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ACO2 1 0.029561 2.0 0.5 0.2 352040 102180 205100 44757 5.5     1.0 -1.0 -2.0 
DYTN 1 0.010947 2.0 0.5 0.2 352040 102180 205100 44757 5.5     1.0 -1.0 -2.0 
NUAK1 1 0.031235 1.8 0.5 0.3 182440 63251 88579 30606 5.3     0.8 -1.0 -1.8 
FTH1 1 0.044182 2.5 0.5 0.2 46205 11553 29979 4673.5 4.7     1.3 -1.0 -2.3 
HNRNPU 1 0.019612 3.9 0.6 0.2 107050 21660 72228 13166 5.0     2.0 -0.7 -2.7 
RPSAP15 1 0.001868 1.8 0.6 0.4 230200 68722 117680 43796 5.4     0.9 -0.7 -1.4 
BRD4 1 0.020145 1.9 0.7 0.3 509030 155970 258430 94630 5.7     1.0 -0.6 -1.6 
IQGAP1 1 9.61E-07 1.8 0.7 0.4 82695 24878 43503 14314 4.9     0.8 -0.6 -1.3 
ISOC2 1 0.0081068 1.1 0.7 0.6 357810 132620 135660 89521 5.6     0.1 -0.5 -0.6 
ANKRD30B 1 0.023804 2.1 0.7 0.3 203710 51920 111110 40674 5.3     1.0 -0.5 -1.6 
EEF1A1 10 1.19E-31 1.9 0.7 0.4 7179000 2004100 3788100 1386900 6.9     1.0 -0.5 -1.4 
HNRNPM 2 0.00015895 4.2 0.7 0.2 226060 41524 154940 29591 5.4     2.1 -0.4 -2.5 
RPS18 1 0.011713 1.9 0.7 0.4 186510 35452 69126 81936 5.3     0.9 -0.4 -1.4 
PKP3 1 0.025178 1.0 0.7 0.7 355020 131940 132030 91054 5.6     0.0 -0.4 -0.4 
MAPK1 1 0.0020731 1.3 0.8 0.7 258770 84880 97039 76849 5.4     0.4 -0.3 -0.6 
DNL1 1 0.032992 1.3 0.9 0.7 137150 45149 52075 39926 5.1     0.4 -0.2 -0.6 
C17orf44 1 0.037931 1.3 0.9 0.8 217360 76571 75933 64858 5.3     0.3 -0.1 -0.3 
FAM73B 1 0.020564 1.3 0.9 0.8 217360 76571 75933 64858 5.3     0.3 -0.1 -0.3 
S100A4 1 0.07239 3.0 0.9 0.3 106120 22934 62611 20579 5.0     1.6 -0.1 -1.7 
CSTB 1 0.031406 1.7 1.0 0.6 318500 108270 121590 88639 5.5     0.8 -0.1 -0.8 
KCP 1 0.15055 0.3 1.0 3.8 191860 46275 19539 126050 5.3     -1.9 0.1 1.9 
LGALS1 1 0.016295 2.2 1.1 0.5 214480 47659 116660 50153 5.3     1.1 0.1 -1.0 
KLK8 1 0.025982 2.3 1.1 0.5 194290 43377 94640 56273 5.3     1.2 0.1 -1.1 
UBB 2 4.80E-05 6.3 1.1 0.2 561810 68669 384710 108440 5.7     2.7 0.1 -2.5 
FOXK1 1 0.050752 3.7 1.1 0.3 97391 5213.6 72156 20022 5.0     1.9 0.1 -1.7 
HAGH 1 0.034776 1.1 1.2 1.1 114330 33202 39531 41600 5.1     0.2 0.3 0.1 
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BAZ1A 1 0.024496 10.6 1.6 0.2 179400 16619 136260 26520 5.3     3.4 0.7 -2.7 
CMBL 3 1.34E-07 1.4 1.7 1.2 870500 206080 319530 344900 5.9     0.5 0.8 0.3 
C14orf43 1 0.038563 41.1 2.3 0.1 4286000 100980 4001600 183400 6.6     5.4 1.2 -4.2 
WDR20 1 0.016108 4.8 3.1 0.6 137030 6091.5 78799 52137 5.1     2.3 1.6 -0.6 
USP46 5 1.36E-10 5.3 3.2 0.6 1790700 135970 977980 676720 6.3     2.4 1.7 -0.6 
MAOB 1 0.047068 0.8 4.2 5.2 124510 11042 14988 98482 5.1     -0.3 2.1 2.4 
WDR48 4 3.68E-07 6.7 4.2 0.6 500080 28716 329380 141990 5.7     2.7 2.1 -0.7 
DDAH1 1 0.039914 25.4 4.9 0.2 1888700 62749 1653800 172170 6.3     4.7 2.3 -2.4 
ABCG1 1 0.024701 20.4 5.8 0.3 979170 32623 752520 194020 6.0     4.3 2.5 -1.8 
CPEB1 1 0.11573 0.4 6.3 14.4 141430 10695 9905.5 120820 5.2     -1.2 2.7 3.8 
DAGLA 1 0.025678 7.4 NaN NaN 34240 2343.5 31896 0 4.5     2.9 NaN NaN 
FAM54A 1 0.024428 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
C1orf96 1 0.011069 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
ZNF280C 1 0.023778 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
CRYGD 1 0.04099 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
HNRNPA1 1 0.0080084 NaN NaN NaN 48787 0 48787 0 4.7     NaN NaN NaN 
FAM186A 1 0.13183 NaN NaN NaN 35420 35420 0 0 4.5     NaN NaN NaN 
STK35 1 0.0455 NaN NaN NaN 103400 103400 0 0 5.0     NaN NaN NaN 
IMPDH2 1 0.022409 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
CBLB 1 0.038884 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
RABEP1 1 0.070771 NaN NaN NaN 102830 0 102830 0 5.0     NaN NaN NaN 
ABCE 1 0.019596 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
CEBPZ 1 0.02083 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
ARL13B 1 0.026317 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
LRCH3 1 0.046699 NaN NaN NaN 226350 0 0 226350 5.4     NaN NaN NaN 
BCL2L11 1 0.018075 NaN NaN NaN 30397 0 0 30397 4.5     NaN NaN NaN 
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CYP2D6 1 0.015545 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
DES 2 0.00086055 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
TAOK2 1 0.056441 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
FCRLB 1 0.083132 3.4 NaN NaN 24429 2620.6 20038 1771.1 4.4     1.8 NaN NaN 
IPI00748203.3 1 0.041971 NaN NaN NaN 1351100 0 1351100 0 6.1     NaN NaN NaN 
IPI00748203.3 1 0.026147 NaN NaN NaN 43214 43214 0 0 4.6     NaN NaN NaN 
FAM59B 1 0.0066949 NaN NaN NaN 453420 0 453420 0 5.7     NaN NaN NaN 
IPI00936336.1 1 0.081038 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
IPI00937073.1 1 0.055539 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
IPI00937519.1 1 0.052502 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 
IPI00937553.1 1 0.081038 NaN NaN NaN 0 0 0 0 NaN     NaN NaN NaN 	  	  
Supplementary Table 1. Full list of proteins from GFP-USP46/GFP-USP46-C44S IP experiments.  
Annotated MaxQuant output file for GFP/GFP-USP46-C44S/GFP-USP46 SILAC experiment. Proteins are annotated with their respective gene names. The 
peptides identified column, indicates the number of peptides seen for each protein. Proteins were black listed either because they were identified in the 
Trinkle-Mulcahy et al. (2008) dataset as an IP contaminant or they were blacklist from commonly seen proteins in IP mass experiment experiments in the lab. 
PEP (Posterior Error Probability) score essentially acts a p value, the lower the number the higher the confidence of correct identification. 
 	  
